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The design and development of medical devices has become an increasing complex 
and regulated process. To date, little if any consideration is given to the regulatory 
requirements when developing medical devices in universities. This has resulted in an 
imposing barrier preventing academic innovation reaching clinical adoption. The scope 
of universities is not to become the legal manufacturer of medical devices. However, 
should the development of novel devices ever aim to benefit patient care and reach a 
clinical setting, design controls must be implemented throughout the project life cycle to 
demonstrate feasibility and safety. 
 The aim of this thesis is to develop user-centred technologies which comply with 
industrial design control practices whilst helping to bolster and promote innovation within 
academia. Four projects relating to medical devices have been designed in response to 
well-defined and end-user-originated clinical needs. These devices can serve as the 
exemplar for the framework developed in this work with each reaching staggered phases 
of development within a controlled design process. Although unique, the devices have 
significant overlapping characteristics that lend the devices to parallel development, 
leveraging in-house know-how and ‘lessons learned’ into the process of innovation. This 
thesis focuses on the novelty and design of the aforementioned projects in a discrete 
structured approach and reflects on the development of each project within the context of 
a design control process which was developed as part of this work.  
It is the ultimate goal of this work to develop a flexible structured system compliant 
with the international requirements for product design and development which may be 
exported internationally. However, the full execution of this ambition was limited due 
physical, and financial limitations. This manuscript will describe the technical and 
commercial opportunity of the user cantered devices and reflect on the success of 
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“What I admire in Columbus is not his having discovered a world, but his having gone 
in search for it on the faith of his own opinion.”              Turgot 
 
Theodore Levitt once said “creativity is thinking up new things. Innovation is doing 
new things”. This presents a challenge in the university setting where the main objective 
is to produce academic research and to invent without a clear sight to market. This 
becomes particularly evident in regulated markets such as medical devices. This thesis 
explores how adapting a linear model of device development to the academic setting may 
be used to bridge the gap between research and commercial innovation and demonstrates, 
through three novel examples, how university projects can achieve both academic merit 
and commercial potential. Chapter 1 presents an overview and objectives of the thesis as 
well as introducing the user-centred medical devices developed within the proposed 
framework. 




This thesis explores the development of novel medical devices within a design 
control framework in a third level institute. To date, little if any consideration is given 
to the regulatory requirements when developing medical devices in universities. The 
implementation of product development controls can be seen as costly and 
burdensome. Furthermore the primary function of universities is not to become the 
legal manufacturer of medical products, therefore the application of standardisation 
during the development phase may not be seen as necessary. However, without a 
documented product development process to demonstrate that a device is safe, 
effective and meets the user needs, project outputs cannot be transferred into the 
clinical setting, limiting their impact on patient care and reducing their commercial 
attractiveness.  
The aim of this thesis is to develop novel user-centred technologies which comply 
with industrial design control practices whilst helping to bolster and promote 
innovation within academia. Three projects have been incorporated into a design 
control process which has been adapted from the linear stage gate approach to product 
development [1]. The stage gate approach has been well documented [1]–[3]. 
However the objective of this work was to adapt the process to suit the needs of early 
stage research and development within the academic setting. These projects can serve 
as the exemplar for the adapted framework described herein. Each device (currently 
at staggered stages of development) is a response to a defined and end-user-originated 
clinical need, derived through a medical device design programme at University 
College Cork (UCC). The BioDesign module couples consultant clinicians with 
interdisciplinary student teams from medicine and engineering to solve real life 
clinical problems in the academic setting [4]. The UCC BioDesign module is co-
ordinated by Dr Pádraig Cantillon-Murphy based on his experience at MIT and 
Harvard Medical School. As a follow-on from the BioDesign module, selected 
projects that demonstrate commercial promise are further developed within the 
postgraduate Biomedical Design Research Group (BDRG) at UCC where much of the 
work described in this thesis was completed. 
An aspirational outcome of this research is to create an entity that can facilitate the 
future exploitation of these devices as commercially viable products. This will involve 
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co-operative research and development between the student, supervisor, clinical partners, 
business partnerships and the regulatory authorities to successfully achieve this goal. 
Working closely with the university Technology Transfer Office, the intellectual property 
surrounding each of the devices was defined and, where appropriate, protected by 
European patent applications.  
 
The objective of designing medical technology within a controlled framework is 
demonstrated through the development of three novel devices, which meet well-defined 
clinical needs, identified by consultant-level clinicians. In the case of each device, the 
level of incorporation of the individual project within the development framework is 
varied depending on project timeline overlapping with the framework development. The 
resulting devices are (1) SecuRetract: an inflatable laparoscopic bowel retractor, (2) 
ProDural:  a device to improve the accuracy of epidural administration, and (3) SafeTrac: 
a rapid endotracheal tube delivery device. Each of these technologies have received 
financial support from Enterprise Ireland. Enterprise Ireland is the government 
organisation responsible for the development and growth of Irish enterprises in world 
markets with a number of different funding supports in higher education institutes. 
Although unique, the three devices developed in the design control framework, have 
significant overlapping characteristics such as inflatable technology, disposability, 
similar pre-clinical pathways to clinical evaluation and suitability for IP exploitation. 
These similarities lend the devices to parallel development to leverage know-how and 
‘lessons learned’ into the process of innovation. However, each device also represents a 
unique engineering challenge.  
The author will also describe a fourth project relating the development of radiopaque 
tumour models which were developed outside of the design control process and will 
explore how one might retrospectively apply a developmental framework to this project. 
1.2.1.  SecuRetract 
The SecuRetract project describes the design and development of a minimally-
invasive retractor used during lower abdominal laparoscopic (keyhole) surgery. Current 
methods used to manoeuvre and manipulate impeding organs, such as the distend loops 
of bowel, during laparoscopic surgery present a number of adverse effects. SecuRetract 
aims to overcome the current difficulties with existing approaches while improving 
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surgical access and reducing complications. The laparoscopic retractor project 
represents a unique collaboration between UCC School of Engineering, the 
Departments of Surgery at Cork University Hospital (Dr Emmet Andrews) and the 
Mercy University Hospital (Dr Micheal O’Riordain), as well as a host of quality and 
regulatory experts (Ms Chrissie Keane - National Standards Authority of Ireland, Mr 
Frank Enright - IncraMed Regulatory Consultants, Ms Angela O’Sullivan - Arwen 
Medical Compliance).  
 
Figure 1.1 Computer render of SecuRetract, the atraumatic laparoscopic retractor, 
pictured in the curved and inflated position. 
Published works relating to SecuRetract include a peer reviewed paper in the 
Annals of Biomedical Engineering describing the early stage design and utility of 
SecuRetract [5], as well as two conference proceedings [6], [7]. The early stage design 
and development of this device was included in a MEngSc thesis which the author 
completed before improving the design as part of this work [8]. Where overlap occurs 
in project timelines, clear reference shall be made to previous works.  
Two Enterprise Ireland Commercialisation Awards have supported both the 
technical and commercial development, utilising in-house resources and external 
services where necessary. The design of SecuRetract has also been recognised with 
multiple awards to include the Enterprise Ireland Roots in Research award (2015), 
and the Boucher-Hayes Medal for Innovation in Surgery from the Royal Academy of 
Medicine Ireland (2014). SecuRetract is patent pending with filings in the USA and 
Europe. The SecuRetract project was developed in parallel with developing the design 
control framework. As a result of such, various stages of development came before 
the corresponding controls were in place which subsequently resulting in 
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retrospectively applying the design controls. A detailed review of the SecuRetract project 
as well as a full list of published work and awards associated with the project is listed in 
Chapter 3. 
1.2.2. ProDural 
ProDural is a device which recognises needle tip entry to the epidural space in 
anaesthesia, improving the ease and safety of epidural administration. Conventional 
means to administer epidurals during labour or therapeutic pain relief require a steep 
learning curve, and can result in significantly high complication rates particularly for 
trainee anaesthetists. The ProDural project represents a collaboration between the 
Department of Anaesthesia (Dr. Peter Lee) at Cork University Hospital (CUH) and the 
UCC School of Engineering. 
 
Figure 1.2. ProDural concept computer render in the charged state. 
ProDural has received a number of awards including winning the Enterprise 
Ireland/Cleveland Clinic Clinical Innovation Award (2013), Top four finish out of thirty 
six early-stage medical devices at the MedTech Innovator IN3 Dublin (2014), and fourth 
place at the M2D2 New Venture Competition Boston from fifteen globally shortlisted 
finalists (2014). A provisional European patent was filed for ProDural and a conference 
paper describing the design and development of ProDural was also published during the 
International Conference on Biomedical Engineering, Zurich, Switzerland [9]. Similar to 
the SecuRetract project, ProDural was developed in parallel to the design control process 
and thus aspects of the development were retrospectively captured within the framework. 




One of the most common difficulties encountered in anaesthesia is airway 
intubation. The problem of airway intubation particularly in patients with difficult 
access was presented by Dr Gabriella Iohom, consultant anaesthetist at Cork 
University Hospital, as part of the 2013 UCC BioDesign module. During the course 
of the module, a viable solution was not offered. The project was subsequently 
incorporated as part of this PhD work where the author re-explored the clinical need 
and leveraging knowledge gather from previous projects, developed SafeTrac.  
SafeTrac is a single-use device providing dynamic manoeuvrability and control to 
improve the efficacy and safety of endotracheal intubation. SafeTrac was awarded an 
Enterprise Ireland Feasibility Award to assess its commercial potential in 2015. The 
SafeTrac project is the most recent project to be introduced through the developmental 
framework. As such, the early stage development of SafeTrac followed the design 
control roadmap despite being the least developed of the three projects.  
 
Figure 1.3. Computer render of SafeTrac with endotracheal tube positioned on shaft 
ready for deployment. 
1.2.4. Radiopaque Tumour Models 
In addition to the three principal project briefly described above, the author has 
also development of a number of contrasting tumour models as part of the Biomedical 
Design Group’s electromagnetic pulmonary navigation project [10]–[12]. The tumour 
models were designed for endoluminal deployment in the lung and are clearly 
identified under CT imagery. The purpose of the novel radiopaque tumour models is 
to enable effective evaluation of the navigation system through targeted sampling of 
identifiable fiducial makers [12], [13] (see Figure 1.4).  





Figure 1.4 Radiopaque tumour model project images with A) the model development, B) 
the model ex vivo placement into a preserved swine lung, and C) the tumour model being 
scanned using computer tomography. 
The tumour model project was not formally accepted as one of the projects to come 
under the development process as initially it was not intended for clinical or commercial 
output. However, since completion of this work, the author has recognised that such a 
model may be extensively used during systems evaluation as well as physician training. 
Therefore, the steps that would be required to retrospectively include a project like this 
one into the design control process will be discussed. 
 
This thesis is divided in five work chapters and a conclusion chapter. The motivation 
behind implementing a design control framework is introduced before presenting a more 
detailed description of the specific research projects. 
Chapter 2 outlines the design control process developed as part of this work. The aim 
of this chapter is not to describe in detail the complexities of regulatory compliance, but 
to introduce a five-phase stage-gate process of controlling the design activities to fulfil 
the requirements of the regulatory bodies. This chapter concludes by highlighting the 
importance and advantages of implementing controls not just in the industrial setting but 
also in the academic one. 
Chapter 3 and the succeeding chapters, detail the device specific design history. These 
chapters focus on the novelty and origins of the device as well as the design evolution 
process in a logical and progressive flow. Each chapter will also relate the development 
of the individual project to the overall design control process. Chapter 3 deals specifically 
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with the SecuRetract project which is the furthest developed of the presented 
technologies. 
Chapter 4 details the design and development activities associated with creating a 
solution to improving the safety and efficacy of epidural administration. The proposed 
solution, ProDural, provides additional confirmation that the epidural space has been 
reached without altering current methods of deployment.  
Chapter 5 explores the development of a low cost disposable device to improve 
the ease of tracheal intubation. The proposed solution, SafeTrac, is at an earlier stage 
of development compared to the previous devices, yet a clear clinical need and 
commercial opportunity has been validated.  
Chapter 6 details additional contributions made by the author relating the design 
and development of radiopaque tumour models. This work began as a response to the 
needs of a semi-automatic bronchoscopic navigation project being developed within 
the BDRG, and presents novel findings with applications in both the training and 
systems evaluation setting. This chapter also reflects on the feasibility or 
retrospectively incorporating the artificial tumour model project within a design 
control process. 
The final chapter, Chapter 7, presents the key findings and novel contributions of 
the thesis, discusses the implementation of a design control process in the academic 
setting and proposes recommendations for future work. 
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 Design Control of Medical 
Devices 
 
“For a successful technology, reality must take precedence over public relations, for 
Nature cannot be fooled.”                                                                           Richard Feynman 
 
 
Medical device design and development is a complex process which must demonstrate 
that a device or system operates as intended, functions in a safe manner, and can continue 
to perform over a specified period of time without failure. Ensuring these requirements 
are met involves the careful integration of clinical needs, controlled design and 
development, implementation of regulatory standards and directives, and administrative 
controls. The design and implementation of such processes can become the determinant 
factor in the success of device commercialisation. This chapter introduces the concept of 
a quality management system for medical device design in the university setting and 
provides a brief overview of the design and development process being implemented 








 “Primum non nocere” or “first do no harm” remains an important aphorism in 
medicine. Medical device design, in an aspiration to meet clinical needs and fulfil 
clinical utility, comes with an inherent risk to the patient and clinician particularly as 
device functionality becomes more complex. However, the establishment of quality 
systems and design controls mitigate this risk and ensure that consistent quality 
devices are produced. This chapter provides an overview of the regulatory 
requirements and outlines how an industrial process for design and development 
control may be adapted to the academic setting.  
2.1.1. European Regulatory Pathway 
In Europe, medical devices cannot be placed on the market without conforming to 
the strict safety requirements of the European Union. The term “medical device” 
covers a very wide range of products, excluding medicines, used in healthcare. CE 
Marking on a product declares that the product complies with the essential 
requirements of the European technical regulations (“Directives”) related to European 
health legislation and is obligatory for products sold in the European Economic Area 
(EEA) since 1993. The three directives are: 
 Active Implantable Medical Device Directive (AIMDD 90/385/EE) [14]; 
 Medical Device Directive (MDD 93/42/EEC) [15]; 
 In Vitro Diagnostic Medical Device Directive (IVDMDD 98/79/EC) [16]. 
These directives have since been updated to account for new and emerging trends 
and technology. Within the Biomedical Design Research Group, focus is exclusively 
given to the medical device directive 93/42/EEC with no present of future plans to 
branch into active implantable or in vitro diagnostic devices. Regulatory approval in 
Europe relies on notified bodies (NB) to implement regulatory control over medical 
devices [17] (e.g. National Standard Authority Ireland, British Standards Institute, 
etc.). The NB is an independent commercial organisation which is audited and 
monitored via the national Competent Authority (CA); a government appointed body 
responsible for monitoring and ensuring compliance with the provisions of the MDD. 
The Health Products Regulatory Authority (HPRA) is the Competent Authority in 
Ireland for human and veterinary medicines, and medical devices. The HPRA and NB 
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have the responsibility to protect the patient and end user by ensuring that medical device 
manufacturers meet the requirements of the relevant legislation [18].  
It is the responsibility of the manufacturer to ensure that their product complies with 
the essential requirements of the relative legislation. For a device regarded as a medical 
device with an intended medical purpose, the overall steps towards achieving the CE mark 
are as follows [19]: 
 Identify the directives and annexes that are applicable to your product; 
 Classify your device and choose conformity assessment procedure; 
 Implant design and quality controls and demonstrate that all the essential 
requirements of the legislation have been met; 
 Maintain technical documentation to support compliance with requirements of the 
directives; 
 Prepare declaration of conformity and supporting evidence; 
 Submit to NB for certification; 
 Register with CA (by manufacturer or an authorised representative); 
 Apply CE marking on your product and/or its packaging and market product; 
2.1.2. USA Regulatory Pathway 
The Food and Drug Administration (FDA) is a public health agency in the United 
States of America who is charged with protecting consumers by enforcing The Federal 
Food, Drug And Cosmetic Act [20], [21]. Since 1976, the US FDA has been the 
responsible authority to regulate all medical devices in the United States. The goal of the 
FDA is to balance two competing views “the public reasonable assurances of safe and 
effective devices” while avoiding “overregulation” of the industry [22], [23]. To 
accommodate these goals, the FDA allows for two different regulatory pathways to 
marketing medical devices. The most common pathway is known as the 510(k) provision, 
which is intended to provide a less burdensome route enabling incremental technologies 
enter the market. A new medical device that can demonstrate “substantial equivalence” 
to a previously legally marketed device can be “cleared” by the FDA for marketing as 
long as the general and special controls, such as manufacturing, packaging, labelling and 
sterilisation are met. The 510(k) pathway rarely requires clinical trials, therefore 
approximately 99% of new medical devices in the US enter the market via this process 
[23].  
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The second regulatory pathway to market entry for new medical devices is the 
Premarket Approval (PMA) process. PMA submissions are similar to new drug 
applications in the pharmaceutical industry and require extensive testing including 
“valid scientific evidence” to provide reasonable assurance of safety and effectiveness 
[23]. The PMA process is primarily targeted towards medical devices that “support or 
sustain human life, are of substantial importance in preventing impairment of human 
health, or which present a potential, unreasonable risk of illness or injury” [24]. The 
Biomedical Design Research Group exclusively targets low to medium risk 
technologies that would fall under the 510(k) pathway as these devices present the 
lowest hurdles toward clinical adoption and shortest timelines to improving patient 
care.  
2.1.3. Classification of Medical Devices 
Within the legislation, medical devices are classified depending on their perceived 
risk. In Europe the classification of medical devices is covered by the European 
Directive 93/42/EEC Annex IX, and the related Irish regulation S.I. No. 252 of 1994. 
The task of classifying a medical device lies with the manufacturer. For medical 
devices, the general classification categories are outlined in Figure 2.1. 
 
Figure 2.1 Medical device classification (MDD 93/42/EEC Annex IX) 
Annex IX of the MDD provides a list of rules to direct the manufacture to the 
correct classification. The rules depend on the duration of contact, the degree of 
invasiveness, whether or not the device is active, and what part of the body is affected 
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by your product. The corresponding route to conformity depending on the classification 
of device is also described in the MDD 93/42/EEC. 
In the USA, all medical devices are placed into classes based upon their degree of risk 
posed by the device and its intended use. The FDA also uses three classifications to 
differentiate the clinical risk of medical devices. Class I devices present minimal potential 
harm to the patient and thus are the least regulatory controlled (e.g. bandages and 
examination gloves). Class II devices are subjected to special controls to include special 
labelling requirements and post market surveillance (e.g. acupuncture needles, powered 
wheelchairs, infusion pumps, surgical drapes). Class III devices have the most stringent 
regulations and are usually those that sustain human life (e.g. implantable pacemaker, 
pulse generators, automated external defibrillators) [25].  
The main difference between the EU and FDA methods to classification is that in the 
USA the manufacture does not follow rules but must find the regulation number that is 
associated with the product code for your device. This may be achieved by either going 
directly to the FDA classification database and search for a part of the device name, or, if 
you know the medical specialty to which your device belongs, go directly to the listing 
for that speciality and identify your device and the corresponding regulation [25]. FDA 
510(k) reports are useful when looking at comparable devices to get an idea of the product 
code and corresponding classification. 
2.1.4. Quality Management System Documentation 
Documentation of the design control process within a Quality Management System 
(QMS) is mandated by both the European MDD and FDA [26]. The process for 
implementing a QMS for medical devices is described in ISO 13485 – Medical Devices 
Quality Management Systems. As part of this work, a QMS based on the requirements of 
the ISO 13485, with particular focus on the document control and design control activities 
(ISO 13485 Clause 4 & 7), has been developed. No single quality system may be applied 
to every organisation, however the overall structure of quality systems universally 
comprise of the following three levels: 
Level 1: Quality Manual - The quality manual is the top level document which 
describes the overall quality system in accordance with the stated quality policy and ISO 
13485 (see Appendix 1).  
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Level 2:  Standard Operating Procedures - The standard operating procedures 
(SOP) establish the practices, procedures, policies and requirements. They are drafted 
from both a technical and clinical perspective and use a general format, with flow 
charts and diagrams as applicable. The quality manual references the applicable 
SOP(s). The SOP’s developed as part of this work primarily focus on document and 
design control activities while utilising existing procurement procedures and 
environmental controls of the university to support supplier and human resource 
activities.   
Level 3: Forms, Records and Specifications - Forms and records provide 
evidence about a past event stating results or activities performed. Laboratory 
notebooks, device specifications, functional characteristics, risk management reports, 
validation and verification protocols, packaging and sterilization processes, and 
manufacturing processes are all examples of records produced as part of a new product 
development (see Appendix 2 for an example). It is these records, specifications and 
reports that will be used to populate the design history of the medical device and serve 
as evidence to demonstrate that the design control process was implanted and that a 


































Figure 2.2 Hierarchy of documentation within a quality management system. 
The complete technical documentation, declaration of conformity, the NB 
decisions and certificates must be kept and retained for five years (fifteen for 
implantable devices) after the final production of the device.  These documents must 
also be available for presentation to the Competent Authority on request. 




Design controls are a set of quality practices and procedures incorporated into the 
design and development processes which are ultimately used to assure that device 
specifications meet user needs and intended use [20]. The design control requirements for 
supplying medical devices in Europe are outlined in ISO 13485 and MDD 93/42/EEC. 
The scope of design control applies to all Class II and Class III medical devices as well 
as select Class I devices (e.g. devices automated with computer software, 
tracheobronchial suction catheters, protective restraints). Design controls are made up of 
a number of elements with documented procedures that include design planning, design 
inputs, design outputs, design review, design verification and validation, and design 
changes which are captured within the QMS. Risk assessment and human factors are 
critical elements and should be considered at every step of the design control process. A 
full description of the design control elements are defined in the medical directive 
93/42/EEC Annex 1, and the FDA regulations 21 CRF 820.30 [20]. 
2.2.1. Application of Design Control 
The desire to translate university led research to clinically viable technology has been 
the focus of intense concern for over two decades [2], [3], [27]. A number of models have 
been developed to align new product development with this desire to bring ideation to 
market faster and more effectively [1], [3], [17], [21], [28], [29]. The design process is 
often represented as a simplified waterfall diagram that illustrates the iterative design, 
verification and validation activities (see Figure 2.3). However, this model lacks the 












Figure 2.3 Application of design controls to waterfall design process [20]. 
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Quality function deployment (QFD) and “house of quality” methods which are 
well documented, aim to map the “voice of the customer” to specific plans and 
parameters that fulfil them [2], [26]. QFD uses matrices that include customer and 
technical information to build a comprehensive understanding of the patient needs. 
QFD can provide a partial overview of the development model and provides a clear 
understanding of the operational definitions and device requirements. However, QRD 
does not provide a complete picture of the design process and thus was not 
incorporated as part of this work [2]. 
One of the most notable process models developed is the stage-gate process [1]. 
Despite there not being a universally applied process to medical device design, 
Pietzsch et al (2009) carried out a systematic review of existing models and proposed 
a stage-gate process based on best practice with input from over 80 seasoned 
commercialisation and regulatory experts [2]. Pietzsch et al (2009) concluded that a 
linear stage-gate model provides a comprehensive description of the activities and 
outputs associated with the development process. Therefore a stage-gate model for 
medical device development, adapted to the academic setting from Pietzsch’s high-
level representation of development phases [2], was developed and expanded upon as 
part of this work. 
2.2.2. Design Control Overview 
The design control process developed as part of this work follows a linear five-
phase approach to the design and development of medical devices [2]. A standard 
operating procedure has been developed (SOP 7.3A Design Control) to describe the 
design control procedure which will be further explored as part of this chapter. The 
phases bridge raw research with device development, beginning with initial concept 
generation and project approval and concluding with product release (see Figure 2.4). 
Although based on the development phases described by Pietzsch et al (2009), the 
author has modified the order and phase deliverables based on the experiences built 
up in the Biomedical Design Research Group. Furthermore, the author has broken 
each of the phases down into an easy to follow roadmap to focus the reader to follow 
a logical ordered approach to executing all the key phase deliverables.  
While this chapter highlights each of the five phases of the design control process 
and emphasises some key associated activities, it is not the intention of universities to 
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manufacture and sell medical devices and therefore it is unlikely that an academic institute 
will progress beyond the outputs of Phase III; Design Development and Verification (i.e., 
a reasonable endpoint for academic projects is up to and may include clinical evaluation, 
without regulatory approval or commercial launch). Despite this, it is essential that 
academic projects with commercial merit and which aim to validate technology in a 
clinical investigation, comply with the essential quality requirements of the national 
competent authority. Furthermore if the intention is to licence the technology to a third 
party or to establish a spin-out entity to commercialise the invention, a QMS which 
accounts for product development from concept stage right through to design transfer and 
product launch, is essential for regulatory compliance and enhances the commercial 
attractiveness for partners and potential licensees.  
 
Figure 2.4 Product development process flow. 
Each of the five phases illustrated in Figure 2.4 will be described in more detail in the 
following sections. At the completion of each phase, the design team convene to review 
the progress before making a decision to proceed with the activities in successive phases. 
However, it should be noted that although the phases are described in discrete steps, the 
iterative process of device development, particularly with mechanical medical devices, 
does not always follow this idealised linear approach, but may overlap between the phase 
boundaries [2]. This typically manifests itself when certain activities such as market 
analysis have advanced towards a later phase, while activities of the present phase may 
need to be repeated (e.g. prototype development). It should also be noted that despite 
focusing on mechanical examples of medical device development, the same phase 
deliverables may be applied to the application of software development. Physical 
requirements are replaced with software requirements specifications and robust design 
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and reliability testing is replaced with performance predictability and good coding 
practices [28]. However, for the purposes of this work, the author has focused on 
hardware development. The activities and phase exit decisions at the end of each phase 
are summarised in Table 2.1. 
Table 2.1 Activities and exit decisions associated with the five-phase design control process 
adapted from Pietzsch et. Al. (2009) [2]. 
 
Phase I Phase II Phase III Phase IV Phase V
Clinical need and problem 
statement definition.
Project core team selection, 
develop project timelines and 
milestones.




Complete transfer of the 
design into production and 
produce pilot batch.
limited market release.
R&D - Define design criteria 
and generate early concept 
solutions, early stage 
technical risk assessment.
Translate the defined user 






Complete final design 
validation (clinical, design, 
process etc.) and assure that 
design outputs satisfy inputs.
Initiate post-market 
surveillance.
Commercial - Financial and 
funding requirements, market 
size analysis, commercial 
opportunity, competitive 
analysis, SWOT analysis.
Initiate documentation - 
Design Development Plan, 
Device Master Record, 
Design History File, Risk 
Management Plan etc.
Update risk assessment 
(DFMEA) and implement 
risk controls/mitigations. 
Complete DHF, DFMEA, 
DMR, Technical File, process 
risk analysis, risk 
management review etc. 
Sales team and physician 
training.
Legal - Intellectual property 
(IP) landscape review
Build and evaluate early 
stage prototype (bench-top, 
animal testing, physician 
evaluation)
Create verification and 
validation (V&V) test matrix 
and approve testing protocols
Develop product branding, 




Reimbursement - Early 
stage regulatory plan and 
reimbursement strategy.
Expanded IP landscape 
review, verify freedom to 
operate. [Optional: provisional 
patent filing]
Develop functional prototypes 
for V&V by end users in a 
simulated/pre-clinical setting 
[Optional: plan clinical 
investigation].
Finalise sales and market 
launch strategy. Finalise 
reimbursement strategy.
Continuous improvement 
programs and update 
design/process control as 
needed.
Initiate risk analysis (e.g. 
Design Failure Mode and 
Effect Analysis (DFMEA)).
Create process validation 
plan.
Finalise manufacturing and 
operations launch preparation 




requirements and strategy for 
clearance/approval.
Confirm intellectual status. 
[Optional: PCT Patent filing]
Complete regulatory 
submissions and obtain 
regulatory approval to market 
device.
 Initiate business plan. Update technical documents 
and business plan 
Build product inventory / 
Mfg. scale up.
There is a market 
opportunity.
Product design requirements 
are fully specified and 
prototype units have been 
approved by a physician.
Design outputs satisfy design 
inputs - Reached design 
freeze.
Validation testing shows that 
the device conforms to user 
needs and requirements.
The market impact is 
determined (i.e., disruptive 
vs. incremental technology).
The product offers a real 
value proposition which 
benefits the customer.
The device has an acceptable 
risk design risk level.
Verification testing shows 
that the design outputs satisfy 
design inputs.
Project risk from a 
regulatory, IP, technical and 
competitive perspective is 
acceptable.
The device's technical 
feasibility is proven and 
optimised.
Device can be developed 
from an IP perspective (i.e., 
no IP infringements).
Device is ready and cleared 
for launch, from both an IP 
and regulatory perspective.
The regulatory strategy is 
feasible (device classification 
and route to market 
clearance).
Manufacturing and value 
chain confidence has been 
established.
The device is ready for pilot 
product and final validation 
before regulatory submission.
Design transfer is complete - 
drawings to manufacturing 
specifications.
Device is ready to transfer 
from concept to active 
project status.
Process and design risk 
assessments are acceptable 
(DFMEA, PFMEA).
Sales/distribution partners are 
equipped to sell product to 
physicians, first customers 
have been identified.
Inventory levels are 










Phase I facilitates early stage research and concept development outside of any formal 
design controls and allows researchers to explore different projects at a conceptual basis 
before committing it to a formal design process. Phase I is also used to explore the 
commercial viability of a concept which critically aims to solve an end-user identified 
need. New projects may be presented from clinical needs identified by physicians/end 
users, or may come about from identifying a gap through related research and/or literature 
review. At the conclusion of Phase I, the project Principal Investigator (PI) makes a 
decision whether or not to pursue the project towards a commercial or clinical evaluation 
endpoint, to terminate the project, or simply to pursue the project solely as an academic 
research topic (see Figure 2.5).  
 
Figure 2.5. Phase I related activities and associated road map. 
2.3.1. Phase I Activities 
The Phase I activities, as summarised in Table 2.1, involve clearly defining the clinical 
need, carrying out some early stage concept generation, and evaluating the commercial 
opportunity.   
Clinical Need Definition - Every project should begin with a clear and definite 
clinical need. Verification of the clinical need may involve direct observation, by 
speaking with clinicians, surveying end users in a clinical setting, carrying our literature 
reviews, engaging with patients and hands-on personnel (nurses, lab technicians), and 
assessing existing technologies that aim to address the clinical need [2]. Once the need 
has been verified, it should be summarised in a succinct problem statement. Examples of 
end-user identified clinical needs and problem statements will be presented in the 
following chapters. 
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Early Concept Generation - Once a clear clinical need has been defined early 
solution generation may begin. Typically concept generation is not addressed until the 
second phase of the device development process [2]. However, in this work it was 
found that by brainstorming and coming up with solutions at this very early stage, the 
inventive process is free from burdensome intellectual infringement considerations 
and market constraints, resulting in a much more diverse range of solutions. The 
number of solutions subsequently converge on review of intellectual property, 
competing technologies, regulations, human factors, clinical and technical risk, design 
manufacturability, and market constraints (e.g., manufacturing costs and potential 
gross margins). Clinician involvement and core group experience of potential design 
for manufacture considerations are key to reducing the number of solution. Tools such 
as TRIZ, which will be discussed in the next paragraph, may also be used to converge 
to a solution. Ultimately a team effort between the inventors, the Principal Investigator 
and the clinicians will decide on what solution should be formally introduced through 
the design process. 
The concept generation for the projects featured in this work initially occurred as 
part of the UCC BioDesign module described in Chapter 1. One brain-storming 
technique used by the BioDesign groups is the Theory of Inventive Problem Solving 
(TRIZ) [4]. TRIZ was first published in 1946 by Genrich Altshuller [30] and is used 
extensively across many industries with increasing interest to universities [31], [32]. 
Altschuller realized that he could syphon the knowledge from the patent database to 
reduce the ideation process to a step-by-step approach based on the application and 
category of project scope. The TRIZ process begins with an ideation brain storming 
session before employing a contradiction matrix to create an array of solutions from 
forty inventive methods inherent to TRIZ, and finally converging on a preferred 
solution(s) [4], [30], [31]. The TRIZ technique towards ideation is well documented 
[33] and is not presented as novel in this work. However, TRIZ was employed for 
early concept generation of the projects described in Chapters 3-5 as part of their 
involvement in the BioDesign module and is proposed as a key brainstorming tool 
during phase 1 of the design control process. 
Preliminary Market Assessment – The preliminary commercial opportunity 
assessment involves a top level assessment of the market size (broken down into 
indications of use and geography) and barriers to market entry, analysis of the 
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proposed solutions’ strengths, weaknesses, opportunities and threats (SWOT) [34], 
product positioning and launch strategy (e.g. target customers, target markets, possible 
route to market), and determination of ideal price point to make the greatest market impact 
[2], [28]. A review of estimated funding requirements may also be carried out at this point. 
This early stage market assessment will be used to generate the basis of the business and 
value proposition for the product. In order to present a more succinct view of the 
commercial opportunity of the three devices presented in this work, Chapters 3-5 present 
the market opportunity unique to each device in a single section at the end of each chapter.  
Preliminary Legal Assessment – Now that a solution has been proposed, the 
researcher can have a much more critical review of the intellectual landscape. Tools such 
as Google Patents1, Patent Lens2, European Patent Office3 and US Patent Office4 are 
useful for reviewing prior art surrounding the proposed design and intention of use. Patent 
law varies between jurisdictions but usually requires that, for an invention to be 
patentable, it must be: 
 Novel (i.e., must have at least some aspect which is new)  
 Non-obvious (in US patent law) or involve an inventive step (in EU patent law) 
 Useful (US patent law) or be susceptible to industrial application (EU patent law 
[35]) 
Judging patentability is performed by a patent examiner on official examination of a 
patent application. However, on completion of the prior art review, an opinion can be 
sought from an IP attorney before filing a provisional patent to secure the proprietary 
filing date on the disclosure. King and Fries (2009) describe the complete patent process 
in more detail while also elaborating on other forms of legal protection including 
copyright and trademarks [26]. 
On review of the prior art, design changes may be required to avoid potential 
infringements. An example of when design modifications were required can be seen 
during the design evolution of ProDrual, where the original BioDesign concept was 
changed on recognition of possible IP infringements as part of this work (see Chapter 4).  
                                               
1 www.google.com/patents 
2 www.lens.org 
3 www.epo.org  
4 http://www.uspto.gov/patents-application-process/search-patents 
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If on further examination it is found that the team cannot overcome core claims of 
a competing patent but would like to pursue a solution with clear benefits and 
additional functionality over an infringement, it is still possible to acquire the licence 
for the patent in question downstream provided the resources are available and the 
justification is compelling. However, in practice, higher level institutional funding is 
often sourced from government state aid bodies and the technology development is 
protected by the appointed Technology Transfer Office (TTO) of the institute. Neither 
the funding bodies nor the TTO would be inclined to support a project without clear 
sight to clean IP protection. Therefore, novelty and freedom to operate often decides 
the continuation of research projects in the university setting. 
Preliminary Regulatory Assessment- The purpose of a regulatory assessment is 
to identify the regulatory pathway for market approval in both Europe and the USA. 
As described in Section 2.1, the EU and the USA require different approaches towards 
market approval and device classification. Once the device description and intended 
use are defined, the FDA 510(k) premarket notification database may be used to 
identify the FDA product code applicable to the device. For example, in the case of 
SafeTrac, the FDA product code BSR and corresponding regulation number 868.5790 
for tracheal tube stylets, would indicate that SafeTrac may be classed as a Class 1 
device (see Chapter 5). Once the device has been classified, the route to FDA 
clearance is determined (e.g. 510(k) or PMA). 
In Europe the Medical Device Directive (MDD) 93/42/EEC Annex IX classifies 
devices as Class I, IIa, IIb and III. In the case of SafeTrac, an invasive device for 
transient use, the device is Class I in accordance with Rule 5. Depending on the device 
classification, the MDD then outlines the route to CE conformance. 
Market Requirement Specification (MRS) – The MRS compiles the results of 
the clinical need definition, concept solution and intended use, market analysis, 
regulatory pathway and legal review. The MRS is presented to the project Principal 
Investigator who will make a decision of whether or not to formally pursue the project 
(i.e., proceed to Phase II) based on whether or not a viable solution has been presented 
with a clear market opportunity and acceptable risk and regulatory assessment (see 
Table 2.1). The content of the MRS may also be used to source funding to support the 
next phase of project development. In the case of the SafeTrac project, the MRS was 
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used to secure an Enterprise Ireland Feasibility award to develop the commercial 
opportunity as well as engaging with a number of esteemed key-opinion leaders for 
clinical feedback (see Chapter 5). 
 
Phase II begins once a project is committed to the quality management system and 
designates a formal “start date” of design controls. Phase II, which is entitled Feasibility 
and Project Planning, is concerned with initiating design records, developing a plan for 
product development, and evaluating design prototypes for technical feasibility with 
continuous feedback from one or more clinical mentors (see Figure 2.6). 
2.4.1. Phase II Activities 
The first activity in Phase II, as listed in Table 2.1, involves selecting a core team and 
setting out general project timelines and goals. The team selection will depend on the 
complexity of project and financial resources but should at least comprise of one or more 
researchers (typically a final year undergraduate or postgraduate student), a Principal 
Investigator (supervising lecturer), and a clinical mentor. It is imperative to success that 
the team should possess multifunctional skills and capabilities, have a common purpose, 
engage in regular communication with shared resources, and draw on outside expertise 
and resources as required. The composition of the team, project timelines and key 
milestones are outlined in a Design and Development Plan. Once formed, the team should 
begin to document design activities through initiation of design records such as the Design 
History File which will be continuously updated until final production and market launch. 
 
Figure 2.6 Phase II activities and associated roadmap. 
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Design History File (DHF) – During Phase II, the DHF will be initiated. The DHF 
is mandated by both the FDA and MDD and contains or references the records 
necessary to demonstrate that the device was designed and developed in accordance 
with the approved design plan and the regulatory requirements. A check list for the 
design file is available in Appendix 3. The completed DHF may include the following: 
 Detailed design and development plan specifying design tasks and deliverables as a 
“living document,” usually in several iterations; 
 Copies of approved design input documents and design output documents; 
 Documentation of design reviews; 
 Verification and validation documentation; and 
 Copies of controlled design documents and change control rationale and records, 
when applicable. 
The outputs from the DHF are the Technical File (TF) (or Design Dossier for 
Class III devices) which is required for CE Marking (MDD 93/42/EEC), and the 
Design Master Record (DMR) as mandated by the FDA (see Figure 2.7). Both the 
DMR and TF contain all of the device specifications and procedures necessary to 
manufacture the final product with elements from the DHF. They also demonstrate 
compliance with the list MDD Essential Requirements (for that product), and the 
company's “Declaration of Conformity” for that product [20], [36] (see Appendix 2). 
SOPs 7.3B and 7.3C developed as part of this work describe the requirements for the 
DHF and TF respectively.  
 
Figure 2.7 Example of records contained within the design history file and its associated 
market specific outputs. 
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Design and Development Plan (DDP) – One of the first documents produced as part 
of Phase II is the DDP which will be located in the DHF. Design plans describe or 
reference design and development activities and define responsibility for implementation. 
The DDP may contain Gantt Charts, defined milestones, tasks, timelines and 
responsibilities. The DDP will refer to key elements of design control such as defining 
design inputs and design outputs, carrying out design reviews, and initiating risk 
management activities. The DDP will also outline a plan for design verification and 
design validation. However these activities will not take place until later phases [20]. The 
plan is a working document that may be updated as the project progresses. 
Design Input – Inputs define the physical and performance requirements of a device 
to be designed. The design input requirements are generated from the clinical needs and 
the intended use as described in Phase I, as well as meeting the requirements of any 
applicable standards mandated in the market(s) in which the product may be used. 
Design Output - Design outputs are used to evaluate the device’s conformance to 
design input requirements. Design outputs describe the acceptance criteria and identify 
the critical performance and safety criteria essential for the proper functionality. Outputs 
are confirmed by verification and validation activities which will be discussed in later 
sections. For example, in the SecuRetract project, a design output may be the measured 
burst rating of the modular balloons which fit within the limitations of the design input 
requirements.  
Design Reviews - Formal documented reviews of the design results are to be planned 
and conducted at appropriate stages of the device's development (e.g., at the end of each 
phase as well as on a regular continuous basis). Design review participants can include 
outside representatives who may provide expertise or input regarding the phase of design 
(e.g., clinical mentor during reviews involving decisions critical to end-user experience). 
An individual(s), who does not have direct responsibility for device design is also 
required during formal design reviews as an independent “voice” [36]. 
Risk Management Plan (RMP) – Risk management should also be initiated during 
Phase II. The design, production and use of a medical device inherently entails some 
degree of risk. The objective of risk management, as described in the ISO 14971 – 
Medical Devices Application of Risk Management, is to minimise use-related hazards, 
and to assure that end-users are able to use the medical devices safely and effectively 
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throughout the product life cycle. The overall process to risk management is described 
in the SOP 7.1 Risk Management, based on the requirements of ISO 14971 (see Figure 
2.8). 
 
Figure 2.8 Risk management process overview. 
A tool used by the Biomedical Design Research Group to identify, analyse, 
evaluate and control risk is Design Failure Mode and Effect Analysis (DFMEA). 
DFMEA is a well-established step-by-step approach for identifying all possible risks 
of failure in a design process and scoring the risk based on the potential severity of 
the adverse event and the likelihood of occurrence (see Figure 2.9). DFMEA is also 
used in the product design development, as risk identification outputs are used as 
design inputs. The DFMEA as described in SOP 7.1 developed as part of this work, 
grades both the severity and occurrence out of five where a score of five would 
indicate a life threatening injury on the severity scale and a score of one would indicate 
negligible or no adverse health consequences. A partial example of a DFMEA as 
completed for the ProDural project may be seen in Appendix 4. 
 
Figure 2.9 Simplified qualitative version of the severity and occurrence scale (A, B) used 
by the BDRG to assess the risk level (C) of a potential hazard. 
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Prototype Build and Assessment – Once all the controls have been established, 
further design development can proceed utilising the design inputs and risk assessment 
outputs as described earlier. The following chapters will focus on the design development 
and prototype testing through an iterative design process with continuous feedback from 
clinicians. The majority of the design development and testing activities presented in 
Chapters 3-5 were carried out during Phase II of the respective projects. The object of the 
testing in this phase, which typically involves physical bench-top and simulated 
evaluations (optional: pre-clinical investigations), is to demonstrate proof of concept and 
to establish technical feasibility. These tests provide confidence to the project team that 
the proposed solution performs as intended before investing in production quality models 
to carry out design verification and validation activities as will be described in later 
sections. 
Business Proposal Update – Phase II will also involve more in-depth research into 
the overall value proposition from a commercial, IP, and regulatory perspective 
continuing from Phase I. This updated review, along with demonstrating technical 
feasibility, may be combined in order to apply for further financial support to continue 
the developmental process. In Ireland, the Enterprise Ireland Commercialisation award is 
ideally suited to support R&D activities as well as achieving commercial milestones for 
higher level institute research projects with real commercial promise and intent. The 
SecuRetract leveraged this source of funding to support its ongoing development over the 
course of this PhD program (see Chapter 3).  
At the conclusion of Phase II, the Principal Investigator and project team will make a 
determination on whether or not to proceed to the next phase of project development 
whilst considering the phase gate decisions as listed in Table 2.1. 
 
Phase III defines the activities and outputs associated with the design development 
and verification phase. Phase III takes the basic prototypes from the previous phase and 
refines same to comply with design for manufacture (DFM). This would normally involve 
a level of engagement with a third party supplier or manufacturer to ensure industrial 
compliance. The final device function, performance and safety requirements will be 
specified and the regulatory, commercial and clinical activates will be fully defined (see 
Figure 2.10). Whilst DFM is discretely addressed in Phase III, it is in fact considered 
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throughout the design and development process. The final DFM in phase 3 comes 
after functional prototypes have been evaluated in a simulated or clinical setting thus 
confirming that the design meets the user needs. Biocompatible materials should 
already have been identified and the changes if any are required should simply 
accommodate the manufacturing process or improve the manufacturing process 
(reduce parts, reduce complexity, modify drafts, etc.) while not changing the overall 
functionality of the device. Once the DFM is complete the device has reached design 
freeze and any future design changes are subject to formal change control.  
 
Figure 2.10 Phase III activities and associated roadmap. 
2.5.1. Phase III Activities 
The principal R&D activity during Phase III involves translating the design inputs 
into detailed requirement specifications including labelling and packaging 
specifications and reaching design freeze. Design freeze denotes that point at which 
the team formally approves a design and any further design changes will have to 
undergo design change controls. Prior to approval of design freeze, functional 
prototypes are produced working with qualified suppliers and design verification is 
carried out. Design validation activities may occur during this phase (e.g. if the 
functional prototypes are equivalent to final production product standards), but 
typically occurs in Phase IV as discussed in Section 2.6.1.  
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Design Verification - Design verification confirms that the specified requirements 
are fulfilled (i.e., design outputs meet design inputs). Design testing to demonstrate 
technical feasibility can involve simulated and physical experimentation of prototypes 
during the design iteration process. However, formal design verification for clinical or 
regulatory approval must be performed on products as close to final production as 
possible. In other words, the legal manufacturer (i.e., the licenced company who aims to 
commercialise the device), must demonstrate the prototype/product used during design 
verification is substantially equivalent in material, functionality, and performance as well 
as similar methods of packaging/labelling and sterilisation to the final product which will 
be placed on the market. Verification may involve biocompatibility, sterility, functional 
testing, packaging / shaking / dropping / shipping and accelerated ageing studies. 
Electronic products have their own series of tests required by various standards for safety, 
electromagnetic compatibility (emitting and receiving) and similar [36].  
Design Changes – Once a design has been formally approved by the PI and team, a 
design control system must be implemented to control any further modifications to the 
verified design. There are the two principal administrative elements of controlling of 
design changes:  
 Document control - involves tracking documents associated with the design 
and listing their status in the revision history. These documents refer to all 
design records, drawings, and specifications which characterise the design. 
 Design control - involves recording deficiencies and corrective actions that 
arise from verification and review of the design and tracking their resolution 
prior to design transfer. 
Both of these elements are documented in the device’s Design History File. 
The complete list of activities conducted during Phase III are itemised in Table 2.1. 
Many of these activities involve updating project records from Phase II (e.g. DDP, RMP, 
DHF, and Business Plan). During Phase III, the team may opt to further their IP position 
by filing a PCT application. The Patent Cooperation Treaty (PCT) provides international 
patent protection by simultaneously seeking protection for an invention in 148 countries 
throughout the world. Subsequent market specific patents may be required (i.e. patent 
nationalisation). 
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The decisions at the phase gate are listed in Table 2.1 and mainly focus on whether 
or not the presented design is ready for pilot production and final validation from an 
IP, business and technical risk perspective.  
 
Phase IV relates to final product validation which essentially provides the 
evidence required for full product launch. Typically this phase involves validation of 
the device in a clinical setting. The final pre-launch activities such as obtaining 
regulatory approval, finalising reimbursement plan [37], go-to-market strategies, and 
full process qualification will also be carried out during this phase (see Figure 2.11). 
As discussed in Section 2.2, it is unlikely that university projects progress into Phase 
IV as the activities therein are more associated with manufacturing and clinical 
validations. However, certain projects, particularly software related with less onerous 
validation criteria and investment requirements, may proceed to Phase IV.  
 
Figure 2.11 Phase IV activities and associated roadmap. 
2.6.1. Phase IV Activities  
The enumeration of activities associated with Phase IV are listed in Table 2.1. 
These activities focus on final preparation of the device for market launch and involve 
completing final design and process validation, closing out the Design History File, 
acquiring regulatory clearance and finalising sales strategy.   
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Design Validation - Design validation confirms by examination and provision of 
objective evidence that the device conforms to user needs and intended use. Design 
validation is to be performed on pilot production units, lots, batches or any of their 
equivalents under defined operating conditions (use of early stage prototypes are to be 
avoided since this weakens the validation purpose). Validation will include testing of 
production units under actual (clinical) or simulated use conditions, with such products 
having been fabricated in a certified production environment. Failure to comply with 
validation requirements can result in future product recalls [36]. SOP 7.3F Design 
Verification and Validation developed as part of this work outlines the procedure for 
verification and validation activities.  
Design transfer – Design transfer is the collective set of activities conducted to 
transfer the device from R&D to manufacturing. The transfer activities ensure that the 
functional specifications of the device are properly transferred into production 
specification. The activities confirm that the device manufacturing process is repeatable 
and produces units that are safe and effective for their intended use. 
Regulatory Submission – As described in Sections 2.1, different routes are required 
for regulatory approval depending on the intended market of sale. For both CE Marking 
and FDA approval, documents must be compiled that define the final product. The 
Technical File (CE) and Device Master Record (FDA) detail for that product [36]: 
 General Information / Product Description / EC Authorized Representative, 
 Classification Determination (93/42/EEC Annex IX [select applicable rule]), 
 Essential Requirements (93/42/EEC Annex I), 
 Risk Analysis, 
 Product and labelling Specifications, 
 Design Control, 
 Clinical Evaluation (93/42/EEC Annex X), 
 System Test Reports / Functional Bench Testing, 
 Lab Testing (e.g., cytotoxic, haemolysis, sensitization, biocompatibility testing), 
 Sterilization validation and Packaging Qualifications, 
 Manufacturing process and qualification, 
 Declaration of Conformity (93/42/EEC Annex II, V, VII), 
 Appendices (further supporting information / details on the above). 
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Once all validation and design transfer activities are completed, and the device has 
been cleared for launch from both a regulatory and IP perspective, the project may 
now proceed to the final phase associated with market launch. 
 
The final phase, Phase V, concerns product launch and continuous post launch 
surveillance to measure and maintain quality and regulatory compliance (see Figure 
2.12). This phase signals the end of the R&D activities for a product and focuses on 
commercialisation and unit sales. None of the devices discussed in this thesis have 
progressed to Phase V. 
 
Figure 2.12 Phase V activities and associated roadmap. 
2.7.1. Phase V Activities 
The activities related to the final phase of the design control process are listed in 
Table 2.1. Product release typically would involve a phased approach starting with a 
limited market release (LMR) to target high-volume medical centres to obtain early 
market feedback from end users, as well as securing distribution partnerships. 
However, these relationships should have already been formed during Phase IV. Other 
product release activities include physician training, continued sales effort, continuous 
improvement programs and implementing post market surveillance.   
Post-market surveillance - Surveillance must be implemented and maintained 
through collection of quality, safety and performance information to evaluate any 
potential or early signs of unexpected results for marketed products. This includes, 
but is not limited to, risk assessment, customer surveys, legal feedback, complaint 
history, clinical data, internal auditing or regulatory actions. Post launch changes to a 
released device design may adversely affect its safety or performance and therefore 
an adequate impact assessment and a review of the design changes is required to 
ensure that all proposed changes do not affect the product safety and efficacy. All 
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changes to the design or production of a marketed device must be notified to the 
regulatory authorities for approval. 
 
Industrial quality management systems and linear stage-gate models for medical 
device design control have been extensively discussed in literature [1]–[3], [17], [26]–
[28]. However, no one system can be applied across all sectors and applications. 
Therefore a unique QMS with SOPs and template records has been developed to suit the 
needs of the Biomedical Design research group. This chapter briefly outlines the design 
control process being implemented at the UCC BDRG as developed as part of this work.  
The five-phase process described herein takes the conventional high level 
development process [2], [3] and expands on each phase through the development of 
milestone orientation flow charts. The nuances of the presented process include an earlier 
emphasis on concept generation to facilitate student ideation prior to development 
activities, utilising institutional procurement processes for supplier management to offset 
approved vendor requirements, exploiting external funding to support prototype and 
business development and leveraging in-house resources and expertise to expedite 
fabrication and verification activities. However, academic led research can only go so far 
within the confined scope of practice of the institution. Therefore, to fully execute the 
design control process to design transfer and product release, a licencing agreement to a 
spin-out entity or established strategic partner will be required. That said, having the 
systems and procedures in place to fulfil the regulatory requirements, reduces the gap 
between stand-alone academic research and industrial application, and serves to heighten 
the commercial prospect and attractiveness of university led research. Furthermore a 
controlled system lends a structured roadmap to expedite project development and 
provide structure to academic researcher.  
This chapter also illustrates the importance of implementing such processes and 
systems in the highly regulated medical device sector. The implications of not introducing 
design controls has been analysed by the FDA (64 FR 52605, October 07, 1996) who 
found that preceding the introduction of design control requirements, 44% of the quality 
problems that led to voluntary recall actions between October 1983 and September 1989 
were attributed to errors of faults designed into the particular device which may have been 
prevented by adequate design controls [38].  
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Currently several of the document control and design control procedures have 
been issued and are being implemented through device design development. 
However, as the SOPs are being implemented, the author and team are discovering 
new ways to improve the procedures to reduce the workload and improve compliance. 
It is the overall goal of the BDRG to share a tried and proven QMS, appropriate to the 
requirements of the university setting and which comply with the regulatory 
requirements for design control, with the wider academic community. This will 
require introducing complete projects through the system and receiving independent 
review of the controls before an effective system may be disseminated.   
Three projects, SecuRetract, ProDural and SafeTrac, were developed in so far as 
possible, within the design control process as outlined in this chapter. Each of these 
projects originated from end-user defined clinical needs as part of the UCC BioDesign 
Module with commercial potential from the beginning. It should be noted that as a 
result of building the quality management system, and developing the design projects 
in parallel as part of this work, some of the developmental activities were completed 
before the corresponding controls were established. However, at all points throughout 
the projects, careful notes were retained and dated, archiving all the key design 
milestones. The current phase of developed of each of the project is illustrated in 
Figure 2.13. 
 
Figure 2.13 Current phase of development of the three projects developed within the design 
control process. 
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In the interest of continuity of thought and ease of presentation, the three projects 
discussed in the following chapters follow a logical progression from their respective 
clinical need definition to their current stage of development and commercial opportunity, 
with an emphasis on novelty, design evolution, prototype development, and evaluation 
techniques. At the conclusion of each chapter, a reflection will be made to consider the 
project’s development within the controlled framework and will discuss the benefits and 
disadvantages of the proposed design control process. 
  





Chapter 3 – SecuRetract laparoscopic Retractor 
37 
 
 SecuRetract: an Atraumatic 





One of the most common frustrations and complications in laparoscopic (“keyhole”) 
surgery is the seven meter long bowel migrating around the abdominal cavity and 
obstructing the surgical field of view. Thus the surgeon is prevented from carrying out 
the procedure. This problem is evident in all lower abdomen laparoscopic surgeries but 
is of particular concern in colorectal and hysterectomy procedures where the bowel is 
especially obstructive. This chapter explores the design and development of novel 
surgical instrument designed to effectively engage and retract the impeding bowel from 










The retractor project arose when two consultant colorectal surgeons, Dr Emmet 
Andrews (Cork University Hospital) and Dr Mícheál O’Ríordáin (Mercy University 
Hospital), independently proposed the challenge of small bowel retraction to an 
interdisciplinary team of engineering and medical students during the 2012 UCC 
BioDesign Module. Following an Enterprise Ireland commercialisation award, the 
project formed the subject of an MEngSc thesis by research which the author 
completed in 2013 prior to commencement of this PhD research [8]. During the 
MEngSc research, the original concept was redesigned and developed to a functional 
prototype which was then evaluated in a pre-clinical study. As a result of the study 
outcomes, the author continued to develop and to refine the design as part of this PhD 
research, within a controlled design framework, and while working closely with 
professional services to achieve a design fit for manufacture. This chapter will 
examine in more detail the unmet clinical need for bowel retraction in lower 
abdominal laparoscopic surgery, and will outline the work undertaken during this 
project to address the need, describing the design process from concept to current 
design. 
3.1.1. Laparoscopic Surgery 
Laparoscopic (keyhole) surgery was first introduced in 1991 and has quickly 
become the gold standard in minimally invasive clinical interventions [39]. The short 
term benefits of laparoscopic surgery include reduced hospital stay, less postoperative 
pain, earlier return to normal activity, improved cosmesis, and overall reduction in 
health-care costs [40]–[42]. Lower abdominal laparoscopic surgery, such as colon or 
uterine resection, is performed with the patient under general anaesthesia. Once a 
pneumoperitoneum (abnormal presence of air or other gas in the peritoneal cavity) 
has been established to 12 to 15 mm Hg with CO2 [43], a number of surgical cannulas 
(trocars) are inserted through the abdominal wall to provide surgical access.  In order 
to ensure a clear line of sight, surgeons need to remove impeding organs such as the 
distended loops of bowel from the operating view [44]. The most common method 
used to retract the bowel involves placing the patient in a steep head-down position 
known as the Trendelenburg position (TP) and using bowel graspers to manipulate 
the bowel [45]. TP involves inclination of the patient's body with his or her head down 
and legs elevated. To optimise surgical exposure, an angle of inclination greater than 
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40° may be required for several hours [45]. This allows the small bowel to glide away 
from the pelvis, creating a working space within the abdominal cavity, which in turn 
allows the surgeon to mobilise the target lesion and retrieve the specimen extracorporeally 
through an enlarged port site. Post anastomosis, the bowel is returned into the peritoneal 
cavity, and the facial defect (incision from instrument port) is closed [46]. 
3.1.2. Bowel Retraction Techniques  
Manoeuvring the seven meter long distended bowel provides one of the most common 
challenges encountered during laparoscopy [44]. By placing the patient in the TP, the 
surgeon uses gravity to retract the bowel (see Figure 3.1 A). However, prolonged TP 
significantly increases intracranial pressure and intraocular pressure due to increased 
venous pressure [47]. In addition to the circulatory effects, steep head-down impacts on 
both the cardiac system, due to increased central venous pressure, and on the respiratory 
system, by decreasing total lung volume, pulmonary compliance, and functional residual 
capacity by 20%, which may lead to hypoxia, hypercapnoea and atelectasis [48], [49]. An 
increase in cerebral blood flow pressure could also impair cerebral circulation [48]. More 
marked changes may be observed in obese, elderly, or debilitated patients. 
 
Figure 3.1 Current method to retract the bowel during laparoscopy with; A) the 
Trendelenburg position [50], B) bowel graspers being used to manipulate the tissue, and 
C) an example of trauma caused by bowel graspers [51]. 
In addition to TP, instruments are required to manipulate the bowel from the operating 
field of view. Commercially available devices are typically too small, difficult to operate, 
provide unsafe retrieval, and lack adjustability [52]. Non-crushing bowel graspers are the 
most common instrument used to manipulate and retain the internal organs (Figure 3.1 
B). The surgeon relies on the haptic feedback from the graspers to delicately manipulate 
the internal organs. However, this feedback is severely limited due to the mechanical 
friction losses and variations in the transmission of forces over the working range [53], 
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[54]. Furthermore, the relatively small tips on the laparoscopic graspers can generate 
high pressures locally on the soft tissue (up to 200 kPa) [55], [56], which may lead to 
injury or perforation (see Figure 3.1 C). Conversely insufficient force will lead to 
tissue slipping out of the graspers. The intraoperative complication rate for 
laparoscopic colorectal surgery is between 7-9% with a rate of conversion to open 
surgery of between 9-13%. The rate of postoperative complications can be as high as 
30% [57] with an incidence of postoperative ileus of between 15-20% leading to 
prolonged hospital stay [51]. One of the main causes of postoperative ileus is 
excessive force applied to tissues from conventional graspers.  
 
Figure 3.2 Commercially available bowel retractors: A) laparoscopic bowel graspers 
(Medline Industries, Inc., Mundelein, Illinois), B) laparoscopic Fan retractor (LocaMed 
Ltd., Farnham, Surrey, U.K.), C) the inflatable Endo Paddle™ retractor (Medtronic,  
Dublin, Ireland), and D) Snowden-Pencer triangular liver retractor (Cardinal Health, 
Dublin, Ohio). 
An alternative to the bowel grasper which may be classified as an instrumental 
retraction technique, is the barrier retraction method [52]. Barrier retractors are 
inserted into the body in a collapsed state, deployed within the body and either held 
by an assistant or may be fixed to the operating table. Numerous disposable and 
reusable retractors are available. The fan retractor, which was originally designed for 
use in upper gastrointestinal surgery, works by rotating a dial in the proximal end of 
the device which in turn deploys a number of blades in a fan-like pattern once placed 
intra-peritoneally (Figure 3.2 B). The fan retractor must be observed closely when 
being closed as inadvertent organ injury may occur if trapped between the retracting 
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blades. In addition, the fan retractor is made from many small components, and runs the 
risk of spoiling the operating field if breakage occurs [52]. The Endo paddle retractor™ 
(Medtronic Covidien, Dublin, Ireland), which is a type of paddle retractor, operates in a 
similar manner. The Endo paddle retractor (Figure 3.2 C) comprises an inflatable paddle 
located on the distal end of a manually operated rod. After insertion, a balloon on the 
distal end of the rod is inflated providing a relatively wide palmated anterior surface 
which creates a soft interface between the balloon and internal organs. However, the small 
bowel may slip around the edge of the inflated surface and migrate into the operating 
field. The triangular retractor (Figure 3.2 D), which is a type of snake retractor, is 
primarily used in liver retraction. The retractor comprises hinged links along its shaft that 
can be manipulated into a curved profile by rotating a hand piece on the proximal end of 
the device. The triangular retractor can fit through a 5 mm operating port. However, the 
possibility of pinching the soft tissue between its links when engaged makes the device 
unsuitable for bowel retraction. In addition, the contact area between the shaft and the 
organ is quite narrow. 
Despite their presentation as laparoscopic bowel retractors, the aforementioned 
devices do not present the critical characteristics to ensure their adoption as the standard 
of care in minimally invasive retraction [52]. The ideal retractor therefore has yet to be 
developed. 
3.1.3. Laparoscopic Colectomy  
Colectomy is a surgical procedure to remove all or part of the colon, and in extreme 
cases, the entire large intestine along with the rectum is removed (proctocolectomy). The 
laparoscopic approach towards colectomy is growing in both popularity and scope of 
indications. During laparoscopic colectomy, the bowel falls into the pelvis and must first 
be retracted in order to mobilise the blood flow to the colon before resection. As discussed 
in Section 3.1.2, this is most commonly achieved through the Trendelenburg positioning 
and utilising existing retraction techniques which are not ideal. 
The most common application of colectomy is to resect malignant tumours (colon 
cancer) arising in the wall of the large intestine or rectum, in most cases from dysplastic 
adenomatous polyps [58]. Colon cancer is the second leading cause of cancer deaths 
among men and women in the US combined. Five percent of the normal population will 
be diagnosed with colorectal cancer in their lifetime. In 2014, 71,830 men and 65,000 
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women were diagnosed with colorectal cancer in the US [59]. Globally nearly 1.4 
million new cases are diagnosed each year [60]. With 1.4 billion people currently 
overweight, incidence of colon cancer is predicted to significantly increase [61]. 
However, when detected early, it can be a treatable malignancy [62].  
 
Figure 3.3 Colorectal surgery showing an example of anastomosis on a cancerous portion of 
the transverse colon. 
Colorectal surgery is also performed to repair damage to the colon, rectum, and 
anus, caused by diseases of the lower digestive tract such as diverticulitis and 
inflammatory bowel disease (ulcerative colitis and Crohn's disease). Injury, 
obstruction, scar tissue and ischemia (compromised blood supply) may also require 
bowel surgery. Crohn's disease and ulcerative colitis, both chronic inflammatory 
diseases of the colon, affect approximately 1,000,000 young adults in the US. Surgery 
is recommended when medication fails patients with ulcerative colitis. Usually, 
surgery is drastic, removing the colon and rectum and creating an interior or exterior 
pouch to collect body wastes. Nearly 3/4 of all Crohn's patients face surgery to remove 
a diseased section of the intestine or rectum. Diverticulosis, the growth of pouches in 
the walls of the intestine, occurs in nearly 1/2 of all Americans by the time they reach 
age 60 and in practically everyone over 80. Diverticulitis may also require surgery to 
remove part of the colon if there have been recurrent episodes with complications or 
perforations [63]. 
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3.1.4. Laparoscopic Hysterectomy  
Laparoscopic hysterectomy is the surgical removal of the uterus, disconnecting it from 
its attachments, using long thin instruments administered through laparoscopic ports (see 
Figure 3.4). Like laparoscopic colectomy, the first step 
in removing the uterus located in the pelvis, is to 
retract the distended loops of the bowel from the 
operating field of view. In 70% of cases the surgical 
site is either partially or completely obstructed by the 
small bowel, making the procedure not feasible 
without retraction [59]. 
Hysterectomy is the second most commonly 
performed surgical procedures undergone by women 
in the US with 570,000 cases performed in 2006 [64], 
and accounts for $5 billion annually in US health care 
spending [65]. More than 80% are for treatment of 
benign diseases, such as leiomyoma, abnormal uterine bleeding, pelvic organ prolapse, 
and endometriosis. Endometrial cancer is the fourth most common cancer in women [59]. 
Approximately 40% of endometrial cancer patients need to have a para-aortic 
lymphadenectomy, which involves surgery in the area of the aorta, and vena cava. 
Minimally-invasive laparoscopic surgery has been demonstrated to be an effective tool 
for this procedure. Its use has been associated with decreased postoperative morbidity, 
pain, recovery time, operative time, and complications as well as increased patient 
satisfaction and quality of life [66].  
For both laparoscopic colectomy and laparoscopic hysterectomy, which are two 
examples of lower abdominal procedures which require extensive bowel retraction, an 
effective solution which gently and effectively removes the bowel from the operating 
field whilst reducing the angle of table tilt, has yet to be developed.  
3.1.5. Problem Statement 
Based on end-user feedback and the current state of laparoscopic retraction, the 
following problem statement was defined: 
Figure 3.4 Laparoscopic 
hysterectomy instrument 
positioning [173]. 
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To reduce intraoperative trauma and improve surgical access during lower 
abdominal laparoscopic surgery, in particular laparoscopic colorectal surgery and 
laparoscopic hysterectomy, by effectively and sustainably retracting the distended 
loops of the small bowel from the operating field of view. 
A list of design requirements was derived from end-user surveys, literature review 
[52] and competing technology assessment. The essential design requirements 
include: 
1. Outer diameter less than 5 mm to accommodate minimally-invasive insertion,  
2. The device should be light weight, easily deployed and easy to use, 
3. Provides a sustained and reliable field of view through retraction of the bowel, 
4. The device must be atraumatic and resist leakage, 
5. It must be ergonomically designed to optimise its operation over a prolonged time, 
6. The ability to be used in a confined space without obstructing the surgical view, 
7. Capable of removal and further reinsertion without incurring damage before disposal.  
 
The design history of the SecuRetract project has changed significantly since the 
original concept was proposed as part of the UCC BioDesign module. This section 
will summarise the prior work carried out on the SecuRetract project as part of the 
author’s MEngSc thesis (see Figure 3.5), before moving onto the additional 
improvements as part of this research [8].  
 
Figure 3.5 Design evolution overview from original concept through succeeding iterations 
as part of a research Masters. 
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3.2.1. Summary of MEngSc Development 
The retractor project became the subject of a Masters by research project supported 
by an Enterprise Ireland Commercialisation award which the author concluded in July 
2013. The MEngSc research and design concentrated on a stand-alone device with a 
control handle and curvable distal end capable of engaging and manipulating the 
distended loops of bowel and its connecting mesentery (a fold of the peritoneum which 
attaches the small intestine to the posterior wall) [5], [7], [8].   
 
Figure 3.6 Sequencing of prior work timelines. 
After an iterative design process, the final laparoscopic retractor designed as part of 
the MEngSc thesis, comprised a control handle, a central shaft, and a number of inflatable 
balloons mounted to the distal end of the device (see Figure 3.7). The design was 
produced using SolidWorks® (Dassault Systèmes SolidWorks Corp., Waltham 
Massachusetts) before developing prototypes in-house using a Dimension Elite 3D 
Printer (Stratasys Ltd., Minnesota, USA), and a HURCO CNC machine (Hurco 
Companies, Inc., Indianapolis).  
 
Figure 3.7 Retractor prototype pictured in its inflated, curved position with non-return 
inflation valve. 
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The distal end of the device comprised five modular dilation balloons mounted in 
series to co-axially extruded tubing which sheaths over the leaf spring and central 
shaft providing an air tight encasing. The co-axial configuration facilitates inflation 
of the dilation balloons and the modular balloons provide a large cushioned surface 
on retraction (see Figure 3.8 B). The balloons and tubing fabrication was supplied by 
Creagh Medical Ltd., Co. Galway, Ireland. 
  
Figure 3.8 A) Spring beam design pictured in the straight and curved positions, and B) 
modular balloon design pictured in the straight inflated and deflated positions [5], [7], [8]. 
The material used to create the printed handle prototypes was acrylonitrile 
butadiene styrene (ABS). ABS is a common thermoplastic used in rapid prototyping 
with a glass transition temperature of approximately 105°C. The handle design 
comprised a thumb dial with an axis of rotation parallel to the shaft. As the dial is 
rotated it axially displaces a lead screw fixed in rotation which further displaces a wire 
that terminates at the distal end of the leaf spring. The degree of curvature of the distal 
end may be controlled by the thumb dial up to a fully curved position, creating a radius 
of curvature of approximately 60 mm.  
3.2.2. MEngSc Prototype Evaluation  
The displacement of the spring beam was simulated using the finite element 
analysis (FEA) tool, Strand7 (Strand7 Pty Ltd., Sydney, Australia) to characterise its 
performance. The simulated FEA model used geometrical and material inputs 
matching the properties of the spring beam [5]. The analysis determined that the beam 
would experience a maximum stress of 450 MPa on deflection, which is 1.3 times less 
than the yield strength of the carbon steel (586 MPa). The analysis also predicted a 
linear relationship between the axial force applied to the modelled internal wire and 
the corresponding deflected angle (see Figure 3.9) 
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Physical bench-top experimentation subsequently corroborated the simulated results 
(Figure 3.9 B). It was determined that an axial tensile force of approximately 20 N is 
required to deflect the beam about an angle of 80 ± 3° from the normal position. The 
restoring force required to return the beam to the straight position measured in excess of 
5 N which exceeds the maximum pull force required to stretch the mesocolon for 
dissection as reported by Visser et al. (2002) (average pull force to stretch the mesocolon 
2.4 ± 1.1N, maximum force measured was 4.7 N) [67].  
 
Figure 3.9 A) simulated FEA model of the axial tension experienced by the internal wire 
used to displace the leaf spring, and B) simulated and experimental axial tensile force 
comparison plot [5]. 
The balloons were also evaluated using bench-top experimentation. The preferred 
inflation diameter of 30 mm occurs at an inflation pressure of approximately 260 mmHg 
with a combined surface area of approximately 250 cm2. The burst pressure was rated at 
approximately 428 mmHg for an elongation at break of 800%. This results in a tensile 
strength of approximately 15.6 MPa [5], [8]. 
3.2.3. Pre-Clinical Investigation 
The MEngSc prototype was laparoscopically deployed in vivo in a porcine model and 
its performance was recorded using laparoscopic video. The pre-clinical animal 
investigation endpoints were technical feasibility and safety. This investigation, which 
took place in May 2013, was approved by both the Irish Department of Health and UCC 
animal experimentations ethics committee. The porcine model is a close anatomical 
model for the human digestive system, and is an ideal model for the technical evaluation 
of new medical devices in colorectal applications.  




Figure 3.10 Prototype used in a pre-clinical animal investigation. (A) External view of the 
device passing through laparoscopic port. (B) View from laparoscopic camera of the distal 
end of the retractor engaging the bowels. (C) View of the retractor’s placement around the 
bowels during a conversion to open surgery to better visualise the operation of the retractor. 
The model used was a female Landrace pig weighing 26.7kg. The animal was 
sedated for the duration of the procedure and was euthanized immediately following 
the procedure without any recovery. Three laparoscopic ports were inserted through 
the abdominal wall (2 x 5 mm and 1 x 12 mm trocars), the largest of which 
accommodated a laparoscopic camera (Olympus Evis Exera BF type 160 series) 
(Figure 3.10 A). The peritoneum was inflated to 15 mmHg CO2 with an Olympus 
UHI-3 insufflator (Olympus, Pennsylvania).  
The pre-clinical investigation was carried out by a consultant colorectal surgeon 
with over twenty years of surgical experience. The retractor was inserted into the 
upper right quadrant through a 5 mm trocar in its deflated and straight form. Once 
positioned within the peritoneal cavity, the retractor was engaged to hook around the 
bowel and its associated mesentery. The mesentery holds the bowel to the posterior 
wall, thus provides an anchoring point to retract the bowel. The device was then 
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inflated, creating a large, soft interface before withdrawing the distended loops of the 
small intestine from the pelvis to a position higher up in the abdominal cavity (see Figure 
3.10 B). The prototype was then deflated and removed back through the surgical port only 
to be repeatedly reinserted and evaluated in both the left upper quadrant and right upper 
quadrant. Further tests evaluated the effectiveness of mesentery manipulation for inferior 
mesenteric arch and lymph node access. The investigation concluded with an open 
surgical investigation to allow clear visualisation of the retraction process (Figure 3.10 
C).  
3.2.4. MEngSc Design Discussion 
Simulated and physical modelling was used to evaluate the MEngSc device design. 
The physical model closely resembled the simulated calculations reflecting the elastic 
nature of the spring steel and the tensile force applied to the internal wire. In addition, the 
engaged device commands sufficient rigidity to retract the bowel from the operating space 
(> 5N).   
The pre-clinical animal investigation proved successful in assessing technical 
feasibility of the retractor. The light weight retractor (0.085 kg) was repeatedly inserted 
through a 5 mm diameter trocar. During the study, the prototype was inflated and deflated, 
and repositioned several times without damaging the internal tissue. Initially the animal 
was temporarily placed in the Trendelenburg position, and the prototype was positioned 
to hook around and engage the mesenteric bowel. Once in place, the animal was returned 
to the supine position and the retractor successfully maintained the bowel from operating 
field of view.  
However, the pre-clinical investigation did have its limitations. Due to the subjective 
nature of this study, it was difficult to obtain quantitative data. The porcine 
gastrointestinal tract, albeit similar in anatomical make-up, was different in size and 
weight compared to a human’s. Therefore, the pre-clinical study was primarily a technical 
feasibility study of the device. The pre-clinical trial and physical evaluations identified a 
number of necessary design improvements which include device orientation, labelling 
and ergonomic modifications to the handle design which are presented in later sections. 




The bowel retraction project was continued as part of this PhD thesis which aimed 
to overcome the limitations of previous design and to develop a design for 
manufacture. The continued PhD research also aimed to carry out a more expansive 
review of the commercial potential of the proposed device as well as engaging with 
key-opinion leaders and identifying clinical champions for early device adoption. 
3.3.1. PhD Design Development 
As a result of the previously described evaluation methods, a number of design 
modifications were made to the retractor design as part of this work. The prototype 
used in the pre-clinical investigation curved about a plane parallel to the frontal view 
of the device (i.e., up-down). However, clinical feedback noted that it would be more 
intuitive if the device curved from left to right as the thumb dial was turned clockwise 
(i.e. a plane parallel to the top view of the device). It was independently noted that 
over time, the carbon steel leaf spring began to show signs of corrosion. Therefore 
stainless steel (grade 301) was sourced and the beam profile was cut from the sheet 
using a laser cutting process. 
During the pre-clinical investigation, one of the dilation balloons were damaged 
most likely due to inadvertent contact with the bowel graspers. Therefore a more 
robust balloon design was sought. A number of balloon and tubing configurations 
were explored ranging from the original spherical dilation balloons to cylindrical 
elastomeric balloons (see Figure 3.11 A-C). Highly-compliant polyurethane balloons 
were chosen as they present a number of performance related advantages. In the first 
instance, elastomeric balloons shrink to a much tighter profile in comparison with 
dilation balloons. The highly compliant nature of the balloons and tubing closely 
conforms to the curvature of the central shaft when actuated and the elastomeric 
material ensures elastic behaviour during the inflation and deflation cycles which 
allow the balloons to deflate completely and rapidly (approximately one second). The 
compliant balloons (fabricated to design specification by Creagh Medical, Co. 
Galway, Ireland) were mounted to a co-axial tubing as before. The embodiments of 
one single long balloon and three cylindrical balloons were investigated (see Figure 
3.11 B, C). However, it was found that the best working design was with three 
modular cylindrical balloons. This modular alignment follows the curvature of the 
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shaft more closely and is quicker to inflate and deflate compared to the single long balloon 
configuration. The single long spherical balloon does not follow the internal curved shape 
as closely as there are no restriction points along its length. In addition, three balloons 
require less bonding points compared to the five spherical balloon design and presents 
fewer gaps along the curved area. 
 
Figure 3.11 Compliant tubing and balloon configurations with (A) five spherical dilation 
balloons as developed during the MEngSc thesis, (B) one single long cylindrical 
elastomeric balloon, and (C) three shorter cylindrical elastomeric balloons, and the 
assembled device with updated handle design (D). 
The fully actuated position of the handle design is predetermined by an inbuilt stop 
which prevents excessive curvature at the distal end. However, as observed during the 
pre-clinical investigation, the user may overexert the force on the dial forcing the internal 
displacement bolt against the internal stop. This may cause handle deformation and or 
force the two sides of the handle apart. The handle was therefore analysed to determine 
the magnitude of deformation. SolidWorks® simulation tool was employed which 
assumes static loading and linear elastic behaviour. The material assigned to the handle 
was ABSplus-P430 (elastic modulus (E) of 2.2 GPa, yield stress (σyield) of 33 MPa [68]) 
to correspond to the 3D printed prototypes. The results highlighted peak stress areas 
within the model which subsequently led to modifying the geometry and increasing wall 
thickness at specific locations until an acceptable deformation was obtained. Simulated 
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external force of 20 N (10 N per side) was applied for FEA analysis. This represents 
the maximum translational force that the user may distribute from the dial to the 
axially acting displacement bolt determined from physical testing. The simulated 
results identified a peak stress value of 3.98 MPa which is significantly less than the 
yield stress (factor of safety of 8.3), and a maximum resultant displacement of less 
than 0.04mm (see Figure 3.12). 
 
Figure 3.12 FEA analysis of the handle illustrating (A) the maximum resultant displacement 
and (B) the areas of maximum stress for an external applied load of 10N per handle part 
[5]. 
The updated design (see Figure 3.11 D), which comprised a re-oriented shaft and 
re-enforced snap-fit handle design, was presented to a number of end-users (n=10) for 
appraisal of clinical utility. Despite presenting an ergonomic and functional solution, 
the thumb dial handle offers a brand new feel and design compared to currently 
available instruments which may lead to reluctance in clinical adoption. Clinicians 
from the Cleveland Clinic Ohio, Cork University Hospital, Mercy University 
Hospital, and the Mater Misericordiae University Hospital, all welcomed the 
atraumatic hooking action of the retractor as a novel and attractive solution to 
increasing surgical access during keyhole surgery. However, it was noted that a 
scissor-like handle design would be more in-line with currently available laparoscopic 
instruments. A scissor-like design presents a level of familiarity and confidence of use 
similar to the conventional handle on a bowel graspers pictured in Figure 3.2 [7]. 
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3.3.2. Continued Design and Development 
As a result of listening to the “voice of the customer”, the author revisited the control 
handle design of the laparoscopic retractor. A clear desire amongst the medical 
community is to balance familiarity of use with operational benefit. Initially a very 
simple, two part design was developed with ratcheting interlocking segments (see Figure 
3.13). However, this design does not present the ergonomic and functional performance 
desired. Subsequent to rapid prototyping this solution and presenting the solution to the 
clinical advisors (Dr Andrews and Dr O’Riordain), it was noted that feel of the device 
was not ideal. The perpendicular position of the finger grips relative to the shaft results 
in additional stress on the wrist to orient the distal end correctly. Despite this finding, the 
physicians recognised the advantage of moving towards a scissors design, albeit with 
further design being required.   
 
Figure 3.13 Scissors handle design concept generated using SolidWorks® computer 
design software. 
The scissors handle concept was subsequently developed further in collaboration with 
Dolmen industrial design house (Dolmen, Dublin 1). Dolmen’s expertise lies in product 
design with a specific focus on human factors design. Subsequent to a national tender 
process, Dolmen were contracted to work with the author to develop an ergonomic handle 
design suitable for manufacturability, supported by the Enterprise Ireland 
Commercialisation award. Initial rough sketches were developed based on visual research 
of commercially available technologies (see Figure 3.14).  




Figure 3.14 A) Visual research of commercially available surgical handles and B) early stage 
sketch development by Dolmen industrial design house, Dublin. 
Once the general form-factor was agreed, a number of iterative designs were 
developed using SolidWorks® (see Figure 3.15). Each iterative design was printed in-
house with ABS before being assessed by the project team. 
 
Figure 3.15 Control handle Design 5 iteration (A-D) with both covered and exposed internal 
design. 
As part of the works with Dolmen, the author and the Dolmen design team 
maintained weekly updates. As the design was iterated, in-house facilities in UCC 
were leveraged to 3D print and evaluate each iteration for ergonomics and 
functionality. Table 3.1 summarises the key design change decisions between the 
iterations in Figure 3.15. 
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Table 3.1 Revision history of UCC-Dolmen SecuRetract handle iteration. 
Rev Description of Current Design  Reason for Design Change 
A-B Roller clutch bearing with instantaneous 
back stop to lock handle in place. Bearing 
unit cost €2/quantity of 500. Trigger used 
to release bearing to allow retractor to 
return to straight position. 8 moulded parts 
in total. 
Replace bearing with spring to reduce 
unit costs. Reduce number of moulded 
parts to 6.  Introduce curve for finger 
slots to improve ergonomics. 
B-C Trigger release and thumb lever solution 
with curved finger slots to accommodate 
the second, third and fourth fingers. 
Enclosed index finger grip on trigger. 
Space between the handle housing 
needs to be made larger to 
accommodate locking mechanism. The 
alignment between the index finger and 
second to fourth fingers should be 
improved for ergonomics. Enclosed 
release trigger may present a risk of 
accidently trapping the index finger 
resulting in accidental discharge. 
C-D Larger handle design to accommodate 
internal locking mechanism which further 
comprises a compliant toothed locking 
design released by a trigger. Positions for 
all fingers have been adjusted. Open 
trigger design. 
Compliant internal locking component 
fractured during prototype evaluation. 
Overall size of handle is too large 
(distance from trigger to centre of 
thumb lever is 11.5cm).  
D Overall size reduced (index to thumb = 
9cm) and compliant locking mechanism 
replaced with torsion springs. Left and 




As summarised in Table 3.1, the internal ratchet arm of design C was prone to failure 
(see Error! Reference source not found.). Figure 3.16 illustrates the failure experienced 
at a corresponding point of maximum stress as determined through FEA simulation with 
SolidWorks® static simulation tool. Despite a maximum stress of 34 MPa, which is 
approximately half the flexural yield strength of ABS (60-73 MPa), fatigue analysis 
determined that after eleven cycles, the part would have a 100% chance of failure at the 
point of maximum stress. 
 
Figure 3.16 Compliant ratchet failure in Design C. 
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Subsequent to the failure analysis and a recognition that design C presented a 
solution which was too large for the average human index to thumb span, the team 
arrived at design D (see Figure 3.18). The compliant locking mechanism was replaced 
by a torsion spring. The specification of the torsion spring was dependent on the 
available geometry. The designated spring comprised of the following specifications:  
 Wire diameter: 0.8mm 
 Outer diameter of Spring: 12mm 
 Inner diameter of spring: 10.4mm 
 Number of active coils: 2.625 
 Body length: 2.9mm 
 Leg length (both leg 1 and 2): 
15mm 
 Direction of wind: left hand 
For material such as music wire (ASTM A228), the torque rate per degree for the 
above specifications is 0.741 N-mm/degree and max torque of 80.228 N-mm (max 
safe travel 108.2 degrees) which provides 3.6 times the required travel (lever rotation: 
30°). 
  
Figure 3.18 A) handle Design D printed prototype, and B) corresponding computer 
drawing. 
Figure 3.17 How to measure torsion springs from 
www.acxesspring.com. 
Chapter 3 – SecuRetract laparoscopic Retractor 
57 
 
3.3.3. Prototype Evaluation 
The updated balloon design described in Section 3.3.1 along with the final 
collaborative effort between the author and Dolmen was assembled and presented to a 
cohort of approximately twenty physicians (see Figure 3.19).  
 
Figure 3.19 Final SecuRetract design, Design 5, pictured in the inflated and curved position 
with key features highlighted. 
The assembled device was assessed in a simulated abdominal model for usability (see 
Figure 3.20). The model provides a demonstration platform to carry out bench top 
experimentation of device insertion and removal through a five millimetre port, review 
of the inflation and deflation protocol and an understanding of the usability of the device. 
Ultimately this model may be used to engage with physicians to trial the device in a 
simulated environment. The model, which includes three instrument ports, represents the 
technical challenges of clashing instruments in the confinements of the abdominal cavity. 
The model also allows for comparison to commercially available retraction instruments 
(e.g. with the single use Endo Grasp™ 5mm grasper (Medtronic, Dublin)). The simulated 
model comprises a semi-cylindrical Perspex dome to represent the anterior abdomen with 
an internal diameter of 305 mm (circumference approximately 950 mm), which is 
comparable to the mean adult female waist aged twenty years and over (mean 952 mm) 
[69]. 




Figure 3.20 SecuRetract picture with anatomical model of the bowel (A) as well as pictured 
inside a simulated abdominal model (B, C) for usability assessment. 
Three silicone rubber inserts were included in the model to facilitate instrument 
port placement and to imitate the rotational behaviour of trocar use through the soft 
abdominal tissues. The selected silicone rubber (Ecoflex® Series, Smooth-on, 
Macungie, PA) has a shore hardness of 00-30 (ASTM D-2240) and elongation at break 
of 900% [70]. The silicone inserts were characterized for penetration force with an 18 
gauge Tuohy needle using a TA.HDPlus Texture Analyzer (Texture Technologies, 
Hamilton, MA) fitted with a 5 kg load cell. The system was controlled using a desktop 
computer running Texture Exponent v3.2 (see Figure 3.21). The maximum measured 
force through a 30 mm thick cylindrical sample was 6.4 N which is comparable to the 
maximum cutting force through the abdominal wall with a Veress needle (4.8 ± 0.8 
N) [71]. The 30mm thickness is also representative of the average abdominal wall 
thickness in adults (23 ± 8 mm [72]). The performance of the silicone was noted by 
the clinical advisor to represent inpatient conditions closely, allowing for the port to 
pivot while protruding through soft material. 
 




Figure 3.21 Ecoflex silicone rubber penetration test results (A) and experimental setup (B) 
using a texture analyser. 
High resolution (50 μm) 3D printed handles were subsequently fabricated (Proto labs 
UK). During the assembly process, it was noted that the snap fit design tended to result 
in a failure of the male snap fit connections which tended to break apart (see Figure 3.22). 
FEA analysis identified that excessive buckling at the male extension of the snap fit 
connection exceeded the limits of the material (ABS) yield strength resulting in an 
immediate fracture of the male extrusion. Furthermore, a snap-fit design presents 
additional tooling considerations for injection moulding requiring additional tooling to 
accommodate the undercuts of the female end of the connection.  
 
Figure 3.22 Fracture during assembly of snap fit connections. 
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3.3.4. Final Design 
The snap fit connections discussed in Section 3.3.3 were subsequently replaced 
with a press fit design and the cap and finger insert were removed to further reduce 
the number of components in the handle to five. A draft of 3° was applied throughout 
the model to cater for tool parting on injection moulding. The internal mechanism and 
bending member configuration were unaltered from the previous design iteration.   
The final SecuRetract design is deployed through a standard 5 mm diameter trocar 
in a straight and deflated position. Once positioned within the patient's abdominal 
cavity, SecuRetract is curved and inflated creating a unique bowel hook. SecuRetract 
provides a soft and effective means to gently pull impeding organs such as the bowel 
from the operating field (see Figure 3.23). The labelling requirements for medical 
devices and symbols to be used are outlined in ISO 15223-1:2016. An example of a 
possible label including symbols for single use, sterilisation method and references to 
lot numbers and shelf life is demonstrated below. 
 
Figure 3.23 Final SecuRetract Design with A) & B) the device in the initial and deployed 
positions respectively, C) packaging render and D example of possible product labelling. 
Final design transfer to manufacture, including documenting work instructions, 
production specifications, process failure mode and effect analysis and equipment 
qualification has yet to be finalised. These activities, as well as any further clinical 
evaluations will be conducted by the legal entity responsible for commercialisation.  




As part of first phases of the design control process, the student design team should 
examine the commercial feasibility of the proposed medical device. The commercial 
feasibility assessment accomplishes two things. First of all it explores whether there is a 
gap in the market and an appetite amongst the clinical community for the proposed 
invention to justify the project investment requirements. Secondly, reviewing the market 
and market requirements provides inputs into the design control process. In the context 
of the SecuRetract project, it is a further intention of the author to commercialise and 
market the laparoscopic retractor presented in this work through a university spin-out 
company. In 2015, the SecuRetract project was awarded its second Enterprise Ireland 
Commercialisation award with the aim of bringing the solution to a point ready for 
investment and market readiness. The following section briefly describes the market and 
commercial opportunity as well as providing feedback from key opinion leaders on 
SecuRetract’s commercial potential. 
3.4.1. Laparoscopic Device Market Opportunity and Trends 
The global laparoscopic device market is valued at $9.5 billion, with a projected 
growth to over $14.8 billion by 2025 and a compound annual growth rate (CAGR) of 
6.5% [73]. North America and Europe will continue to account for more than 60% of 
global laparoscopy devices market to 2019 [74]. Today there are approximately 10.7 
million laparoscopic procedures performed worldwide [75]. Qualitative feedback from 
surgeons has suggested that SecuRetract has utility in 1/3 of these procedures [6] which 
translates to a total available market of over 3.5 million procedures. 
As described in Sections 3.1.3 and 3.1.4, both colorectal and hysterectomy surgical 
procedures require extensive bowel manipulation to isolate the target organ for surgical 
intervention. Hysterectomies are generally described as a subset of the gynaecological 
market along with ovarian cyst removal and tubal ligation. The laparoscopic colorectal 
and gynaecological markets are forecasted to reach a collective value of $6.58 billion in 
2025 with a CAGR of 7.1% and 6.1% respectively (see Figure 3.24). 




Figure 3.24 Global laparoscopic device market value share of colorectal surgery and 
gynaecological surgery [74]. 
Colorectal surgery is expected to be the fastest growing application with an 
average CAGR of 7.1% with gynaecological surgery having a CARG of 6.1% [74]. 
Today the total number of colorectal and hysterectomy procedures carried out 
annually in the US and EU is estimated to be between 2 - 2.7 million procedures [59], 
[64], [74], [76], [77], of which approximately 0.8 – 1 million (40%) are performed 
laparoscopically as extrapolated from available market data [76], [78]–[80]. 
The rise in obesity in the U.S and Canada (34.9% of the 2014 adult population) 
will lead to increased risk of colon cancer [81]. In Western Europe, the laparoscopic 
devices market is expected to witness robust growth, mainly attributed to government 
policies such as diagnosis-related group (DRG) reimbursement, which provides 
opportunities to hospitals to upgrade their surgical devices and techniques for more 
economical and technically advanced procedures. Other drivers towards increased 
trends in laparoscopic surgery include rising private and foreign investments in the 
laparoscopic devices market, promotional activities in developing regions, and 
growing popularity of single incision laparoscopic surgery [74]. 
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3.4.2. Current Technologies 
The laparoscopic device market is a competitive landscape. Ethicon (Johnson & 
Johnson), Covidien (Medtronic), Karl Storz, Olympus, Cook Medical, and Richard Wolf 
all provide versions of laparoscopic instrumentation. However, to date an effective 
laparoscopic retractor capable of atraumatic retraction of the distended loops of bowel 
has not been developed [52]. As listed in Section 3.1.2, the most common instrument 
presently used to retract the bowel is the retraction graspers. In addition, a number of 
inflatable deployable retractors have been developed to overcome the trauma associated 
with the graspers. The following table illustrates the reported strengths and weaknesses 
of some select retraction instruments.  
Table 3.2 List of deployable, atraumatic laparoscopic retractors and their associated 
strengths and weaknesses. 
Competitor Strengths Weaknesses 
Retraction Graspers 
 
Standard, low profile (5 
mm diameter port). 
Several versions and 
manufacturers 
Tissue trauma and injury, 
mechanical friction losses, 
high local tip pressure, tissue 
slippage at tip 
EndoPaddle™ (Covidien) 
 
Large inflatable contact 
area, easily and quickly 
deployed 
Requires 12mm trocar, provides 
limited control, not suitable for 
bowel retraction (bowel may 
slip from retractor) 
ExtraHand™ (Medtronic) 
  
Soft inflatable end, cheaper 
than EndoPaddle, designed 
for open surgery and/or 
laparoscopy 
Limited contact area and control 
of the bowel, risk of tissue 
slipping, requires an operator, 




Rake-like shape to retract 
the bowel, soft inflatable 
interface, may be clamped 
to bedside 
Little manoeuvrability, relies on 
retraction very close to the 
operating space, reduced 
surface contact area 
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3.4.3. Competitive Advantage 
In a response to the present unmet need for safer bowel retraction, SecuRetract has 
been developed as previously described to overcome the weaknesses of currently 
available device. Figure 3.25 highlights the four principal design advantages of the 
SecuRetract device. 
 
Figure 3.25 Key design advantages of SecuRetract 
A Design Failure Mode and Effect Analysis was carried out as part of the Risk 
Management operating procedure developed as part of this work in line with ISO 14971. 
Following the potential sources of failure listed in appendix C of ISO 14971, the most 
severe risk level identified was level two (see Section 2.4.1). These risks relate to potential 
device failure relating to misuse or inadvertent contact with auxiliary devices such as a 
diathermy used to cauterise tissue. The potential clinical effect caused by malfunction is 
the release of the bowel resulting in unexpected migration into the operating field 
disrupting the procedure. However, the risk of inadvertent rupture is common to all 
inflatable devices and is typically mitigated through robust design of materials and 
effective communication of device intended use and instructions for use. Other potential 
risk which are common to all medical devices involve sterility, incorrect labelling, and 
adequate which are overcome thought he implementation of quality and process controls.   
Chapter 3 – SecuRetract laparoscopic Retractor 
65 
 
3.4.4. Key Opinion Leader Feedback 
Over the project lifetime, SecuRetract prototypes have been presented to over fifty 
surgeons across Europe and the USA. SecuRetract was presented to surgeons at the 
Cleveland Clinic, Massachusetts General Hospital, Brigham and Women’s hospital, the 
European Colorectal Congress (ECC), Stanford Medical Centre, SAGES surgical 
conference and to a host of Irish physicians. During the course of the ECC in Munich, 24 
surgeons were individually surveyed on the immediate use of SecuRetract in their clinical 
practice [6]. The author procured a stand in the exhibition hall of the ECC and engaged 
with surgeons who were willing to complete a questionnaire. The experience of those 
surveyed ranged from newly appointed surgical physicians to established surgeons in 
their late fifties. The principal results of the survey are as follows: 
 Of the 24 surgeons surveyed 67% would use SecuRetract immediately (Figure 3.26).  
 A further 25% would like to use SecuRetract pending further clinical data. 
 Two respondents (8%) specialised in open procedures did not see a need. 
 Over half of those surveyed said they would use SecuRetract at least once a week 
(approximately 1 in 3 procedures). 
 Colectomy (95.5%) and rectal (72.7%) surgery are the most immediate applications.  
 Other indications include bariatric surgery (36.4%) and gastrectomy (22.7%). 
 Sixteen European surgeons signed up to use SecuRetract when available. 
 
Figure 3.26 Colorectal Congress results [6]: A) Example of part one of the survey, B) 
feedback on usability of SecuRetract, and C) feedback on frequency of use of SecuRetract. 
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SecuRetract was also presented to a number of US and Irish clinicians during one-
on-one interviews during the course of this research. A summary of the key points 
from three selected interviews are listed in Table 3.3. 





Surgery              
Cleveland 
Clinic, Ohio 
Prof. Kessler thoroughly examined the prototype. The handle 
design felt comfortable and easy to use. He especially liked the 
balloons creating a soft interface with the internal organs. It was 
noted that SecuRetract would not be used for every procedure but 
would be of particular use in cases where gravity alone is not 
sufficient to retract the bowels (approx. 1/3). Prof. Kessler offered 
to test SecuRetract as soon as there is a prototype is available. He 
also showed the device to a few of his colleagues who were also 
interested in testing SecuRetract and remarked favourable on the 








Prof. Cindy immediately liked SecuRetract, noting that there is 
nothing like it currently on the market. Cindy was particularly 
impressed with the balloons and the curved shape. Cindy was 
immediately able to use the device with little or no instruction. The 
size and shape fitted perfectly. It was remarked that it felt like other 
devices in terms of operation, and the size and feel of the handle 
was very comfortable. Cindy noted that the benefits include 
"reduced surgeon frustration". One of the most frustrating parts of 
colorectal surgery is using table tilt. Often the patient has to be 
restrained to avoid slipping. Reducing table tilt will greatly 
improve patient safety as well as reducing surgeon frustration. 
Interestingly Cindy noted that she would be tempted to use 
SecuRetract in open surgery to overcome the frustration of trying 








College Dublin   
Prof. Cahill liked the very elegant and ergonomically pleasing 
design. He envisaged using the device in laparoscopic colectomy 
and rectal procedures although his own use of the device would be 
limited to a few cases. He saw a greater need in developing markets 
where surgeons would be less experienced in laparoscopic surgery. 
He indicated willingness to be part of initial clinical investigations 
with the device at Mater Misericordiae University Hospital. 
3.4.5. Intellectual Property Review 
As part of the Masters research described in Section 3.2.1, a preliminary European 
Patent was filed for SecuRetract on the 21st December 2012. During the course of this 
PhD research, an international PCT was filed before SecuRetract entered into the 
nationalisation phase with filings in both Europe and the USA in 2015. 
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The author worked with the university technology transfer office to publish each phase 
of the IP process. Subsequent to a European patent filing at PCT phase, an international 
search report and written opinion is generated by the European Patent Office. The search 
report provides an opinion on the inventiveness and novelty of the proposed invention as 
well as providing an opinion on the overall unity of the application and associated claims. 
In the case of SecuRetract, the search report recognised the novelty and inventiveness of 
SecuRetract. However, the report also identified a number of claims which were 
determined as being too close to previously disclosed inventions and thus for the final 
utility filing, the number of claims were reduced to remove any potential infringements. 
The final novel claims focused on protecting the actuation and inflation of the distal end 
which is unique to the SecuRetract device. 
3.4.6. Regulatory Feasibility Review 
Europe: 
SecuRetract was classified as a Class IIa device via classification rules defined within 
the Annex IX of European Directive 93/42/EEC as amended, and schedule 9 of related 
Irish regulation (S.I. No. 252/1994), and in particular to rule seven pertaining to surgically 
invasive devices for short term use. As a Class IIa device there are a number of conformity 
assessment routes feasible for the SecuRetract device. This includes the application of 
Annex II, EC Declaration of Conformity (Full quality assurance system). Annex II 
requirements include the following: 
i. Declaration of Conformity by the manufacturer, 
ii. An assessment by a Notified Body of the manufacturer’s Quality System versus the 
requirements of EN ISO 13485:2012, 
iii. Compilation of a Technical File for examination of the product design by a Notified 
Body. 
CE marking in accordance with Annex II is feasible for the device with a Technical 
File derived from within an EN ISO 13485 certified Quality Management System. The 
Essential Requirements Review must reference, and the Technical File must contain a 
“Clinical Evaluation” Report. This report should include a clinical literature evaluation 
of reputable clinical articles that demonstrate the prevalence and relative safety of 
laparoscopy retractors on the market. 
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Providing adequate data is provided in a format that conforms to the 
Manufacturers and Notified Body’s Guidance MEDDEV. 2.7.1, it is likely that the 
legal manufacturer’s selected Notified Body will accept the safety and effectiveness 
of the device without the need for human trials. Considering the invasive nature of the 
device it is conceivable that the legal manufacturer may be required to pro-actively 
commit to collecting information on quality, safety or performance of the Medical 
Device after it has been placed on the market. 
United States: 
For FDA Classification guidelines, a device which falls within the controls of 
product Code GCJ, associated with endoscope and accessories (FDA regulation 
number 876.1500), may be deemed as a Class II device. Therefore the submission 
type is 510(k) as determined in Product Code GCJ. 
In order to successfully submit a 510k application for SecuRetract, the device must 
be proven to be “substantially equivalent” to one or more existing approved devices 
on the US market. It is apparent that numerous devices with the same product code 
and similar intended use are already approved on the US market. Devices such as the 
A-Lap™ retractor (EZsurgical, 510k application K082291) and the ExtraHand™ 
balloon retractor (Medtronic, 510k K962005) have been identified.  
Design verification and design validation data derived within a 21 CFR Part 
820.30 Design Control process will be necessary to determine and demonstrate the 
equivalence of SecuRetract to one or more predicate devices. On the basis that at least 
x10 potential predicates exist, including devices with similar technology, a US 510k 
application for SecuRetract will be feasible and is deemed an appropriate regulatory 
pathway. The 510k application will be subject to FDA review prior to approval. 
Providing adequate data is generated to demonstrate substantial equivalence with 
predicates it is unlikely that human trial data will be necessary to support the pre-
market approval 510k application. This is ultimately at the discretion of FDA 
reviewers but it is a relatively low risk to this pathway considering the prevalence of 
predicate devices on the market. Any potential patient risks can be assessed and 
mitigated by applying the FDA recognised standard ISO 14971:2007 with the Design 
Control process and by supporting the application with a Clinical Evaluation Report, 
including a Clinical Literature Review.  




An essential part of any laparoscopic surgery is to ensure that the surgeon has 
sufficient exposure to visualise the operating field and surrounding structures to perform 
an effective and safe procedure. Laparoscopic retraction has advanced greatly since it was 
first introduced in 1991, yet a safe and effective laparoscopic retractor has yet to be 
universally acknowledged [52], [82]. Through an iterative design process and continual 
consultation with end users, SecuRetract was developed. The presented solution has the 
potential to displace currently available laparoscopic retraction devices due to a number 
of key operational and performance advantages.  
3.5.1. Technical and Commercial Review 
The main proposed advantage of SecuRetract over alternative deployable retractors is 
that it can be adjusted and manoeuvred to suit any lower abdominal surgery. The device 
may be inserted through a 5 mm diameter port which, in turn, reduces recovery time when 
the facial defect (incision) is closed post-surgery. The inflatable nature of the device 
negates the risk of tissue perforation, and the cylindrical balloons increase the surface 
area with the bowel wall reducing contact pressure. Due to the unique mesenteric hook 
profile, SecuRetract can retract a far larger section of the bowel compared to the 
traditional laparoscopic retractors discussed in Section 3.1.2. Therefore, laparoscopic 
surgery may be undertaken at a reduced Trendelenburg position (less head-down). This 
will reduce intra-operative complications, reduce operational time, and consequently, 
decrease hospital costs. In addition, SecuRetract offers improved ease of laparoscopic 
access by means of its rapid deployment and retraction through a single 5 mm diameter 
port. This feature is particularly amenable for extending the device’s use to clinical 
indications outside of colorectal surgery (e.g., upper gastrointestinal interventions). The 
curvature and length of the shaft may also be altered to provide a selection of SecuRetract 
devices as appropriate to a specific procedure.  
While the results of this preliminary analysis, experimentation and end-user feedback 
are encouraging, a clinical investigation will be required to investigate the efficacy of 
small bowel retraction in the supine position and comparing same to commercially 
available techniques. Results from the pre-clinical investigation have led to a number of 
design improvements which have enhanced the operational performance and ease of use 
over the course of this PhD. As a result, the current solution points to a promising 
Chapter 3 – SecuRetract laparoscopic Retractor 
70 
 
alternative laparoscopic retractor to improve surgical access and to help alleviate 
complications during laparoscopic colectomy and hysterectomy. 
3.5.1. SecuRetract Design Control Review 
The laparoscopic retraction project began before the implementation of the quality 
management system, therefore the design control framework had little influence over 
the early stages of development. Despite this, the author had recognised the stage-gate 
approach early into this PhD work and throughout the development of SecuRetract, 
the main milestones were targeted prior to formally describing same in a controlled 
procedure. All records were maintained of all design development activities which 
were subsequently used to retrospectively populate the project’s Design History File. 
One limitation with the verification of medical devices in general, is that all 
verification protocols to be included in the regulatory submission, have to be 
completed under good laboratory practices in order to assure accurate results. This 
presents difficulties to small research groups who may not have access to such 
resources. Further financial investment is required to support these actions which will 
be addressed by the licenced company responsible for commercialisation.  
The author found the implementation of quality controls to be time consuming and 
quite burdensome. In particular, it was difficult to maintain and catalogue routine 
design meetings and design iterations as often new ideas and improvements came 
through unscheduled discussion with practitioners or experimental testing. In the case 
of the SecuRetract project, all the design documents such as the Design and 
Development Plan, were retrospectively populated. Therefore the plan reflects what 
was achieved rather than setting goals and timelines from the beginning. Furthermore 
much of the design history file is still being populated and will not be completed until 
the device is finally ready for design transfer in Phase 4 of the design control process. 
As discussed above, much of the final activities are subject to further funding to access 
the appropriate resources. However, once a completed design quality system has been 
established and evaluated through the development of several projects, the author 
appreciates that such a roadmap to design control and development will be invaluable.  
The control process will serve to frame the project output requirements and to 
determine the essential steps towards clinical adoption and regulatory approval. The 
author does recognise that a dedicated quality controller may be required to ensure 
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compliance and to routinely schedule review meetings which often may be more difficult 
than anticipated owing to the busy nature of university staff and clinical advisors. On 
reflection, had this project been prospectively implemented into the deign control process 
rather than retrospectively, the author believes that more focus would have been placed 
on design for manufacture at an early stage and that the overall timeline would have been 
significantly reduced by following a clear and focused development plan. SecuRetract is 
currently in Phase III of the project design and development cycle, as described in Chapter 
2. Table 3.4 qualitatively estimates the progression of each stage gate activity. The 
outstanding actions left in Phase III involve finalising production processes, and to build 
production units to undertake design verification and validation activities. 
Table 3.4 SecuRetract project progression. 
 
 
Phase I Phase II Phase III Phase IV Phase V








100% 100% 80% 0% 0%
Concept Solutions / 
Early Risk Assessment
Define Design Inputs Manufactures / 
Suppliers Identified
Final Design Validation Post-Market 
Surveillance
100% 100% 80% 0% 0%





Update / Implement 
Risk Controls
Complete DHF, DMR, 
Technical File 
Sales and Physician 
Training 
100% 100% 75% 25% 0%
Early Intellectual 
Property Review




Artwork / Traceability Expand Sales Effort









100% 100% 50% 75% 0%
Risk Analysis Update Process Validation Plan Manufacturing 
Qualification 
Quality Audits







 Business Plan Update  DHF / 
Business Plan 























Chapter 4 - ProDural Epidural Device 
73 
 





Epidural analgesia is a form of regional analgesia involving the careful placement of 
a needle tip into the narrow epidural space between the spinal dura and the ligamentum 
flavum, and the subsequent injection of drugs through a catheter placed into the epidural 
space. Epidural administration is the standard therapeutic method for pain relief during 
labour and has changed very little since it was first introduced at the start of the twentieth 
century. However, with a very steep learning curve and relatively high failure rates among 
trainee anaesthetists, the current method is not ideal. This chapter presents a possible 
solution to improve the safety and efficacy of epidural administration. The proposed 
solution, developed as part of this PhD, is consistent with traditional methods and 











The clinical need for which this project is based on was presented at the 2012 UCC 
BioDesign module by Dr. Peter Lee, Consultant Anaesthetist at Cork University 
Hospital. As an undergraduate at the time, the author was a member of the original 
team tasked to produce an early stage solution. Aside from referencing the concept 
from the BioDesign module, all work described within this chapter was conducted by 
the author as part of this PhD. In the context of the design control process, this project 
has advanced to Phase III. The following sections will detail the clinical need to 
improve epidural administration as the principal application, and an alternative 
clinical indication associated with creating a pneumoperitoneum during laparoscopy. 
4.1.1. Epidural Administration  
Epidural administration of local anaesthetic and/or opioids is performed for 
analgesia and anaesthesia in the perioperative or peripartum period or to provide 
analgesia before surgical procedures and labour. It is also commonly used as a 
therapeutic method for pain relief. The US Department of Health and Human services 
reported that 70.85% of births in the US in 2011 involved epidural or spinal 
anaesthesia. This amounts to approximately 2.76m deliveries involving the provision 
of epidural/spinal anaesthesia during labour. Epidurals block the nerve impulses from 
certain spinal segments resulting in decreased local sensation. Although epidural 
anaesthesia has been part of anaesthetic practice since 1901, localisation of the 
epidural space remains technically difficult [83]. Epidural analgesia has been 
described as the gold standard of pain control [84].  
 
Figure 4.1 A) Initial positioning of epidural needle between protruding spinous processes, 
and B) advancement of epidural needle using the loss of resistance technique. 
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The technique requires a clinician to blindly pass a needle through soft tissue and 
ligament between the caudally protruding spinous processes of the vertebrae. 
Confirmation of needle tip entry to the epidural space is most commonly achieved by the 
loss-of-resistance (LOR) technique; a sudden, yet subtle, pressure drop at the needle tip 
which is sensed at the syringe plunger. The needle is grasped with the non-dominant hand 
and pushed toward the epidural space while the dominant hand (thumb) applies either 
constant steady pressure, or pulsing intermittent pressure on the syringe plunger. Once 
the epidural space is entered, the pressure applied to the syringe plunger allows the 
syringe medium, which may be air or saline or a mixture of both,  to flow without 
resistance into the epidural space [85]. Once the operator detects the LOR and is satisfied 
that the epidural needle is in place, the syringe is removed and a catheter is threaded 
through the needle into the epidural space. Finally the needle is carefully removed, 
leaving the catheter in place to provide medication either through periodic injections, or 
by continuous infusion. 
 
Figure 4.2 Graphical representation of the epidural space and surrounding anatomy 
with an epidural needle tip positioned in the epidural space. 
The epidural space is a very thin layer located between the interspinous ligament and 
the subarachnoid space which in turn is protected by the dura mater (see Figure 4.2). The 
ligamentum flavum is a dense layer of tissue located immediately before the epidural 
space and presents the greatest resistance to needle advancement. The midline approach 
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is a common method for needle advancement and involves orientating the needle until 
it is orthogonal to the patients back and advancing the needle through the interspinous 
ligament and finally the ligamentum flavum. In 2009, Tran et al. [86] estimated the 
average force and syringe pressure required to penetrate the ligamentum flavum in a 
human subject using the continuous pressure technique and the midline approach. It 
was found that the force and pressure applied in the ligamentum flavum was 
significantly higher than the interspinous ligament (see Table 4.1). The estimated 
pressures were calculated to be around 37.5 ± 20.0 kPa for the ligamentum flavum 
and 15 ± 5.3 kPa for the interspinous ligament [86]. These pressure values were 
assumed as operational pressures for future designs. 
Table 4.1 Penetration force and estimated pressures for human subjects while advancing an 
epidural needle using the midline approach [86]. 
Region 
Favg           
(N) 
Fmax           
(N) 
Pavg               
(kPa) 
Pmax        
(kPa) 
Interspinous Ligament 2.0±1.4 4.6±1.3 15.5±12.0 34.9±17.4 
Ligamentum Flavum 5.0±3.0 6.0±3.0 31.5±28.0 39.5±30.3 
p-value <0.05 <0.05 <0.05 >0.25 
4.1.2. Epidural Failure 
Accidental dural puncture (i.e., entry into the subarachnoid space) is the most 
significant complication associated with regional anaesthesia but the incidence is 
hugely dependent on clinician experience. For experienced clinicians puncture rates 
are typically between 1-3% [87]. However, for trainee anaesthetists, the mean epidural 
failure rate is one in every five consecutive epidurals for the first 50 epidurals 
performed [88] (see Figure 4.3). Proficiency in the loss-of-resistance technique is 
difficult to teach or demonstrate. As many as 60 attempts at epidural anaesthesia may 
be required before a 90% success rate is achieved [89], [90]. The technique may also 
be unreliable in patients with altered vertebral anatomy or calcified spinal ligaments, 
while epidural anaesthesia failure rates are greater in obese patients [91]. There is an 
urgent need to provide confirmation of epidural entry for these novice end-users. The 
most benign consequence of these so-called ‘spinal taps’ is severe and prolonged 
headaches for the patient which occurs in approximately 86% of accidental dural 
puncture. Patients with severe post-dural puncture headaches may be readmitted and 
treated with an epidural blood patch leading to additional insurance and healthcare 
costs [92]. 




Figure 4.3 Epidural failure rate for every five consecutive epidurals taken from 
Dashfield et al. (2000) [88]. 
A more common complication of epidural administration is a ‘false positive’. Based 
on haptic feedback, the clinician incorrectly assumes the epidural space has been reached. 
This is more likely to occur in obese patients due to air or saline leakage as the epidural 
needle passes through layers of fatty tissue giving false LOR feedback. In rare 
circumstances (<1% [93]), complications associated with the current LOR technique may 
also include pneumocephalus, spinal cord and nerve root compression, subcutaneous 
emphysema, venous air embolism, and neurological injury [83]. 
4.1.3. Current Solutions and Technology 
The regional anaesthesia global market is dominated by a small number of players 
with three brand leaders in the US; Perifix® (B.Braun, Melsungen, Germany), Portex® 
(Smiths Medical, Kent, UK) and Epilor™ (Becton Dickinson (BD), Franklin Lakes, NJ, 
USA). In the UK, Portex has a dominant position with an estimated 85% epidural market 
share. The most prevalent technology is the loss-of-resistance (LOR) syringe. 
Polyproplyene LOR syringes are cheap to manufacture and represent the single largest 
competitor. In 2006, 99% of anaesthetists in the U.K. used some form of the LOR 
technique to identify the epidural space, be it a continuously applied pressure or a pulsing, 
intermittent pressure to the syringe plunger (LOR to saline continuous 58%, saline 
intermittent 16%, air continuous 4% and air intermittent 21%) [94]. In recent years, 
developments such as fibre optics [95], ultrasound [96], products such as Compuflo® 
(Milestone Scientific, Livingston, NJ, USA) [97] which employs sensors to detect the 
pressure drop and the Acoustic Puncture Assist Device (Equip Medikey, Gouda, 
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Netherlands) [98] have been developed to replace the conventional manual LOR 
technique. However these high end alternatives have struggled to achieve market 
penetration due to expensive up-front investment and lack of clinical inertia. A list of 
selected commercially available epidural devices are listed in see Table 4.2. 
Table 4.2 List of epidural administration technology. 
Product Supplier Description Disadvantages of Product 
LOR Syringe 
 
Multiple Low cost, single use. 
LOR technique. Clinical 
gold standard. Ease of 
manufacture. 
Relies exclusively on haptic 
feedback to determine if needle tip 
has entered the epidural space 
leading to a steep learning curve 





Single use. Does not use 
the LOR technique. Low 
cost. Spring loaded. 
Difficult to detect false positives, 
and there is a chance of the spring 








Single use. Syringe 
attachment. Localise 
epidural space by means 
of a visual signal. Does 
not maintain LOR 
technique. 
Additional steps to assemble the 
syringe-Epidrum-needle 
configuration. Risk that the needle 








Single use. Screw-based 
needle for securing to 
surrounding tissue. No 
visual indicator. Does 
not maintain LOR 
technique. 
Relies on a slow and delicate 
screwing process. Risk of tip 
getting blocked with matter. 
Presents a complete shift in 






for monitoring pressure 
variation on entry.  
High-cost solution which relies on 
electronic sensors to confirm 
entry.  
A number of these devices still avail of the pressure drop technique which include 
Episure™ (Indigo Orb, Irvine, CA, USA) [99] and Epidrum® (Exmoor, Somerset, 
UK) [100] (see Table 4.2). Both of these devices are “charged” prior to application 
and automatically retract once the epidural space has been reached. However, instead 
of the user receiving a tactile feedback, these devices provide solely visual 
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confirmation when the epidural space has been reached, thus creating uncertainty of 
correct needle placement. Other emerging devices include Epiphany and Omeq are not 
yet commercially available but represent significant differences from current clinical best 
practice and are therefore expected to face significant resistance towards adoption based 
on end-user feedback.  Epiphany relies on slowly advancing the blunt needle tip towards 
the epidural space by using the threads to produce a controlled forward screw like motion.  
 Syringe solutions such as Episure and Epidrum have struggled to gain market 
penetration. The National Maternity Hospital Holles Street (Dublin) suspended any future 
trials on the Epidrum device due to false readings. Both devices discharge slowly as they 
pass through the low density fatty tissue and are difficult to recharge.  
4.1.4. Laparoscopic Pneumoperitoneum 
Another potential application of a natural cavity detection device is to identify the 
abdominal cavity to create a pneumoperitoneum (the 
introduction of gas to create space in the peritoneal cavity) in 
advance of minimally invasive surgery. This task is currently 
completed using a trocar or a veress needle (see Table 4.3). A 
trocar functions as a portal during laparoscopic surgery to 
insert instruments and to create a pneumoperitoneum. Trocar 
insertion has been identified as the most dangerous risk of 
laparoscopic surgery. Despite advances in trocar technology, 
the creation of a pneumoperitoneum along with insertion of 
trocars remains the source of significant injuries to the wall and 
vasculature [101]. The overall incidence of major vascular 
injury due to trocar and veress needle entry is 1.1/1000 [102] and constitutes 1/5 of all 
medical insurance claims associated with laparoscopic surgery [101].  
Several studies [103]–[105] suggest that the initial trocar insertion is the most 
dangerous aspect of trocar use, and possibly the most dangerous step in minimally 
invasive surgery. Champault (1996) [104] found that 83% of vascular injuries, 75% of 
bowel injuries, and 50% of local haemorrhage injuries were caused during primary trocar 
insertion. Unfortunately, a large fraction of trocar injuries are not diagnosed at the time 
of injury. Krishnakumar (2009) [24] reports that some 30-50% of bowel injuries and 13-
50% of vascular injuries are undiagnosed at the time of surgery. The mortality rate from 
Figure 4.4 Trocar 
Placement through 
abdominal wall [174]. 
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bowel injury is between 2.5-5% [25] and the mortality rate for all bowel and vascular 
injuries is between 3-30% [108]. 
There are three common clinical approaches for initial trocar placement during 
laparoscopic surgery. The open or Hasson technique involves insertion of a Hasson 
cannula which allows insufflation during laparoscope entry. The closed technique 
involves blindly inserting a Veress needle (a spring loaded needle) followed by 
insufflation and trocar insertion. The direct entry technique involves immediate and 
blind entry with a trocar. While direct entry reduces procedural time, the three 
techniques have comparable rates of complication and all three are widely practiced 
depending on surgeon’s preference [109]. It is estimates that 40% of surgeons use 
(closed) Veress needle insufflation prior to primary trocar insertion, while 30% use a 
direct (no insufflation) trocar insertion method and 30% use the Hasson method [110].  
Table 4.3 List of surgical technology used to establish a pneumoperitoneum. 




Multiple Low cost, single use. Outer 
shield reduces initial 
puncture pressure.  
Initial blind puncture risk. No 
evidence of lower injury rates 




Covidien (US) Single use. Blunt tip may 
reduce risk of abdominal 
wall injury 
Significant additional force 







Reusable and single-use 
available. Facilitate 
laparoscopic visualisation 
during insertion.  
Optical trocars require initial 
Veress needle insertion and 
do not reduce risks associated 
with gas embolism.  
Veress Needle 
 
Multiple A spring-loaded needle 
used to create 
pneumoperitoneum for 
laparoscopic surgery 
Can lead to vascular and 
organ perforation. Not as 
commonly used as a trocar. 




Two clear unmet clinical needs have been described. When broken down to an 
engineering problem, the issue involves the detection of a cavity (be it the epidural space 
or peritoneal cavity) beyond a dense penetrable membrane (posterior tissue or abdominal 
cavity). The design process focused on the clinical application of epidural administration 
as this was seen as the greater clinical need. The following sections will describe the 
design iteration process; initially during the BioDesign module and subsequently as part 
of this PhD thesis, while focusing on a defined clinical need. 
4.2.1. Problem Statement 
To develop a means of improving the accuracy and safety of detecting the epidural 
space during epidural administration which can reduce the risk of intraoperative 
complications, reduce the incidence of false positives, and offers a cost effective, user 
friendly solution. 
4.2.2. Design Criteria  
A list of design criteria was derived from end-user surveys, literature reviews and 
competing technology assessment. The resulting requirements were subsequently 
considered during the design process. These requirements include a solution which:  
1. Consistently and reliably informs the operator when the needle tip has entered the 
epidural space. 
2. Is light-weight, durable, easy-to-use and requires minimal set-up, to cope with the 
practicalities of everyday clinical practice. 
3. Maintains the existing LOR techniques with minimal time lag between detection 
and conveying the information to the user as the distances involved are small.  
4. Reduces the steep learning curve. 
4.2.3. BioDesign Solution 
The original concept, which was developed as part of the author’s BioDesign group, 
comprised a modified LOR syringe and an attachable pressure drop detector. The 
attachment provides an additional visual signal that the epidural space has been reached 
(see Figure 4.5).  




Figure 4.5 Original solution developed as part of the BioDesign Module illustrating the 
detachable pressure drop detector and modified syringe. 
The proposed solution operated on the same principle as the existing LOR syringe 
(see Figure 4.5). The pressure drop detector, which further comprised an expandable 
diaphragm (bellows), is inserted between the syringe and Tuohy needle (a needle 
design commonly used to locate the epidural space with a curved tip). As the needle 
is advanced towards the epidural space and pressure is applied to the plunger, the 
diaphragm rises upward. Once the epidural space is reached, the diaphragm will 
collapse as the air or saline solution used to charge the barrel exits the syringe through 
the needle. The collapsing mechanism acts as secondary visual confirmation that the 
epidural space has been reached. 
However, the BioDesign solution included a number of limitations that needed 
addressing. The bellows-actuated visual indicator presents manufacturing difficulties 
and may pose operational limitations depending on the orientation of the bellows (i.e., 
if suspended upside down, would the internal pressure be sufficient to overcome the 
effects of gravity). Further design development was therefore required as well as 
assessing the market size and end-user demand. 
4.2.4. PhD Design Evolution Overview 
The epidural project was included as one of the devices to develop further within 
this PhD research. The original concept, albeit not technically viable, did present an 
interesting concept to include a visual indicator to improve epidural administration. 
One of the first actions was to carry out a more expansive review of the Intellectual 
Property Landscape (i.e., Phase I of the Design Control Process). It was here that the 
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author identified the EpiDrum device (see Table 4.2) which presented cause for concern 
from an intellectual property perspective [100]. To that end the design criteria was 
expanded to include a device which incorporates a built-in pressure drop detector which 
removes the assembly process of EpiDrum and is specifically designed to enable both 
continuous and pulsing loss-of-resistance techniques. 
The design cycle followed an iterative process looking at different mechanical means 
of detecting a pressure differential. The solutions were subsequently rendered using 
SolidWorks (Dassault Systèmes SolidWorks Corp., Waltham, MA, USA) and developed 
in-house using rapid prototyping technics such as 3D printing to assess their potential 
merits of meeting the design criteria (see Figure 4.6). 
 
Figure 4.6 Concept iteration: V1 original solution from BioDeisgn module, V2 radially 
expanding balloon on distal end, V3 chimney design with expandable membrane, and 
V4 final design iteration.  
 Similar to the SecuRetract project, inflatable technology was used to provide a cost 
effective and functional method of detecting a pressure differential. Each design was 
prototyped and presented to clinical advisors for feedback. The principal design reasons 
for each iterative advancement are summarised in Table 4.4  
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Table 4.4 ProDural revision history summary. 




V1 is reflects the BioDesign 
concept. Attachable visual indicator 
with expandable bellows. 
Design for manufacture of the bellows not 
practical. Potential infringements of the 




V2 comprises a radially 
expanding, elastomeric cuff, 
located at the distal end of a 
modified syringe. Provide 360º 
axial rotation visual confirmation 
of pressure increase with plunger 
advancement. Epidural space 
localisation confirmed through 
collapse of cuff. 
Excess volume 
on inflation (>40 
mm3). Risk of 
over injection of 
air / saline on 
locating epidural 
space. Dilation balloons have a high cost 





Finger slot design presented in V2 
retained in V3. Movement to 
chimney design with more cost 
effective, expandable elastomeric 
disk design. 
Finger slot removed. 
Risk of catching 
user’s finger during 
use and dislodging 
epidural needle tip 
from space.  
V4 V4 illustrates an improved chimney 
design with to accommodate 
injection moulding as well as a snap 
cap design to house and secure 
elastomeric diaphragm. 
  
The final design, V4, provides both visual and haptic feedback of needle entry into 
the epidural space and is consistent with traditional LOR syringes. This is achieved 
by integrating a visual indicator (inflatable diaphragm) at the distal end of an LOR 
syringe. By mating the syringe with a needle, the device provides visual confirmation 
of entry into the epidural space with rapid and immediate collapse of the inflatable 
diaphragm. This mechanical process results a low cost, and highly manufacturable 
solution. As part the design control process, a Design Failure Mode and Effects 
Analyses was carried out as presented in Appendix 4. The following sections will 
describe the prototype development and evaluation of ProDural’s clinical utility.  
 
Figure 4.7 Detail of the final ProDural design taken from Appendix 5. 




In order to demonstrate proof of concept, a minimally viable, functional prototype was 
required. LOR syringes are manufactured using high pressure injection moulding, usually 
in polypropylene for both the syringe and plunger and TPE for the plunger cap. Injection 
moulding is an expensive process for developing prototype grade devices, therefore other 
rapid prototyping methods were investigated. In-house 3D printing (Dimension Elite, 
Stratasys) could not produce functional prototypes. A 3D printed barrel would leak air or 
saline through the porous ABS material due to the layered FDM (Fused Deposition 
Modelling) process. Therefore, for design evaluation, a standard 7ml LOR syringe was 
modified (Epilor, BD), to accommodate a visual indicator secured using adhesive epoxy 
(Loctite).  
The visual indicator was prototyped by machining Polymethyl methacrylate (PMMA) 
rods to varying internal (7.5mm, 10mm, 12mm ID) providing a range of possible 
configurations (see Appendix 5). The PMMA rods (trade name Perspex) are readily 
available, cost effective and easy to machine due to its high impact, shatter proof 
mechanical properties. Material selection for the diaphragm was critical to the 
development of this device. The material must have be capable of elongation well above 
400% as the diaphragm is inflated from a disk to a hemi-spherical shape. For ease of 
prototyping and first proof of concept, rubber latex was used with varying thicknesses 
(0.135mm, 0.18mm, and 0.25mm). Latex has a high tear strength with an elongation at 
break of typically over 800%. The thickness of the latex was measured using a digital 
micrometre and incrementally stretching the sample in a vice to characterise the variance 
in wall thickness with planar elongation (see Figure 4.8) 
 
Figure 4.8 Measuring thickness of latex samples. 
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Two models were used to evaluate the prototypes and provide end-user feedback. 
The first model was a banana which is commonly used as a model for initial 
instruction in epidural catheterisation [111]. The proximal, dense surface of the 
banana represents the patient’s skin. As the needle advances and passes through the 
fruit of the banana it is comparable to the interspinous ligament. Finally as the needle 
reaches the opposite surface of the banana, the change in density is representative of 
the needle reaching the ligamentum flavum [9]. The second model was an anatomical 
mock-up, produced via reverse moulding, with a 3D printer and liquid silicone rubber 
(Ecoflex® 00-30, Smooth-On, Macungie, PA) (see Figure 4.9). As described in 
Chapter 3, Ecoflex 00-30 presents material properties similar to soft tissue. The 
silicone model provides a visual representation suitable for demonstration purposes.  
 
Figure 4.9 A) the banana model used in early proof of concept testing, and B) a rapid 
prototyped model of a section of the vertebrae with layered varying durometers of 
silicone simulating interspinous tissue. 
Both the banana and silicone models effectively demonstrated the functionality of 
the initial prototypes. The diaphragm inflation pressure and the immediate 
responsiveness of diaphragm collapse on pressure drop detection, were in line with 
the end-users expectations. From this preliminary evaluation, the end user indicated 
that the thinnest diaphragm (0.135mm) presented the best surface inflation at a 
familiar plunger pressure (20-30 kPa). In addition, visual evaluation and repeated use 
confirmed an airtight seal around the diaphragm indicating an adequate snap-fit cap 
design. These models demonstrated initial technical feasibility. However more in-
depth testing was required to fully define the material requirements. 
4.3.1. Bench Top Evaluation 
To determine the biaxial characteristics of the elastomer diaphragm, the bubble 
inflation technique was used [112], [113]. The visual indicator is in fluid 
communication with a pressure gauge and a manual inflation pump (see Figure 4.10). 
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The bubble inflation pressure was manually controlled by an Encore inflation system 
(Boston Scientific, Natick, MA). A video camera (resolution of 1980 × 1080 pixels) 
recorded the inflation pressure corresponding to the bubble height. Experimental 
assumptions included truly equi-biaxial stretching at the pole of the bubble, uniform 
thickness at the pole and planar expansion near the rim. It was also assumed that the 
balloon would display spherical symmetry throughout its expansion. Prior to beginning 
the experiments, an experienced end-user was asked to blindly determine the typical 
pressure exerted on the plunger during epidural administration with a conventional LOR 
syringe. The results, which were captured with a pressure gauge, indicated that the 
operating intra-plunger pressure range varied from 2 to 5 psig for both continuous and 
pulsing LOR techniques.  
 
Figure 4.10 Experimental apparatus to evaluate the biaxial characteristics of latex rubber 
diaphragm at room temperature (21°C). 
Three data sets were taken for a 0.135 mm thick latex diaphragm as selected from the 
banana model evaluation. The values for each of the data sets were consistent (see Figure 
4.12). When evaluating the stress values of a specific material undergoing deformation it 
is essential to specify if the stress values are to expressed as engineering stress (σeng) or 
true stress (σtrue). With hyperplastic materials undergoing significant elastic deformation, 
true stress should be considered to account for changes in cross-sectional area.  
The relationship of true stress to engineering stress for both uniaxial and equi-biaxial 
tension [112] can be expressed as: 
/true eng        (1) 
where λ is the stretch ratio in the direction of the applied load and is expressed as the 
ratio between the current length l and the initial length of the polar zone l0: 






                    (2) 
Engineering stress for the bubble inflation case is a function of pressure P, radius 






        (3) 
Assuming the membrane is flat in unstrained state (follows membrane theory of 
plates (flexural rigidity is negligible)), then the equation of maximum displacement 
at centre of a clamped circular membrane is given by (4): 




                        (4) 
 
Where wo is the central displacement, r is the radius, P is the pressure, E is Young’s 
Modulus, t is the thickness, and k1 is a constant.  
4.3.2. Bench Top Results  
Camera footage analysis generated the real-time inflation pressure P and 
corresponding bubble height. The parameters rc and l were determined by arc-fitting 
to the bubble’s radius of curvature using AutoCad software (Autodesk Inc, San Rafael, 
CA). The polar surface of the bubble was marked to indicate the elongation of the arc 
length as the bubble expanded. Figure 4.12 compiles the resulting values of the bench 
top evaluation with a polynomial trend line fitted to the plotted pressures. 
 
Figure 4.11 Graphic determination of the arc length l and radius of curvature rc at a 










Figure 4.12 A) inflation/deflation cycle pressures and elongation ratio relationships for a 
latex membrane, and B) true stress and the stretch ratio with a fitted polynomial trend line 
during bi-axial bubble inflation testing 
The elastomer initially demonstrates quasi-linear behaviour for small elongations (λ ≤ 
1.8). The material then begins to yield as it quickly expands at almost constant pressure. 
The final domain of large deformation (λ ≥ 3.8) sees the material undergoing strain 
hardening. The prototype remains within the elastic region for pressures up to 
approximately 25 kPa and elongations of 380%. Based on the findings of Tran et al. [86], 
the membrane would reach the domain of large deformations (P ≈ 37 kPa, λ ≈ 4.7) when 
passing through the ligamentum flavum. However this falls short of the burst pressure 
which was experimentally measured as 62 kPa at an elongation of approximately 960%. 
Figure 4.12 also illustrates the relationship between the true stress and the stretch ratio 
for three samples of a least square fit of thin latex diaphragm (t0 = 0.135 mm). Again for 
the latex material tested, a linear plastic relationship exists up until an elongation ratio of 
approximately 380%.  
Despite proving to be a very compliant and effective material during the early 
prototype evaluations, latex contains proteins and chemical allergens which may make it 
unsuitable as a material for medical devices. Natural rubber latex can be classified as a 
USP (United States Pharmacopeia) Class VI plastic, which certifies that the material is 
biocompatible and meets the requirements for leachates. However, more and more the 
market seems to be moving away from natural rubber as a result of concerns over possible 
adverse effects of Latex. Therefore an investigation into alternatives with similar 
characteristics to latex (i.e., high tensile strength, low elastic modulus and elongation at 
break > 600%) was required.  
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4.3.3. UMass Lowell Design Collaboration 
The ProDural project was entered into the Massachusetts Medical Device 
Development Centre (M2D2) New Ventures Competition, Lowell, MA, USA in 2014. 
ProDural finished as one of four medical device winners from 15 finalists, who 
presented to a panel of distinguished judges from Smith & Nephew, UMass and Mass 
MEDIC. This included entrants from Europe, South Africa and North America. The 
prize awarded $5,000 worth of consultation from Smith & Nephew and UMASS 
Lowell which was used to carry out further device development as well as health 
economic analysis which will be discussed in later sections of this chapter.  
As a result of the M2D2 New Venture competition, the author collaborated with 
Professor Stephen McCarthy and the plastics engineering team at University of 
Massachusetts Lowell to develop a highly compliant, biomedical grade diaphragm to 
replace the latex. Preliminary analysis compared the theoretical and actual behaviour 
of latex, silicone rubber, urethane rubber and liquid silicone (Dow Corning®). Table 
4.5 provides an overview of the estimated principal mechanical properties of each of 
the examined materials. Following early assessment, the liquid silicone rubber Dow 
Corning® C6-530 Class VI elastomer was selected based on its high tear strength 
(27.5kN/m), tensile strength (8.2 MPa), elongation (831%) and its reported use as a 
medical grade elastomer.  










Est. Tensile Strength 20-30 Mpa 5-8 Mpa 20-30 Mpa 8.2 Mpa 
Est. Elongation at 
Break 
750-850% 200-800% 300-450% 831% 
The Dow Corning C6-530 samples were formed using compression moulding. The 
two part process was mixed by hand while adding a blue pigmentation and then de-
aired in a 700 mmHg vacuum for 1 hour. The resulting mixture was spread evenly 
onto aluminium plates separated using brass shims. The plates were then pressed 
together at 300MPa and 120˚C for 5 minutes. A 12.5 mm circular punch tool was used 
to extract membranes from the resulting sheet of Dow Corning. 




Figure 4.13 Pressure test setup with A) test setup with low pressure air regulator, B) CAD 
assembly drawing adapted from ProDural dimensions, and C) 3D printed prototype. 
This process was repeated to produce a number of sheets of varying thickness of 
between 76 – 203 µm. The samples were subsequently assembled in an Objet Eden 3D 
printer model produced with VeroWhite photo-cured material, and connected to a low 
pressure air regulator which was monitored with a precision gauge. The resulting 
displacements and inflation pressures were captured and graphically analysed using 
ImageJ software (see Figure 4.13). 
The diaphragm constraints were determined due to the geometrical restrictions of 
standard 7ml LOR syringes. As detailed in Appendix 5, an aperture with a diameter of 
7.5 mm may be created using a snap fit cap design with an overall outer diameter of 
11mm. This provides sufficient wall 
thickness to create the overlap required for 
the snap fit connection. Based on end-user 
feedback, the desired inflation pressure to 
create an inflated diaphragm (i.e., bubble 
height ≥ aperture diameter/2) was estimated 
at 20kPa. The burst pressure was rated at 60kPa 
which provides a factor of safety of 1.5 of the maximum pressure recorded by Tran et. al. 
(2009) [86]. The resulting pressure and corresponding displacement curves are plotted in 
Figure 4.15. Each of the samples demonstrated a quasi-linear behaviour with sudden 
rupture on reaching maximum burst pressure rating.  
Figure 4.14 Selected detail of diaphragm 
cap (see Appendix 5). 




Figure 4.15 Results from pressure testing with varying sample thickness. 
Figure 4.16 provides a more detailed look at the resulting displacements at the 
desired operational inflation pressure of around 20kPa. 
 
Figure 4.16 Displacement at 20.7kPa for liquid silicone of varying film thicknesses 
(source UMass Lowell). 
The C6-530 silicone rubber has great balance of tear strength and elasticity. A film 
thickness of between 6.5 mil (165 μm) and 5 mil (127 μm) meets the operational 
performance constraints. However, thicknesses with vertical displacements greater 
than the aperture radius at 20kPa ruptured at pressures lower than 60kPa. The 
thickness can be further fine-tuned to allow large displacements and high rupture 
pressures. A film thickness of 8 mil (203 μm) was recommended since it will not 
rupture at 60kPa, which is within the margin of error for maximum operating pressure 
presented by Tran et al [86]. 
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4.3.4. Failure Mode Analysis 
A DFMEA of the ProDural device was produced as part of the design control process 
(see Appendix 4). The only additional risk, when compared with standard LOR syringes, 
relates to the visual indicator. The indicator may fail either by leakage at the cap or over-
inflation of the membrane causing rupture. The clinical impact in either case is minor, 
resulting in a failed attempt to identify the epidural space, requiring a replacement device. 
Other risks such as over advancement of the needle beyond the epidural space is common 
with the existing method. All identified risks are reduced so far as possible to acceptable 
levels in terms of probability of occurrence and severity to the patient. Acceptable risk 
levels are described in the risk management standard operating procedure (SOP 7.1). Risk 
mitigation methods include risk reduction through inherent safety in design, risk 
reduction by protective measures in the manufacturing process, and risk reduction 
through the supply of information for safety. 
 
A pre-clinical human cadaver study was completed by a consultant anaesthetist, Dr 
Peter Lee, at the University College Cork FLAME laboratory. The primary objective of 
the study was the technical feasibility of ProDural in locating the epidural space with both 
air and water as an inflation medium. The secondary objective was to compare ProDural 
to existing technologies for (1) amount of fluid injected on reaching the epidural space, 
(2) ease of use, (3) effectiveness in finding the epidural space, and (4) length of needle 
insertion. Finally a number of different ProDural prototypes were used varying in 
diaphragm material and thickness and aperture diameter to determine optimum 
characteristics based on end user feedback.  
Several repeated tests were executed to establish the effectiveness of ProDural at 
identifying the epidural space in a freshly preserved cadaver. The unembalmed cadaver 
used in this investigation was that of a 99 year old female. The cadaver was in excellent 
condition, frozen within 24 hours and thawed 48 hours before the investigation, and the 
vertebral column was intact from the cervical to T11 vertebrae. The spine demonstrated 
scoliosis consistent with cadaver age. The cadaver was placed in the supine position with 
a slight right tilt. Using the conventional LOR technique and an 8ml Perifix syringe 
(B.Braun), the clinical investigator introduced a needle tip into the subarachnoid space in 
the region of T5. Once the subarachnoid space was located, a catheter was inserted and 
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methylene blue dye was infused into the subarachnoid space. This approach facilitated 
investigation of dura puncture where blue dye would become visible on aspiration.  
4.4.1. Epidural Administration with Air as the Inflation 
Medium 
The first assessment was to compare ProDural with conventional LOR syringes (8 
ml Perifix and 7 ml Epilor syringe) using air as the inflation medium. The 
conventional LOR syringe was firstly used to identify the epidural space at T9. Using 
the midline approach and a pulsing LOR technique, the clinician identified the 
epidural space. The needle depth (4.8 mm) and the volume of air injected (2.5 ml) 
were recorded. The syringe was then removed and the needle site was aspirated. Blue 
dye did not become visible on aspiration, therefore it was concluded that the dura had 
not been punctured. The needle was then removed. The test was repeated in the same 
region using a ProDural syringe. ProDural was advanced using the midline approach 
as before until an apparent collapse of the visual indicator was observed (see Figure 
4.17). The position of the needle was marked as point 1 (P1) and both the needle depth 
(4.6 mm) and injected volume (1 ml) were measured. Subsequent aspiration failed to 
identify blue dye. The ProDural syringe was removed and the needle was left in place. 
Succeeding dissection would demonstrate whether or not the needle at this point 
punctured the dura.  
 
Figure 4.17 ProDural prototype used in pre-clinical cadaveric trial in A) its inflated state 
advancing towards the epidural space, and B) its deflated state on needle tip entry into 
the epidural space. 
It was noted that there was no apparent negative effect using ProDural over the 
commercial LOR syringe in terms of ease of use. The instant collapse of the 
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diaphragm resulted in less air being inserted into the epidural space and allowed the 
clinician to maintain the LOR technique. The pink visual indicator was easily apparent 
and preferred over the more neutral white diaphragm. 
4.4.2. Epidural Administration with Water as the Inflation 
Medium 
The next assessment was to establish whether or not there was a perceivable difference 
using water as the inflation medium. The insertion region for this test was T10. The 7 ml 
Epilor syringe by BD was used for the conventional syringe as the graduations on the 
barrel were more defined. The barrel was charged with 5 ml of water and the syringe and 
needle were advanced until a loss of resistance was perceived whereupon the syringe had 
discharged to 3 ml (2 ml injected). The needle length measured approximately 4.5 mm. 
Aspiration ruled out dura puncture, and the needle was removed. 
ProDural was also charged with 5ml of water and advanced until the bulging 
diaphragm collapsed. The resulting needle length measured approximately 5mm and the 
volume of fluid injected measured approximately 1 ml. The ProDural syringe was 
removed and the needle left in place. The point was marked as P2. 
The ease of use and effectiveness was comparable to the existing LOR syringe with 
no perceivable drawbacks. The near instant collapse of the visual indicator reduced the 
user’s reaction time, thus reducing plunger advancement. There was no apparent 
disadvantage in using water over air. 
 
Figure 4.18 Cadaver assessment of a 10ml ProDural prototype. 
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4.4.3. Aperture Diameter Impact Assessment 
The next assessment reviewed prototypes of varying aperture diameters on device 
performance and usability. The three sizes assessed were 6.6 mm, 7.5 mm and 10 mm 
(site marked P3). There was no perceivable difference in the ease of use between the 
larger and smaller prototypes. The larger diameter required less pressure to displace 
the diaphragm outwards and its percentage elongation is not as extreme (see Figure 
4.18). In addition the larger inflated surface further emphasised the loss of resistance 
when detected. However, the smaller prototype may look neater and less cumbersome 
at little or no cost in performance. The decision on final device geometry may 
therefore depend on appearance and ergonomics.  
4.4.4. EpiDrum Comparison  
The final test compared the Epidrum device to ProDural. An Epidrum device (see 
Figure 4.19) was charged and advanced with an epidural needle towards the epidural 
space in the region of T6. Despite several attempts the Epidrum bulge failed to 
collapse. The pressure required to inflate Epidrum was far less than that of ProDural 
and thus may have led to tissue lodging and blocking the advancing needle.  
 
Figure 4.19 Epidrum epidural location device in use as it is advanced towards the 
epidural space. 
The 10 mm diameter, pink latex ProDural device was then used in the same 
location. At this point, the area was becoming compromised due to the number of 
insertion attempts with Epidrum, thus the visual indicator in ProDural would begin to 
leak as soon as it was charged and it was nearly impossible to further locate the 
epidural space in this region. 
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The 10 mm prototype then moved to the cervical region between C6-C7 and reapplied. 
The smaller 6.6mm diameter ProDural with a 0.13 mm thick latex membrane and a further 
ProDural with a 0.18 mm thick latex membrane were subsequently used until the epidural 
space was located (point P4). The thicker 0.18 mm prototype, which was charged with 
air, displayed a very evident loss of resistance on reaching the epidural space. It was noted 
that the initial pressure to form a defined bulge was greater in the 0.18 mm thick 
prototype.  
Additional sites were selected to further compare Epidrum with ProDural. However 
all subsequent attempts failed to locate the epidural space. The vertebral column was no 
longer sufficiently intact to carry out further tests. 
4.4.5. Pre-Clinical Dissection 
The investigation concluded with a dissection in order to demonstrate that the epidural 
space had been reached and that the dura was not punctured (see Figure 4.20). An 
anatomist dissected the region in a layer-by-layer fashion and care was taken to expose 
the distal tip of the epidural needle without moving it from its position. The needle 
positioned at points P1 and P2 were first to be examined. After careful dissection it 
became clear that at these locations, ProDural successfully located the epidural space 
without puncturing the dura. The dissection continued to expose points P3 and P4. It was 
noted that the needle tip in each case was located in the epidural space without underlying 
dural puncture. 
 
Figure 4.20 A) posterior dissection to reveal tip of ProDural placed epidural needles, and B) 
close up view of needle tip location P1 illustrating that the dura was not damaged and the 
needle tip was successful placed in the epidural space. 
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4.4.6. Pre-Clinical Conclusions 
ProDural was found to be at least as effective and easy to use as a conventional 
LOR syringe. In both the air and water tests, ProDural introduced less fluid on 
detection of loss of resistance (65% reduction) and was subsequently proven to have 
reached the epidural space without puncturing the dura by means of exposing the 
needle tip through dissection. The immediate collapse of the visual indicator improved 
the reaction time of the user preventing excessive advancement of the plunger and 
epidural needle. Clinical feedback cited a bright colour (e.g., green or yellow) as 
preferable for the diaphragm. In most cases, the epidural is administered in a dark 
labour ward in the middle of the night, and bright colours would aid in the detection 
compared to more neutral colours. It was found that thinner membranes performed 
better due to the smoother transition from the elastic to plastic states. The diameter of 
the diaphragm played little role in performance and may be refined to look most 
appealing to the end user. There were several shortcomings in the investigation. The 
model used was not optimum due to the age and absence of the lumbar region. As the 
investigation progressed, it proved increasingly difficult to determine the epidural 
space. Due to the degrading effect of repeatedly introducing needles, it was not 
possible to carry out several repeat tests along the vertebral column. Notwithstanding 
these limitations, the study indicated that ProDural represents a very promising device 
for identifying the epidural space. Furthermore, the success rate in identifying the 
epidural space indicates an effective design solution. More studies are necessary to 
determine if ProDural can effectively reduce rates of accidental dural puncture or 
‘false positive’ rates. The results of the bench-top trials and pre-clinical investigations 
were presented at IASTED International Conference on Biomedical Engineering, 
Zurich (2014) the proceedings of which were subsequently published [9]. 
 
A second objective of the epidural project was to assess the commercial feasibility 
of the resulting device with the aim of exploring business opportunities. The ProDural 
project was successful in applying for a clinical innovation award (2013), sponsored 
by Enterprise Ireland and supported by the Cleveland Clinic Ohio. This award was 
leveraged to evaluate the commercial feasibility of the proposed device as well as 
accommodating meaningful engagement with clinicians at the Cleveland Clinic to 
evaluate clinical utility. In addition, the M2D2 New Ventures award previously 
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described, was used to produce a health economics report in collaboration with Smith & 
Nephew (Smith & Nephew Inc., Andover, MA). The following section will describe the 
results of commercial feasibility assessment. 
4.5.1. Epidural Market Assessment 
The European market for regional anaesthesia was estimated at $14.8 million in 2011 
with projected growth to $30.7 million by 2018. A Frost and Sullivan report (M7C3-54, 
2011) listed an average epidural tray cost of $15 (estimated syringe cost is $2-$4) with 
strong market growth. Key market growth drivers include emerging market epidural 
uptake especially in obstetrics, increasing incidences of therapeutic epidurals, and 
continuing increases in general surgery volumes due to obesity.  
The US Department of Health and Human Services indicate that based on information 
provided by a total of 36 reporting states and the District of Columbia, in 2011 out of 
3.267 million live births, approximately 2.3 million or 70.85% involved the application 
of epidural or spinal anaesthesia during labour. This rate was higher for Whites (74.6%) 
compared to Blacks (7.32%) and Hispanic (61.6%) and, as a general rule, the level of 
treatment with epidural or spinal anaesthesia declined with the advancing age of the 
mother. Given that the total number of live births in the US was 3.99 million in 2015, 
applying the 2011 epidural rate suggests that approximately 2.82 million deliveries in 
2015 involved the provision of epidural/spinal anaesthesia during labour (see Table 4.6). 
Separate to labour applications, there are also over 8.9 million therapeutic epidurals 
performed in the U.S. each year [115]. Based on the current incidence rates of accidental 
dural puncture (approx. 1.5% [87]), this equates to approximately 175,000 clinical events 
costing the US healthcare system an estimated $330 million dollars per year (based on an 
inpatient day cost of $1,878/day [116]).  
Table 4.6. Global Epidural Market 2013. 
Market Annual births Neuraxial 
block rate 
Epidural or spinal 





Ireland 74,000 37% 27,380 5335 32,715 
UK 729,674 33% 243,225 74,000 317,225 
USA 3,900,000 71% 2,763,150 8,900,000 11,663,150 
EU28 4,396,326 33% 1,465,442 586,219 2,051,661 
Total 4,214,000  4,499,197 9,565,554 14,064,750 
EU27 is UK-correlated and does not include ROI/UK   
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The typical Medicare reimbursement for an epidural shot is $200 if given in a 
doctor’s office, $400 if done at a surgery centre and about $600 if performed at a 
hospital [115]. Between 1994 and 2001, use of epidural injections increased by 271% 
and facet joint injections by 231% among Medicare beneficiaries [117]. Total 
inflation-adjusted reimbursed costs (based on professional fees only) increased from 
$24 million to over $175 million over this time period. More recent data indicate 
continued rapid growth in use of spinal injection therapies among Medicare 
beneficiaries, with an increase of 187% in use between 2000 and 2008. 
The scope of application outside of anaesthesia is vast. Numerous clinical 
indications were assessed by clinical engagement (e.g., PEG tube placement, trauma 
settings, abscess and urinary drainage etc.). Trocar placement was identified as high-
potential due to (1) clear unmet clinical need, (2) large volumes, and (3) clear go-to-
market strategy leveraging existing relationships with clinical champions.  
ProDural may find use in both closed and direct trocar insertion techniques 
representing a global market opportunity of over 10.7 million annual laparoscopic 
procedures (see Section 3.5.1). By replacing high-cost Veress needles (US $22-45) 
with a low-cost device, a commercially viable proposition may be possible.  
4.5.2. Key Opinion Leader’s Feedback 
With the support Enterprise Ireland, two of the promoters (Dr Peter Lee and Conor 
O’Shea) travelled to Cleveland Clinic (Nov 2013) where a clinical focus group was 
conducted with a number of Cleveland anaesthetists. The key outcomes from the focus 
group are as follows: 
 As much as one dural puncture occurs per week within the training programme in 
Cleveland (i.e., 1/30-40 procedures per week). 
 Approximately one in every 20-25 procedures would result in a spinal tap, with a 
blood patch typically required once per month.  
 It would be difficult to prove that a device can reduce the already low incidence of 
spinal taps as this is quite small number and may not sway the purchasing bodies.  
 It may be more useful to demonstrate a reduction in the number of false positive 
administrations particularly in obese patients as this is a more significant problem.  
 When compared to the Epidrum and Episure devices, ProDural was preferred for 
usability amongst the clinicians.  
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 The fact that ProDural allowed clinicians to continue LOR with air or water was rated 
positively.  
 Conceptually and intellectually, the respondents were interested in ProDural’s facility 
to provide a visual indicator that the epidural space had been reached. 
 From a teaching point of view, having a visual indicator is very useful when 
confirming that a trainee has reached the epidural space.  
 It was largely felt by this group of anaesthetists that a clinical trial would be required 
before adopting such a device but they were willing to test ProDural once available. 
ProDural was also presented at a number of other Irish and US clinical centres (CUH, 
Mater Dublin, Harvard Medical School, Brigham and Women's hospital, Massachusetts 
General Hospital). In general, there was positive feedback from anaesthetists in both the 
US and Ireland as evidenced by their willingness to support clinical studies. However, 
the clinicians while expressing their interest in discovering new devices were also quick 
to point out that anaesthetists as a profession, particularly those working in maternity 
hospitals, tend to be conservative in their choice of techniques and tools. This frequently 
translated to a resistance to change.  
As part of the M2D2 New Ventures Competition, a report was produced in 
collaboration with Smith & Nephew which summarised the results of three interviews 
with anaesthetists (a fellow in Pain Management, an Associate Professor of 
Anaesthesiology and a Professor of Anaesthesiology). The three respondents, whose 
identity remained anonymous, had varying levels of post-residency experience (years: 3, 
22, 30). The key comments made were as follows: 
 An additional safety measure is attractive. Education would be the major application 
for this device 
 If the miss is a dural puncture, 50% of patients get a spinal headache, 50% are free of 
any symptoms. For those with a spinal headache, 50% need a clot to seal the hole. 
50% respond to medication & hydration.  
 Other uses for this technology (include) entering the abdominal cavity in laparoscopic 
surgery. Both the epidural space and the abdominal cavity are under slight negative 
pressure. 
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 Novel idea. Some people are better than others with haptic feedback. Hard to say 
whether this is based upon experience only. Those who don’t do many epidurals per 
year may be more receptive to this technology.  
 We need a better way to identify the epidural space than we currently do; it is very 
operator dependent. If used in teaching, it is possible this will be rapidly adopted. 
 Concerns: Will the indicator add significant weight to the syringe? Is air entering the 
epidural cavity? (“An air bubble can prevent anesthetic from working. If it injects 
0.5cc, it’s ok; we can aspirate that. It would be unacceptable to inject 3cc of air”). 
In addition to engaging with the clinical community to assess the clinical utility of 
the presented device, ProDural received commercial validation in the form of securing 
a top four finish at the MedTech Idol (Innovator) Dublin 2014. Thirty-six early-stage 
medical devices entered the international contest and ProDural was among just four 
finalists to take the stage for the MedTech Idol competition organised by RCT 
Ventures at the Informa Investment in Innovation (IN3) Medical Device 360° Dublin 
conference. 
4.5.3. Health Economics Analysis  
As a further result of the work carried out with Smith & Nephew, a review of the 
addressable US market size based on CPT coding information, and a basic health 
economics assessment was also carried out. The Current Procedural Terminology 
(CPT) code describes medical, surgical, and diagnostic services and is designed to 
communicate uniform information about medical services and procedures among 
physicians, coders, patients, accreditation organizations, and payers for 
administrative, financial, and analytical purposes [118]. Using the Truven Health 
Analytics tool which reports information on billed CPT codes, data was analysed for 
2011-2014 on a number of relevant procedures where an epidural needle placement is 
required. This information yielded the following observations: 
1. The number of spinal/epidural placements annually in the US is at least 7 million 
per year, as reported by the Truven Health Analytics site.  
2. The number of spinal/epidural placements annually in the US could be as high as 
30 million, as back-calculated from the number of epidural blood patches, one of 
the treatments for post-dural puncture headaches, of which there are over 50,000 
administered annually in the US. 
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In terms of health economics analysis, a paper by Dakka et al [119], was identified 
with a retrospective analysis of patients receiving dural punctures with a cutting needle, 
limited to a single centre. Costs associated with post-dural puncture headaches (PDPH) 
at Henry Ford Hospital in Detroit, Michigan were estimated, and then, using the actual 
rate of PDPH among patients and taking the literature-reported rates for PDPH following 
lumbar puncture, the theoretical cost savings that would have occurred, had atraumatic 
needles been used, were calculated. The theoretical cost savings were $45,435 for the 274 
patients (or $166 per patient), assuming no difference in price between the two needles. 
Given that this figure corresponds to a theoretical elimination of 27 headaches, the costs 
per headache can be assumed to be $1,682 ($45,435/27 = $1,682 per patient additional 
cost burden resulting from a PDPH). 
If the ProDural device is able to eliminate 4 out of 5 accidental lumbar punctures, in 
experienced hands, this will reduce the PDPH from 2.5/1,000 to 0.5/1,000 (assumes a half 
of accidental punctures result in PDPH). If the PDPH costs are taken from the Dakka 
paper, this reduction in PDPH will realise a cost savings of 2 × $1,682 = $3,364 for 1,000 
patients, or $3.36 per patient. 
Taking the $3.36 per patient cost savings and using a 11.72 million figure for epidurals 
in the US (8.9 + 2.82 million), and assuming no price differential between ProDural’s 
syringe and existing syringes, the total benefit to the healthcare system would be 11.72 
million × $3.36 = $39.42 million if all epidural syringes were converted to ProDural 
technology. In theory, ProDural could charge an extra dollar over the existing syringes 
and the cost savings to the payers would still collectively be $27.7million (11.72 million 
× $2.36). 
4.5.4. Intellectual Property Prior Art Review 
A European provisional patent (EP14150806) was filed as part of this PhD research 
project for the presented invention entitled “An indication device and method for locating 
a natural cavity in a body” in January 2014. The provisional patent application identified 
the key novel and non-obvious features of the device compared to prior art. The principal 
comparable devices are those that use the differential pressure method to indicate entry 
into the epidural space. The two closest competing patents identified were US 7,175,608 
(Epidrum) [99] and US 5,902,273 (Yang and Yang, not commercialised) [120].  




Figure 4.21 A) US patent number 7,175,608 (Epidrum), and B) US patent number 5,902,273 
(Yang and Yang). 
The key distinguishing, novel and non-obvious features of ProDural which are not 
evident from review of the identified prior art were: 
 An all-in-one syringe including diaphragm membrane construction, 
 Maintenance of the LOR technique on epidural entry,  
 Visual indication by means of a deflating diaphragm integrated within the syringe 
body. 
In addition, the present device has the potential to provide visual indication of 
entry into any natural body cavity which is subject to transcutaneous needle puncture. 
Clinical settings where this is relevant include but are not limited to:  
 Identification of the peritoneal cavity during laparoscopic surgery 
 Percutaneous endoscopic gastrostomy (PEG) tube placement 
 Percutaneous suprapubic catheterisation for bladder drainage 
 Percutaneous abscess drainage 
 
Figure 4.22 ProDural design with visual pressure drop indicator integrated into the 
distal end of the syringe barrel. 
Subsequent to the provisional patent filing, a European Search Report identified a 
potentially infringing patent filed on the 24th February 2010 in China. CN201409922 
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(Dong Sun) discloses a syringe device whereby one embodiment (Figure 4.23) of the 
invention includes a visual indicator on the syringe barrel comprising an elastomer. 
However this device operates on a different principle to that of the present invention. 
CN201409922 does not maintain the loss of resistance technique upon entry into the 
epidural space. In this disclosure, the plunger is rotated into place rather than pushed. This 
differs significantly from the ProDural embodiment and does not make the embodiment 
of ‘922 compatibly with maintaining loss of resistance on epidural entry. 
 
Figure 4.23 Potentially infringing patent (CN201409922) discovered during European 
search report. 
In addition, ‘922 discloses an elastomeric member (41) connected to the pedestal of 
the indication column via a spring which under increased intra-barrel pressure, stretches 
upwards. As the plunger is rotated via a slotted configuration and increases pressure 
within the barrel, it excites the membrane causing it to extend outward. At this point, LOR 
is no longer used and the complete syringe and needle assembly are advanced by pushing 
the system toward the epidural space until such time as a pressure drop at the needle tip 
is detected causing the spring to collapse the membrane. This embodiment is significantly 
different to the ProDural proposition.  
Despite clear differences in construction and deployment of ProDural and 
CN201409922, the overall claims disclosing a visual indicator incorporated into a syringe 
barrel to signal epidural entry presented an issue for the ProDural project. Limitations of 
resources for both time and finances prevented further exploration of the IP to investigate 
other areas of novelty to secure clean protection. To the knowledge of the team, patent 
‘922 and its inventor Dong Sun never proceeded to commercialise this filing which 
presents opportunities for future IP acquisition or indeed licencing. The clear differences 
in design and method of use also presents an opportunity for further device development 
to overcome concerns of inventiveness and to proceed with successful patent filings.  
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4.5.5. Device Regulatory Classification 
The regulatory classification of the presented device follows the rules listed in 
Annex IX of Directive 93/42/EEC as amended, and schedule 9 of related Irish 
regulation (S.I. No. 252/1994). ProDural falls within the scope of the directive as a 
medical device, as defined in Article 1 of Directive 93/42/EEC and Article 2 of the 
national Regulation. 
This device will be designated as a standalone device, with an intended use of 
signalling correct location or entry of a probe such as an epidural needle or the like 
into a natural cavity in a body through both visual and tactile feedback for a continues 
use less than 60 minutes (transient) and is non-invasive. Therefore according to rule 
2 of 93/42/EEC Annex IX, ProDural may be classified as a Class I device. 
Furthermore, ProDural may be classified as a Class 2 device under FDA 
recognized consensus standards, specifically related to regulation number 880.5860 
and product code FMF which is concerned with the device name “syringe piston”. 
 
The goal of this work was to design and develop a medical device which can 
advance the efficacy of epidural administration with a potential alternative application 
of peritoneal cavity detection in laparoscopic surgery. With over 2.8 million patients 
receiving epidural or spinal anaesthesia during labour in the US alone, it is of 
paramount importance to identify a more reliable method of epidural administration. 
The proposed solution maintains the popular tactile feedback associated with the LOR 
technique whilst potentially enhancing operational performance through an integrated 
visual pressure drop detector.  
4.6.1. Technical and Commercial Review 
The instantaneous collapse of the diaphragm may improve the clinician’s reaction 
time thus preventing excessive needle advancement and reducing the risk of 
accidental dural puncture. ProDural may also reduce the risk of false positive readings 
in obese patients as the clinician may vary the applied pressure to determine when the 
epidural space has been reached. The contrasting bright surface of the diaphragm 
ensures clear visibility even in a dimly lit maternity ward. Finally, ProDural may 
reduce the steep learning curve associated with epidural administration as the bulging 
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diaphragm allows teaching clinicians to visually determine correct placement by their 
trainee doctors. 
The final development of a fully specified ProDural device to design freeze was 
hampered due to financial and time limitations. However, the solution proposed in this 
work does point to a promising and effective method of identifying the epidural space. 
Further design verification is required to prove that the current snap fit design is sufficient 
to prevent any leakage from the inflated diaphragm. In addition, further work is required 
to finalise a material which is biocompatible and meets all the design specifications. 
Finally, additional resources are required to get further opinions on patentability and to 
explore additional novel functionality. 
While the results of this preliminary analysis and experimentation are encouraging, a 
clinical investigation will be required to investigate whether or not ProDural can 
statistically reduce the incidence rate of accidental dural puncture and for false positive 
readings. The size and cost of a future clinical study which would be sufficiently powered 
to show the efficacy of ProDural at improving patient safety, has yet to be determined. 
The mechanical experiments defined the relationships between the inflation pressure and 
true stress and stretch ratio for the current device configuration. The pre-clinical study 
served as a technical feasibility evaluation verifying the proof of concept and suggested 
that ProDural is at least as effective and easy to use as existing LOR syringes. The most 
significant advancement noted in the study is the improved reaction time on reaching the 
epidural space. This may reduce the risk of accidental dural puncture and consequently 
reduce costs to the healthcare provider due to shorter hospital stays. It was also 
demonstrated that ProDural introduced less volume of injection fluid that would 
otherwise dilute subsequent anaesthesia and may cause air embolisms and or other 
complications [83], [121]. 
Future work is required before ProDural may be evaluated in a live human 
investigation. The operational nature of ProDural is one that requires a smooth transition 
from the original undisturbed diaphragm position to the inflated state (λ ≈ 4). The highly 
elastic nature of natural rubber latex with an elastic modulus of between 1 and 5 MPa was 
ideal for the early technical evaluation of ProDural. Collaborative work with UMass 
Lowell analysed the physical and mechanical characteristics of a medical grade silicone 
rubber. However questions still exist relating to the performance of this material. From a 
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commercial point of view, ProDural has a potential of fulfilling a gap in a quickly 
expanding market with meaningful cost benefit from a health care providers point of 
view. The current results point to a promising alternative epidural space location 
device which has the potential to help alleviate complications and cost in epidural 
administration. 
4.6.2. Design Control Review 
Similar to the laparoscopic retractor project described in Chapter 3, the epidural 
project began before the design control process was implemented. However, as with 
SecuRetract, all commercial research and design development activities were 
recorded and used to populate the Design History File. Currently ProDural is in Phase 
III of the design and development process as described in Chapter 2. As qualitatively 
illustrated in Table 4.7, the ProDural project has only began to progress through the 
Phase III activities. Despite independently classifying each of the five phases of 
design development, certain activities have progressed beyond the phase boundary. 
As a result of the Enterprise Ireland Clinical Innovation Award and the M2D2 New 
Venture Award, particular emphasis has been placed on the commercial opportunity 
and market launch strategy, which exceeds what is typical of the earlier phases.  
At times during the implementation of design controls, the documentation seemed 
burdensome; having to document the justifications for design iterations, populate the 
DDP and DFMEA and record interactions with the end-users. However, on reflection, 
these records served to command project focus and achieve target milestones as well 
as proving detailed historic evidence of developmental activities. Due to the inherent 
simple nature of ProDural in terms of design, retrospective population of the DHF 
may be achieved quite easily. However additional time and resources are required to 
fully populate the DHF to ensure compliance with the requirements of the design 
control process. The main drawback from retrospectively applying a controlled design 
process to a project is that certain activities, such as planning for design for 
manufacture, occur later on whereas earlier consideration may have led to different 
material selection at an earlier phase.  
The ProDural project provides a case study of what typically occurs when a 
seemingly novel solution comes against potential intellectual property infringements. 
Despite presenting an exciting proposal to and end-user identified need to a global 
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problem, the ProDural project struggled to get the financial aid to support more extensive 
development activities. In the corporate world, entities have additional resources to 
pursue formal opinions of patentability and/or focus on specific functionality or aspects 
of the design whereby claims may be secured. Alternatively, the option of 
acquiring/licencing the patent in question would be pursued should the project align with 
corporate strategy. However, in the case of university projects which typically rely on 
government and/or departmental finances to support product development, the prospect 
of infringing claims can be a detrimental factor to securing aid. Despite this, the ProDural 
may still serve as an exemplar to the introduction and administration of the design control 
process developed as part of this work. 




Phase I Phase II Phase III Phase IV Phase V








100% 100% 20% 0% 0%
Concept Solutions / 
Early Risk Assessment
Define Design Inputs Manufactures / 
Suppliers Identified
Final Design Validation Post-Market 
Surveillance
100% 100% 20% 0% 0%





Update / Implement 
Risk Controls
Complete DHF, DMR, 
Technical File 
Sales and Physician 
Training 
100% 75% 20% 10% 0%
Early Intellectual 
Property Review




Artwork / Traceability Expand Sales Effort









100% 100% 0% 20% 0%
Risk Analysis Update Process Validation Plan Manufacturing 
Qualification 
Quality Audits







 Business Plan Update  DHF / 
Business Plan 























Chapter 5 – SafeTrac Tracheal Intubation Device 
111 
 





Tracheal intubation, often simply referred to as intubation, is a medical procedure that 
involves the placement of a flexible plastic tube into the trachea (windpipe) to preserve 
an open airway or to serve as a conduit through which to administer certain drugs. Despite 
tens of millions of these procedures being performed annually worldwide, airway 
intubation remains one of the most difficult anaesthesia activities. This project aimed to 
develop a low cost disposable device to improve the ease of intubation, particularly in 
cases of difficult intubation. Unlike previously described devices in this thesis, this 













The intubation project began as a response to the clinical need proposed by Dr 
Gabriella Iohom and Dr Peter Lee, consultant anaesthetists at Cork University 
Hospital, as part of the UCC Biomedical Design module. Following proposal of an 
initial concept design in 2013 by one of the BioDesign groups which failed to offer a 
viable solution to the clinical need, the author began to start researching potential 
solutions as part of this PhD (2014). The following sections will detail the unmet 
clinical need and detail the development activities carried thus far which is now in 
Phase II of the design control process. 
5.1.1. Endotracheal Intubation 
The first step in Phase I of the design control process is to investigate in more 
detail the clinical need (identified by the clinicians in this case) and to define a 
problem statement. One of the most common difficulties encountered in anaesthesia 
is airway intubation. Endotracheal intubation involves placing an endotracheal tube 
(ETT) into the patient’s trachea to create an artificial air passage for breathing (see 
Figure 5.1). Typically an ETT is used on patients under-going surgery to provide for 
the administration of anaesthesia, when ventilation of the lungs is necessary, or in an 
emergency when a patient is injured and has lost the ability to breathe independently. 
The traditional approach consists of inserting an ETT through the mouth or nose, using 
a Macintosh laryngoscope (direct laryngoscopy). The tube placement follows a non-
trivial trajectory, through the mouth/nose, past the vocal cords, into the trachea and 
not the oesophagus.  
 
Figure 5.1 Endotracheal tube (A) and inflation cuff (B) inserted into the trachea (C) 
avoiding the oesophagus (D) [122]. 
Chapter 5 – SafeTrac Tracheal Intubation Device 
113 
 
A flexible stylet or "bougie" is often inserted through the centre of the endotracheal 
tube during introduction to enable navigation. Intubation may be performed by 
individuals with varying levels of medical experience and skill levels. Less experienced 
clinicians have far lower intubation success rate (typically 80% [123]). In addition, a 
patient’s trachea region may be obstructed, or the anatomic path from the mouth to the 
trachea may be tortuous. Conventional intubation devices and techniques may cause 
damage to tissue within the patient’s airway leading to swelling or bleeding. Failed, 
difficult, or delayed intubation is a primary cause of litigation claims and failure to 
intubate is reported in 1 in 50-100 cases [124]. 
Difficult tracheal intubation (DTI), which is associated with grades 3 & 4 airway 
access classification (see Figure 5.2), may lead to oxygen desaturation, hypertension, 
dental damage, admission to ICU, complications at extubation, arrhythmias, 
bronchospasm, airway trauma, CICV, and the sequelae of hypoxia (cardiac arrest, brain 
damage, and death) [125].  
 
Figure 5.2 Direct laryngoscopy grading system [126], [127]. 
Laryngoscopy performed in the operating theatre under controlled circumstances 
carries a risk of difficult intubation in up to 10% of cases [128], [129]. Unfortunately, 
physical findings on examination of the airway discriminate poorly between potentially 
easy and difficult intubations [130], [131]. Thus, anaesthetists need to be prepared for the 
unanticipated difficult airway. In addition, there are circumstances that lend themselves 
to a high risk of difficult laryngoscopy and tracheal intubation, such as emergency 
intubations outside the operating theatres, (e.g., emergency departments, and intensive 
care units). For a list of complications see Table 5.1 and Table 5.2. 
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Table 5.1 Summary of complications and incidence rates from Cook and MacDougall-Davis 
[132]. 
Complication Incidence  Clinical setting Knock on effect  
Can't intubate can't ventilate 
(CICV) 
1 in 5,000 General anaesthetics Emergency surgical airway 
(ESA) 
Emergency surgical airway (ESA) 1 in 50,000 General anaesthetics 25% of anaesthesia-related 
deaths 
Emergency surgical airway (ESA) 1 in 600 Emergency department 
(ED) 
Failure results in risk of death 
CICV requiring ESA 1 in 200 Emergency department 
(ED) 
25% of anaesthesia-related 
deaths 
Minor complications - e.g. 
difficulty with direct 
laryngoscopy 
0.5-1% General anaesthetics Rarely of great clinical 
consequence 
Failed intubation 1 in 1,000 -
2,000 
Elective setting Failure to intubate 
Failed intubation 1 in 250 Rapid sequence induction 
(RSI) in the obstetric 
setting 
Failure to intubate 
Failed intubation 1 in 50 -
100 
Emergency department 
(ED), intensive care unit 
(ICU), and pre-hospital 
Failure to intubate 
Direct tracheal intubation (DTI) 
(grade 3 and 4) 
10.10% General Failed laryngoscopy in 0.1% 
DTI occurrence with previous 
DTI  
24% General Intubation failed in 30% of 
previous DTI 
Increase risk of DTI due to 
obesity (BMI>35 kg m-2) 
Odds ratio 
+ 1.34 
General Increase risk of DTI 
Increase risk of DTI due to 
absence of neuromuscular 
blocking agents  
Odds ratio  
+ 1.48 
General Increase risk of DTI 
Adverse events (general) 3.70% General 14% of events lead to death 
Table 5.2 Main categories of injury claims associated with respiratory events from 
American Society of Anaesthesiologists Closed Claims Project (ASACCP) [132]. 
Injury claim % of claims Clinical setting 
Inadequate ventilation 38% Non-emergency surgery 
Oesophageal intubation 18% Non-emergency surgery 
Difficult tracheal intubation (DTI) 17% Non-emergency surgery 
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Anaesthetists are increasingly turning to video laryngoscopes for normal as well as 
difficult tracheal intubations in both the elective and emergency setting. Compared to 
standard direct laryngoscopy, these devices offer better views of the airway, require less 
force to intubate the trachea, and facilitate guidance of a trainee by sharing the view of 
the airway with the instructor [129]. Despite these advantages, limitations remain. Better 
airway inlet visualization does not translate into increased success with intubation [133]. 
For example, it is impossible to intubate the trachea in 4% of patients using a Glidescope 
(a type of video laryngoscope) despite a satisfactory glottis view and the use of a 
preformed stylet or flexible introducer [134]. Reasons for failure include (i) the inability 
to manoeuvre the endotracheal tube into the trachea or (ii) the endotracheal tube abutting 
the anterior portion of the larynx when using the stylet [129]. While use of an expensive 
fibrescope or bronchoscope overcomes these challenges [135], such technology is not 
always accessible or financially supported.  
5.1.2. Current Technology 
The endotracheal market is a rather crowded one. The standard laryngoscope handle 
and blade is the most common instrument used to elevate the tongue and mandible to allow 
visualization of the cords. The blade can be straight (Miller) or curved (Macintosh). Miller 
blades are usually reserved for paediatric patients while most physicians use a Macintosh 
blade for adults (see Table 5.3). The blade must be long enough to reach the vallecula (the 
space between the base of the tongues and the epiglottis). Once correctly positioned, the blade 
is used to guide the endotracheal tube into position. 
A malleable stylet can also be used in conjunction with the laryngoscope to aid ETT 
insertion. The stylet is inserted inside an endotracheal tube to make it more rigid, or to change 
the shape of the tube. For example, the tip of the endotracheal tube can be bent slightly to 
facilitate passage through the cords. It is recommended that the stylet be used in all emergency 
intubations. In this way, if the shape of the tube needs to be modified, the stylet is already in 
place. The stylet should be lubricated prior to insertion into the endotracheal tube, so that it 
is easy to remove. 
Technology specifically designed to aid in difficult intubation includes video 
laryngoscopes, fibreoptic lighted stylets, flexible tube guides, endoscopes and steerable 
guides. Table 5.3 compares the perceived advantages and disadvantages associated with 
these technologies. 
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Table 5.3 Comparison of commercially available technology. 





The traditional global 
standard for tracheal 
intubation and successful 





Reusable, low cost per 
use, robust and virtually 
unbreakable. 
Not reliable for difficult 
intubation, requires 
multiple sizes, risks of 




Direct visual confirmation 
of intubation in real-time 
(Multiple products 
including V-Mac and C-




Direct visualisation of the 




High initial purchase cost 
($10,000), not always 
available, not always 
successful in accessing 




Lighted stylet provides 
transabdominal lighted 
confirmation of entry 
(Multiple products 
including Bonfils & 
Brambrink (Karl Stortz), 
Shikani, PocketScope & 
Levitan (Clarus Medical), 
Tube-Stat (Medtronic). 
Visual confirmation by 
means of the 
transabdominal light 
position. 
Expensive (compared to 
flexible tube guides) -
$100-150, infection risk 
with re-use, no multiple 
sizes, no working 





Flexible devices provide a 
low-cost reposable or 
disposable alternative to 
visual verification. 
(Multiple products 
including Aintree, Frova 




Low cost ($5-45), soft 
Coudé tip (Smiths), 
reusable (Cook, 
Verathon, Thruphatek), 
malleable, multiple sizes 
available (Cook). 
Lack of control (no tip 
deflection), pre-formed 
or fixed shape on 
insertion, unreliable, 
infection risk on re-use, 




These flexible intubating 
endoscopes allow the ET 
tube to be mounted 
coaxially. The scope 
intubates the trachea and 
the tube is slid forward 
(Several products, 
reusable and disposable, 
such as Ambu aScope). 
Cost per intubation using 
a reusable or a disposable 
has been calculated by 
Ambu to be slightly more 
than $300. They are most 
useful for planned 
difficult intubations. 
Shafts are often 
unnecessarily long to 
allow for variations in 
anatomy. Can be difficult 
to release the ET tube 
without assistance. 
Considered expensive 





Steerable Stylet used to 
position ETT during 
intubation. Very few 
products available. E.g. 
Rapid Positioning 
Intubation Stylet (RPiS) 
(Airway Management 
Enterprises). 
When combined with 
VL, the RPiS has the 
ability to flex and 
retroflex the distal tip 
which can improve 
access for the solo 
practioner during difficult 
intubation. 
Lack of human factor 
design, limited 
functionality, relatively 
high market price cost of 









From reviewing the clinical need and current solutions which attempt to meet that 
need, it became clear that a potential gap exists in the intubation market. Difficult tracheal 
intubation, which may result in failure to intubate, occurs in 5.8% of cases for the overall 
population and 15.8% for obese patients [131]. Current solutions are either ineffective (a 
flexible bougie) or vastly too expensive (endoscopes) to have on hand in case of an 
emergency situation. Based on end-user feedback (see Section 5.3.3), the single greatest 
limitation with current introducers and scopes, is the lack of control at the tip to 
effectively steer the endotracheal tube to the target area. Despite being able to now 
visualise the airway using video laryngoscopes, the physician still cannot manoeuvre the 
tip around the epiglottis into the trachea. Therefore a solution which can match the 
manoeuvrability and control of a high-end endoscope, but with the cost effectiveness of 
a flexible tube glide, may present a very attractive value proposition to the health care 
sector.   
5.2.1. Problem Statement 
Develop a cost efficient, dynamic means to improve ease of airway intubation 
allowing for controlled distal tip manipulation to navigate around the epiglottis while 
being capable of use in conjunction with a visual means such as a video laryngoscope. 
5.2.2. Design Criteria and Concept Solution 
As illustrated in Figure 5.3, the concept ideation process converged quite quickly on 
a means of creating an articulating distal tip with an ergonomic control handle. The 
principal design input requirements were to develop a solution to the defined problem 
statement which includes: 
 An outer diameter and length to receive a wide range of ETT sizes. 
 Distal tip deflection in both the up and down directions to a maximum of 90°. 
 Quick engagement and release of the ETT. 
 Ergonomic and intuitive to use. 
 Left and right, single handed use. 
 Minimal setup/assembly. 
 May be used with video laryngoscopy.  
 




Figure 5.3 Intubation concept ideation with A) understanding the anatomical constraints, 
B) single handed plunger concept with gearing or linkage distribution, and C) single handed 
thumb dial actuated concepts. 
The design criteria included producing a solution which could be used for a wide 
range of endotracheal tube sizes. The rule of thumb when sizing the ID of an ETT 
is: 𝐼𝐷 =  
𝑎𝑔𝑒 𝑖𝑛 𝑦𝑟𝑠
4
+ 4. Therefore, adopting a similar design as the SecuRetract 
construction (Chapter 3), a 5mm OD tube configuration may be suitable to children 
and adults from the ages of 4 years and up. The initial focus is on the adult population 
and further design iterations may be subsequently pursued for new-borns, and infants. 
A number of different methods of transferring an axial force and handle designs were 
considered to allow positioning over the patient’s airway (similar to a bronchoscope).  
 
Figure 5.4 Design concept for an intubation delivery device with perspective view (C) and 
cross sectional detail (A and B) developed by the author as part of this PhD. 
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5.2.1. Design Development 
The design concept, which was developed as part of this PhD, comprises a shaft, 
control handle and articulating distal tip (Figure 5.4 and Figure 5.5). The shaft terminates 
with a leaf-spring actuator, which leverages the existing solution for single-plane 
actuation employed in the SecuRetract device. The leaf spring may be displaced in two 
directions, (±90˚) by engaging one of two wires thus providing dynamic tip articulation. 
The wires continue from a cap fastened to the distal end of the leaf spring to a dial built 
within the control handle. The leaf spring returns to the original straight position once the 
dial in the control handle has been released. A flexible sheath covers over the shaft and 
clips onto the control handle providing an air-tight encasement. The overall length of the 
shaft must be long enough to suit a range of ET tubes. Adult tubes can be 30 cm long. 
Therefore, the device must be long enough to pass the 30 cm long tube over the shaft and 
to allow sufficient additional length to extend the articulation tip beyond the sheathed 
ETT. 
 
Figure 5.5 Proposed solution to enable safe intubation with key features highlighted.  
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The design of the control handle was inspired by conventional endoscopes and 
may be used in either the left or right hand of the user. The length of the grip space on 
the handle was based on anthropomorphic data. The hand breath for males from the 
1st to the 99th percentile varies from 8.2 – 9.6 cm, and for females from 6.9 – 8.6 cm 
[136]. Therefore a handgrip length of 8 cm was decided to accommodate both the 
male and female population. The original sketches were rendered and detailed using 
SolidWorks®.  
To use SafeTrac, firstly the ETT is sheathed over the shaft of the device. A tapered 
friction grip at the handle’s base secures the ETT in position but provides for easy 
release of the ETT when required. The ETT and device are inserted into the patient 
following the airway profile until the distal tip of SafeTrac is positioned in the larynx 
(vocal cords). The device’s thumb-actuated handle provides an intuitive user-interface 
for actuation and positioning of a pre-formed rigid shaft which extends beyond the 
ETT length. The shaft’s leaf spring actuator facilitates single-plane articulation of the 
distal tip around the epiglottis and larynx, enabling easy positioning of the tip within 
the trachea. Once the tip of the ETT is steered into position within the trachea, 
SafeTrac is withdrawn and the ETT is advanced as required following conventional 
means for assessing correct placement of the ETT within the patient’s airway (i.e., 
using the graduations along the length of the tube to estimate placement depth, 
inflating cuff and checking for effective seal). A video laryngoscopy may be used to 
aid in visualising placement. However this is not necessary, and conventional standard 
laryngoscopes may be instead used to obtain a view of the vocal folds and the glottis 
during administration.  
5.2.2. Concept Prototype Evaluation 
Based on the strength of the concept design, along with the 
market feedback which will be discussed in Section 5.4, the 
SafeTrac project progressed to Phase II of the design control 
process whereby initial prototype development and evaluation 
took place. Computer aided drawings were used to produce 
rapid-prototyped solutions developed using in-house facilities. 
The handles were printed using fused deposition modelling 
(FDM) and comprised of five parts (see Figure 5.7). The left 
Figure 5.6 Exploded 
view of SafeTrac handle 
render in SolidWorks. 
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hand housing accommodates the central shaft securing it at the distal end of the handle. 
A cam insert in the proximal end provides an axial displacement of a wire tendon, 
operably connected to the articulation tip, and which provides a deflection of at tip of ± 
90°. The handle further comprises a lever to rotate the internal cam, the matching right 
hand housing and a fastening cap used to tighten the right and left sides together.  
 
Figure 5.7 Prototyped solution shown in the deconstructed position, and assembled position 
insert. 
The shaft comprises a stainless steel (grade 316) hypo tube with an OD of 4.2 mm, 
bonded to a spring member (0.4 mm thick stainless steel grade 301) and sheathed with a 
polyurethane extruded tubing. The bonding process used silver solder with an overlap 
length of 25mm to provide a large and easily bonded interface well in excess of the 
recommended single lap-joint overlap distance (3t – 6t). Bench top trials indicated that 
an axial force of approximately 25N is required to displace the 80mm long spring member 
90° (vertical displacement of 51mm). The distal portion of the hypo-tube has a curve with 
a radius of curvature of 180mm in line with the curvature of a standard ET tube. This aids 
in positioning SafeTrac in the airway. The resulting early-stage prototype was suitable 
for proof of concept evaluation.  
The prototype was evaluated in a simulated clinical setting using an Ambu® Airway 
Management Trainer at South Infirmary Victoria University Hospital, Cork. This manikin 
model simulates the tongue, epiglottis and pharynx with semi-soft material enabling 
qualitative feedback on device performance. Two consultant level anaesthetists (Dr 
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Gabriella Iohom and Dr Peter Lee) compared the traditional rigid laryngoscope, 
flexible bougie delivery and the SafeTrac device. The GlideScope video laryngoscope 
was used to visualise navigation around the epiglottis. The purpose of the evaluation 
was to get user feedback on the usability and design of the device. 
 
Figure 5.8 Simulated clinical testing using a respiratory manikin: A) Ambu® Manikin, B – 
C) laryngoscope delivering ETT, D) GlideScope video laryngoscope, E) SafeTrac prototype, 
F) flexible bougie, G) steerable flexi scope, H) SafeTrac delivering ETT. 
Both physicians noted the significantly improved user interface and control 
associated with the SafeTrac compared to the flexible bougie. The distal end of 
SafeTrac could be quickly steered into the trachea avoiding the oesophagus much 
more easily than the bougie. The Manikin did however have several limitations. The 
rubber nature of the material used to produce the manikin was quite stiff and less 
compliant than biological tissue. The rubber finish presented a significant friction 
coefficient, compounded by the lack of moisture that would be present in a live model, 
resulted in an almost sticky sensation when trying to slide the ET tube off the device 
into the trachea.  
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The evaluation also identified some key design limitations and recommendations with 
the presented SafeTrac prototype. A release ring/lever may be included to dislodge the 
ETT with the user’s fourth finger from the tapered interface. The rigidity of the shaft 
should be increased. It was noted that whilst introducing the 
ET tube with SafeTrac, the user would apply a bending 
moment due to the stiff nature of the rubber manikin that 
would deform the central steel shaft. A stiffer hypo tube 
material or one with a greater wall thickness is therefore 
required. The overall handle size was also scaled to 90% of 
the original length (see Figure 5.9). Finally, a significant 
amount of force (>25 N) is required to displace the distal 
end. This force is difficult to apply with such a small thumb 
lever on the handle. Therefore, a larger lever distance or a 
geared internal mechanism may be required to reduce the 
force requirements on the user. Further design refinement is 
required at Phase II of the design control process with a greater emphasis on user 
requirements and design for manufacture before the alpha or “basic” prototype is 
identified and assessed prior to moving onto the next Phase of product development.  
The device’s usefulness both with and without the video laryngoscope was noted 
where SafeTrac was successfully deployed with the use of a GlideScope as well as a 
standard laryngoscope with equal ease. It should be noted however, that the users were 
extremely experienced and in the opinion of the author, it would be easier to introduce 
SafeTrac under video guidance. Video footage is available at the following link: 
https://youtu.be/YfmozaCyogg. 
 
The manikin trial also identified a significant failing in the concept prototype. After 
repeated use, the spring member attached to the distal end of the hypo tube failed and 
fractured immediately after the solder bond (see Figure 5.10). This failure coincides with 
the fixed end and area of maximum stress for a flat spring member. Analysis was 
subsequently carried out to characterise the theoretical stress in the system and to identify 
a possible configuration to prevent permanent deformation.  
Figure 5.9 Reduction in 
handle size based on 
feedback from prototype 
evaluation. 




Figure 5.10 Fractured spring member at point of maximum stress at the fixed end of the 
compliant member. 
A nonlinear solver in SolidWorks® was used in this analysis. The main difference 
between a linear and nonlinear analysis, is that an iterative approach is used to solve 
nonlinearity allowing a change in model stiffness and variable loading, as each 
iteration is ran independently. Nonlinear simulations also account for the actual 
material properties such as yielding which is ignored in the linear approach (Hooke’s 
law). A system is considered nonlinear if the stiffness and external force vector are no 
longer linear. The equation for nonlinear analysis is therefore given by 
[K(u, F(u))]{u} = {F(u)}, where the stiffness matrix [K] is the function of 
displacement {u} and external force vector {F}. In the case of a flat spring member 
fixed at one end, the external force vector is changing constantly as the member curves 
about the axis of rotation. In addition, large displacements lead to a change in stiffness 
as the model’s shape adjusts from a straight to a curved profile, resulting in geometric 
nonlinearities.  
The simulation model comprised a flat member matching the prototype geometric 
properties for length and width (L=80mm, W=3.3mm), and varying thickness’s (t= 
{0.4, 0.3, 0.2, 0.15 mm}) to analyse a range of configurations. The members were 
fixed in both translation and rotation at one end, and a rotation condition of 3.14 
radians was created at the opposite end. The simulation ran one hundred step 
increments to evaluate in detail the effect of curvature from 0°, past the desired 90° 
and all the way to a fully curved 180° beam (see Figure 5.11). The maximum 
deflection required to navigate around the epiglottis is estimated to be between 60-
90°. However, in the case that the spring member is physically extended beyond the 
operational parameters, the simulated model was extended up to a deflection of 180° 




Figure 5.11 Nonlinear simulation of a curving flat wire beam from 0° to 180° ran by the 
SolidWorks® Simulation add-in. 
5.3.1.  Simulation Results 
Table 5.4 provides an overview of the maximum stress experienced in the simulated 
system at the fixed end of the model. As expected, with reducing beam thickness, and 
corresponding moment of inertia, the bending stress is likewise reduced. The material 
selected for the analysis was 301 stainless steel with an elastic modulus of 197 GPa to 
match the physical model [137]. At a thickness of 0.4mm and a curvature of 90 degrees, 
a bending stress of approximately 877MPa which is greater than the material’s yield 
strength of 515 MPa [137]. In fact, this simulation indicates that the bending system with 
yield at a curvature only 54°. 
Table 5.4 Simulated maximum bending stress (MPa) corresponding to a given beam 
thickness and deflected angle from fixed end of spring member. 
 Deflected Angle (°) 
Thickness 
(mm) 
180  120 90 60 
0.4 1756 1159 877 579 
0.3 1236 814 617 407 
0.2 826 545 412 272 
0.15 620 408 310 204 
Based on this nonlinear simulated analysis for 301 stainless steel spring member with 
the given geometrical constraints, a material thickness of 0.2 mm would remain within 
the elastic region of a stress strain curve up to a curvature of approximately 112° (see 
Figure 5.12). A thickness of 0.2 mm is typically the thinnest sheet stocked by suppliers 
and is readily available. 




Figure 5.12 Simulated bending stress with increasing angle of deflection for a 0.2mm thick 
301 stainless steel with a modulus of 197 GPa. 
An alternative approach to adjusting the material thickness is to identify a material 
with a greater yield strength to prevent permanent deformation during the operational 
limits. Table 5.5 lists selected steels from the SolidWorks® material library with yield 
strengths up to 710 MPa. Processes such as hardening and tempering increases the 
material yield strength but also makes the material more brittle. Whereas processed 
such as annealing has the opposite effect. An example of a cold-formed full hard 301 
stainless steel can have a 0.2% yield strength of up to 965 MPa [138] which would 
indicate that it would remain in the elastic limit but would require significantly greater 
axial force to create the desired curve. Further analysis is required to carry out both 
simulated and physical testing with additional materials. However, based on this 
analysis, and for ¼ hard 301 stainless steel with a yield strength of approximately 515 
MPa, a 0.2 mm thick sheet would remain elastic within the operational limitations 
below a curved angle of 90°. 
Table 5.5 Select steel materials evaluated in the nonlinear simulation with values 
corresponding to those provided by the SolidWorks® material library.  
Material Elastic Modulus 
(GPa) 




AISI 4340 steel  (normalised) 205 1110 710 
Alloy steel (SS) 210 724 620 
AISI 1045 steel (cold drawn) 205 625 530 
AISI 4340 steel  (annealed) 205 745 470 
201 annealed SS 207 685 292 
AISI 316 SS sheet 193 580 172 




The intubation project was awarded an Enterprise Ireland Feasibility funding in 2015 
(CF-2015-0241-Y). The deliverables of the feasibility fund were to carry out in-depth 
market and customer research, and to ultimately determine the commercial potential of 
SafeTrac. This funding vehicle is complementary to the design control process and simply 
supports the design teams engagement with key opinion leaders which ultimately is used 
to define the clinical need, establish the design criteria, and populate the market 
requirement specification during Phases I. 
5.4.1. Intubation Market Size Assessment 
According to a market research report published by Markets and Markets, the total 
global anaesthesia and respiratory devices market was worth $12.7 billion in 2015 [139]. 
Globally there are an estimated 65 million annual intubations performed[130], [131]. 
Based on an estimate of 1 in 10 intubations requiring an assistance device [131], [132], 
the total potential market lies at 6.5 million units per year. Approximately 85% of 
intubations occur during non-emergency surgery and 15% are in the emergency room or 
ICU [140]. Between 3% and 17% of all intubations may be classified as difficult [130], 
[131]. In the obese population it is approximately 14% [141]. With increasing levels of 
obesity and associated co-morbities, the intubation market is estimated to grow at a 
compound annual growth rate of 9% (radian insights, 2014).  
Difficult intubations are also reported in children. According to the 4th National Audit 
Project by the Royal College of Anaesthetists in UK, difficult intubations account for 9% 
of all intubations in emergency departments (EDs) in paediatric age group. These 
statistics call for the provision of a difficult airway trolley (DAT) dedicated to paediatric 
use in all emergency departments [142]. There is no particular difference between the 
incidence of tracheal intubation difficulties in USA and European countries, as various 
studies from UK and USA have reported comparable rates ranging from 1-12 % [143]. 
5.4.2. Commercial Opportunity 
SafeTrac is applicable to two significant market segments within the overall 
intubation and laryngoscopy market. These include: 
 Cases where an unexpected difficulty arises during direct laryngoscopy or video 
laryngoscopy 
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 Cases which are expected to be difficult due to known patient characteristics and in 
which video laryngoscopy is planned. 
In both of these markets, the technology for ETT guidance and placement includes 
bougies and stylets which cannot provide the required manoeuvrability in cases of 
difficult positioning. The proposed device has the potential to allow intubation 
without upgrading from direct laryngoscopy to video laryngoscopy or, in the case 
where video laryngoscopy is already deployed, from video laryngoscopy to the 
intubating endoscope. 
In this environment, a commercial opportunity exists to bring SafeTrac to the 
market as an intermediate-cost endotracheal introducer that may be used in 
conjunction with video laryngoscopes. This device has the potential to displace 
bougies and stylets as the standard of care for intubation. Manufacturing costs of 
SafeTrac are estimated at $20-$25 allowing an end-user price of $100 and a gross 
margin around 75-80%, an acceptable industry standard. When used in combination 
with a video laryngoscope (costing approx. $15 per disposable blade), as an alternative 
to an intubating scope, considerable savings per case of up to $195 are feasible (i.e. 
$115 versus $270-$310). 
5.4.3. Key Opinion Leader Feedback 
Four leading experts and influencers in anaesthesiology were interviewed as part 
of the clinical assessment of SafeTrac (see Figure 5.13). The key opinion leaders were 
selected based on their extensive publication history in areas of airway management 
and difficult tracheal intubation. The interviews took place over telephone 
communication and were recorded for posterity. Prior to each interview, the experts 
was furnished with material information and a video of use as described in Section 
5.2. 
 
Figure 5.13 Clinicians interviewed as part of SafeTrac’s assessment. 
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Each of the clinicians were enthusiastic about the technology and encouraged further 
development. Some of the main comments included: 
  “This device could work with that more difficult anatomy.” 
 “The big advantage of this particular instrument that you have is that now once 
you are in you can get it to deflect down to go down into the trachea.” 
 “I think over all the idea is a great idea. Passing the tube is the biggest problem 
we see with video laryngoscopes and this idea is a good one.” 
 “This is something that makes it easier for the operator to advance the tube but 
I like the idea and there is need for it.” 
 “It certainly looks as though you offer something different to other devices 
that are currently on the market and available.” 
 “A potential niche for this is that not everyone has a fiberscope. This would 
be a useful adjunct.” 
  “If you can make a disposable one that is higher quality than the competitors 
and yet it's reasonably priced then why wouldn’t people go for this.” 
The major negative point expressed by the interviewees relates to pricing as SafeTrac 
would essentially be displacing existing cost effective solutions such as the common 
bougie. Therefore, in order to gain traction, a low manufacturing cost solution which can 
demonstrate clinical and economic benefit during ET tube placement, particularly during 
difficult tracheal intubation, is essential. 
5.4.4. Intellectual Property Review 
The elegant design of the proposed solution fits neatly 
between the high end / high cost steerable video bronchoscopes 
and the low tech / low functionality bougies and stylets (e.g. 
Gliderite). A provisional patent review has identified a number 
of disclosures competing in this space [144], [145]. Many of the 
identified patents have been filed over 20 years ago and therefore 
are no longer protected. These disclosures describe a means of 
articulating a distal tip, typically relating to the field of 
cardiovascular studies and diagnosis (see Figure 5.14). Freedom 
to operate on certain aspects of the SafeTrac design is therefore 
reasonable. However, through the future design and 
Figure 5.14 spring 
guide identified during 
IP review (US patent 
number 3,521,620). 
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development of SafeTrac, a number of innovative and non-obvious features will be 
added to secure IP protection to set this invention apart from the treats of competitors 
(e.g., smart sensing (CO2, pH) within the steerable tip). Additional design features 
include an ergonomic handle with torsion spring return and a friction grip taper to 
engage the proximal end of an ET tube, as well as the facility for single-handed ETT 
deployment.  
5.4.5. Regulatory Pathway 
Through partnership with an independent regulatory expert (IncraMed, Galway 
Ireland), an appraisal of the regulatory classification and pathway was carried out 
which again fed into the market requirement specification during Phase I of the control 
process. The main purpose of this engagement was to verify the authors review 
following the medical device directives and FDA guidelines and to establish the future 
requirements towards regulatory approval. However, it should be noted, that 
independent reviews are not required as one can self-certify device classifications, but 
in this instance, the activity was supported by the Enterprise Ireland Feasibility award. 
US FDA Product Code Review 
a) Based on preliminary product concept specifications this review has identified the 
FDA Product Code BSR as likely to be applicable to the device. 
b) The code corresponds to FDA Regulation number 868.5790, tracheal tube stylet. 
c) In accordance with the requirements of this regulation number the device is Class 
I in the United States. 
d) No premarket notification application and FDA clearance is required before 
marketing the device in the U.S. However, manufacturers are required to register 
their establishment with FDA. 
e) No clinical data should be necessary for this device but a Clinical Evaluation 
Report including an examination of published literature and similar devices is 
recommended. 
EU Classification and Approval Feasibility 
a) In order to market a medical device on the European market it must bear the CE 
mark and conform to the requirements of 93/42/EEC as amended by 2007/47/EC. 
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Article 9 of the directive classifies devices as Class I, IIa, IIb and III. Classification 
is determined in accordance with Annex IX of the directive. 
b) As an invasive device for transient use (i.e. normally intended for continuous use 
for less than 60 minutes) the device is Class I in accordance with Rule 5. i.e. “All 
invasive devices with respect to body orifices are in Class I if they are intended 
for transient use.” 
c) In accordance with the MDD, article 3, an Essential Requirements review will be 
necessary to meet Annex I. 
d) In order to affix the CE mark, an EC declaration of conformity in accordance with 
Annex VII will be required before placing the device on the market. 
e) Based on Annex VII there is no requirement to; 
 Lodge an application with a notified body for assessment of the Quality System. 
 Lodge an application for examination of the technical documentation for the 
product. 
 
This chapter outlines the early stage design and development of an endotracheal tube 
introducer, which may answer a clearly defined clinical need and has received positive 
end-user feedback on the clinical utility. 
5.5.1. Technical and Commercial Review 
The early stage solution presented in this chapter called SafeTrac comprises a 
manoeuvrable distal end to facilitate ease of endotracheal tube placement. The 
articulating tip affords the operator the control to navigate around the epiglottis exposing 
a direct route to the trachea. Conventional stylets lack the manipulation required for first 
time accurate placement, reducing the risk of dental damage, admission to ICU, 
complications at extubation, arrhythmias, bronchospasm, airway trauma, awareness, 
CICV, and the sequelae of hypoxia. This is particularly useful for obese patients with a 
BMI > 35 kg/m2, patients with DTI, and patients with a torturous anatomic path from the 
mouth to the trachea. 
Unlike alternative devices, this solution comprises specific features that allow it to be 
used in conjunction with video laryngoscopes (VL) in a complementary fashion that 
provides an external view of tube placement. VL is quickly becoming the standard of care 
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in intubation but cannot manipulate the tip of the tube independently and may require 
SafeTrac to aid in tube placement.   
Despite only beginning the Phase II development cycle, key opinion leader 
feedback and market assessments point to a large unmet market which may be future 
exploited by the SafeTrac device. While not finalised, the current solution provides a 
good basis for IP protection with significant manoeuvrability and controllability 
coupled to a rigid shaft. Future design analysis will seek to improve stability of the 
current shaft and bending member, optimise the ETT friction grip at the handle’s base, 
and minimise part count and assembly costs downstream. In order to present 
meaningful advantages over competitors, clinical utility must be first validated and 
key differential features over conventional introducers must be further developed to 
build a compelling IP portfolio.  
5.5.2. Design Control Review 
Unlike the SecuRetract and ProDural projects (Chapters 3 and 4), the SafeTrac 
project was developed from the get-go within the design control process. This 
involved following the phased flow charts of the development cycle summarise in 
Chapter 2. During Phase I, the author was able to propose a number of concepts to 
solve the clinical need presented in Section 5.1 as well as conducting preliminary 
commercial and legal assessments. This was compiled into a Market Requirement 
Specification (MRS) which subsequently served as the foundation of an Enterprise 
Ireland application (Commercial Feasibility Award as described in Section 5.4). The 
CF award was used to progress the IP, regulatory and commercial know-how to the 
current stage of development. However, the MRS is not designed to be exclusively 
used to attract funding. The primary object of the MRS is to present a report to the 
principal investigator to decide on whether a project is worth formally pursing further 
within a controlled framework. In the case of SafeTrac, where the origins were firmly 
rooted in a clinician identified need, and a rapidly expanding commercial market, the 
project was approved for further development. 
As the first project to be fully implanted under the design control process, the 
author experienced for the first time the difficulty in complying with all the procedural 
requirements. For example, under good documentation practices typically 
implemented in R&D environments, a laboratory notebook must be routinely 
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reviewed by the Principal Investigator. Design review meetings with independent 
observers must be routinely scheduled. Risk analysis should be reviewed and approved 
from a medical point of view from a clinician / medical expert. All of these activities 
required significant time and personnel management to coordinate scheduling, which can 
be difficult in even the smallest design teams. Furthermore, for small teams, the time to 
initiate and begin to archive documents as part of the design history file can be quite 
burdensome. This burden may be offset with a dedicated quality administrator.  
The SafeTrac project and its QMS implantation has only begun initiation and 
significant work is still required to generate a documents within a design history file to 
facilitate translation into the clinical environment. Further financial and personnel 
resources will be required to progress SafeTrac along the project life-cycle before a 
clinically and commercially attractive proposition is achieved. The current level of 
progression is qualitatively summarised in Table 5.6. 
Table 5.6 SafeTrac project progression. 
  
Phase I Phase II Phase III Phase IV Phase V








100% 50% 0% 0% 0%
Concept Solutions / 
Early Risk Assessment
Define Design Inputs Manufactures / 
Suppliers Identified
Final Design Validation Post-Market 
Surveillance
100% 50% 0% 0% 0%





Update / Implement 
Risk Controls
Complete DHF, DMR, 
Technical File 
Sales and Physician 
Training 
100% 25% 0% 0% 0%
Early Intellectual 
Property Review




Artwork / Traceability Expand Sales Effort









100% 50% 0% 0% 0%
Risk Analysis Update Process Validation Plan Manufacturing 
Qualification 
Quality Audits







 Business Plan Update  DHF / 
Business Plan 
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 Radiopaque Pulmonary 





This chapter details additional work completed by the author relating to the 
development of radiopaque tumour models in bronchoscopy. This research relates to a 
larger research project within the Biomedical Design Research Group at UCC, which 
aims to develop a semi-automatic bronchoscopic navigation system for pulmonary 
disease biopsy. The work described in this chapter was not conducted within the design 
control process as it was initially solely an exercise in academic research without clinical 
or commercial intent. However, this work does present the opportunity to investigate how 
an already established project may be retrospectively introduced into a quality system and 











This work relates to the design and development of a number of contrasting tumour 
models that may be endoluminal deployed in the lung and are clearly identified under 
CT imagery. This project was a response to a need to produce identifiable and 
retrievable tumour models that can be used for ex vivo and in vivo evaluation of a 
semiautomatic bronchoscopic navigation platform [10]. The clinical need was 
presented by Doctors Marcus P Kennedy and Kashif Ali Khan (respiratory medicine) 
and represents a collaborative effort between UCC’s School of Engineering and Cork 
University Hospital, and sought to develop a means to evaluate the effectiveness of a 
novel tracking system, but also which may be used during bronchoscopic training. 
The results from this work were subsequently published in the Journal of Bronchology 
and Interventional Pulmonology [12]. 
6.1.1. Radiopaque Tumour Markers 
Radiopaque markers or fiducials are a point of reference in CT imaging and are 
used clinically to mark sites for biopsy or resection [146]. Solid markers such as gold 
spheres and radiopaque clips have been described in the literature [147], [148]. 
However the purpose of this work was to investigate a model which mimicked soft-
tissue to target lesions and to evaluate a novel virtual bronchoscopy system [13], 
[149]–[151]. Despite reported attempts, an effective pulmonary tumour model capable 
of being sampled using standard bronchoscopic techniques to confirm successful 
localisation of the nodule has yet to be developed [152], [153]. 
 
Figure 6.1  A) an example three gold sphere markers implanted into the vertebral bodies 
[147], and  B) a breast sonogram showing an introducer and radiopaque clip marker in a 
solid mass [148]. 
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Tissue-mimicking materials have been commercially developed to test ultrasound 
equipment with similar attenuation and speed of sound properties to soft tissue by 
modelling the tissue as an isotropic, homogeneous material. Large silicone based training 
systems such as Blue Phantom™ have been developed to accurately replicate the 
ultrasound behaviour of anatomy simulation. However, these are high cost systems and 
have yet to be applied as implantable / injectable fiducial markers. Common commercial 
materials include urethane rubber, condensed milk and hydrogels [154]. Hydrogels are 
the most frequently used models [146] and comprise of a network of hydrophilic polymer 
chains. An example of an injectable hydrogel is polyethylene glycol (PEG). PEG is an 
inert chemical widely used in pharmaceuticals, cosmetics and medical devices [146] 
which has a paste-like consistency in the body and slowly liquefies before being absorbed 
[146]. While easily deployed and mimicking the acoustic properties of soft tissue [146], 
[155], the fact that PEG does not congeal to form a bulk-like substance means that it is 
unsuitable to mimic soft tissue tumours.  
Gelatin is among the earliest materials used for soft-tissue mimicking. Gelatin is a 
colourless, foodstuff derived from collagen that sets to a homogenous gel on cooling. 
While representative of soft tissue acoustic properties, reported disadvantages with this 
mixture include instability with varying temperature, susceptibility to microbial invasion, 
and difficulty in evenly distributing the graphite scatters, glass microbeads or silica during 
cooling [156], [157].   
Another popular hydrogel is agarose [157]–[159]. Derived from agar, agarose obtains 
bulk-like consistency with low attenuation of ultrasound and high tensile strength [158], 
[160]. Agarose is readily available as a white powder which easily dissolves in near-
boiling water, forms a gel when cooled [161], and has acoustic properties (speed of sound 
between 1498-1600 m/s) [157] comparable to soft tissues such as muscle, tendons, 
ligaments, fascia, fat, and fibrous tissue (average 1561 m/s) [157]. However agarose has 
not been previously endoscopically deployed as a tumour model. 
The aim of this work was to develop novel radiopaque tumour models and to 
quantifiably assess the appropriateness of the models as clinically relevant analogues to 
pulmonary lesions. A further objective of this work was to identify methods to test the 
artificial tumours that accurately reflect the in vivo clinical environment. Such tumour 
models may have an application in bronchoscopic training by providing radiopaque 
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markers for the trainee to target, as well as providing a testing method to evaluate 
emerging bronchoscopic imaging and navigation systems.  
6.1.2. Agarose Tumour Model Development 
Based on the review described in Section 6.1.1, agarose was selected as one of two 
tumour models based. Agarose’s similar acoustic properties to soft tissue, its ready 
availability, and its ease of fabrication made it an attractive first material to review as 
part of this work. Agarose type I-A used in this work (Sigma Aldrich), has a gel 
strength >2500 g/cm2 at 1.5% concentration and a gel point of 36±1.5°C [162]. The 
protocol for developing the agarose tumour models followed  a trial and error approach 
beginning with adopting previously published recipes [158], [159], [163]. The focus 
was to develop a mixture with low viscosity at relative low temperature (40-50°C) to 
facilitate in vivo endobronchial injection with a high contrast medium for CT.  
Four agarose-based models (A-D) were evaluated. As a comparison, the first model 
(A) recreated the recipe proposed by Chmarra et al. (2014). To enhance the visibility 
of the models under magnetic resonance imaging, an iodine–containing contrast, 
Omnipaque™ (GE Healthcare, Buckinghamshire, U.K.) was included in all 
subsequent models. The final agarose mixture (model D) also contained the 
preservative dimetridazole [164] (Sigma-Aldrich, St. Louis, MO, USA), an anti-
protozoan used in human foods, which lengthens shelf-life of the tumour models by 
preventing nucleic acid synthesis of micro-organisms [165].  
 
Figure 6.2 Method for developing agarose based tumour models demonstrating A) 
measuring reagents and B) mixing and heating composition. 
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The reagents and quantities for the investigated agarose model compositions are listed 
in Table 6.1. The compositions were prepared by combining and heating the mixture 
above 95°C to bring the components into a well-mixed and heated solution (IKA® RCT 
Safety Control Magnetic Stirrer). The mixture was allowed to cool to 50°C before being 
transferred into 25 ml air tight sample containers. The tumour samples were then cooled 
in a fridge overnight to yield a firm elastic material with a dense gelatin-like consistency.  
Table 6.1 Composition of reagents used in agarose tumour models. 
 Model A Model B Model C Model D 
Agarose (A0169 SIGMA) [g] 7.5 2 1.5 1.5 
Glycerol (99% GC SIGMA) [ml] 30 10 nil nil 
Sephadex® (G2580 SIGMA) [g] 4 nil nil nil 
Omnipaque™ 300mg I/ml [ml] nil 4 10 20 
Dimetridazole (D4025 SIGMA) [g] nil nil nil 1 
Food colouring [ml] 0.1 1 0.75 0.4 
Distilled water [ml] 158.4 83 87.75 77.1 
6.1.3. Tripe Tumour Model Development 
Motivated by undocumented but anecdotal reports from the project’s clinical advisors 
of its usage, the second novel model investigated was beef tripe, a sponge-like edible offal 
from the chambers of the bovine stomach. Tripe, a soft tissue in its own right, acts as a 
scaffold for contrasting medium and offers an elastic structure that may resemble a 
pulmonary tumour once endobronchially deployed (see Figure 6.3).  
 
Figure 6.3 Beef tripe (A) prepared into segments soaked in Iodine (B) and enriched in food 
dye prior to use (C). 
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The locally sourced beef tripe (A O’Reilly & Sons, English Market, Cork) was 
prepared by cutting the tripe into 50 mm rectangular segments and placing the 
segments into 25 ml containers filled with iodine (Omnipaque™ 350mg I/ml) and food 
colouring. The softer superficial layer extending from the denser lining of the tripe was 
removed leaving a homogenous, elastic consistency. The samples were left to soak 
overnight and were further injected with iodine immediately before use. The 
mechanical properties of each of the agarose samples and the tripe material were not 
characterised as part of this work as the primary objective was to create a detectable 
radiopaque mass for bronchoscopy, whereby properties such as stiffness and elastic 
modulus were not essential to the application. Furthermore, the mechanical properties 
at varying concentrations have already been well documented [166]. 
Table 6.2 List of physical models used to evaluate the various tumour model types. 
Evaluation Method 
Model Type Chicken Fillet Swine Lung Pre-Clinical Investigation 
Agarose A  - - 
Agarose B  - - 
Agarose C    
Agarose D -   
Tripe  - -  
 
The physical simulations used to evaluate both the agarose and tripe models are 
listed in Table 6.2. The first three agarose tumour models (A-C) were evaluated in a 
soft tissue explant (chicken fillet) and the resulting CT images (120 kVp, 650 mA, 
slice thickness 0.6 mm) were assessed for CT contrast (GE Discovery VCT PET/CT 
64 Slice CT Scanner) following direct injection through a 21 gauge aspiration needle 
(SmoothShot TBNA NA-411D-1321, Olympus). An experienced end user (radiology 
technician / clinician) then reviewed the CT images to verify the resulting scans 
resembled in vivo soft tissue. The agarose samples were first heated to bring them into 
a solution before being injected into separate models for comparison.  




Figure 6.4. A) Agarose tumour model injection into soft tissue explants (chicken fillets), B) 
vacuum chamber and swine lung model with implanted tumours being scanned with CT, C) 
placement of tumour models during pre-clinical investigation with diagram and endoscopic 
image of agarose model placement and D) diagram and endoscopic image of tripe tumour 
placement. 
Agarose models C and D were evaluated in an inflatable swine lung model [13]. The 
preserved swine lung was inflated in a vacuum chamber and held at a constant vacuum to 
achieve inflation (see Figure 6.4 B). Eight tumour models (four of each sample) were 
injected by an experienced operator into the left and right lungs, in the upper, middle and 
lower lobes. A bronchoscope (Olympus Evis Exera BF - 1T160) and adapted Olympus 
SmoothShot with the needle removed to increase flow through the catheter were used. 
Each model was injected in the liquid form before cooling to a radiopaque mass. The 
swine lung was subsequently scanned (inhalation and exhalation) using CT to determine 
the tumour model’s detectability. 
6.2.1. Soft Tissue Explant Investigation Results  
CT imaging illustrates the clinically-relevant contrasting ability of the agarose models 
A, B and C compared to the background intensity of the chicken model (see Figure 6.5). 
In each instance, a vial containing the model mixture was placed next to the tissue 
analogue. Model A, which recreated Chmarra’s et al. (2014) work closely resembles the 
attenuation characteristics of the soft tissue chicken model. In the CT image, there is little 
or no discernible difference between the agarose and the surrounding soft tissue. The 
Hounsfield Units (HU) (scale to describe radiodensity) measured 85±8 HU, similar to 
that of the liver (60HU).  However, models B and C, which include the contrast medium 
Omnipaque™, demonstrate stark contrast between the tumour model and the tissue (see 
Figure 6.5 A-D). 




Figure 6.5 Assessment of tumour models in a chicken fillet with A) model A as proposed by 
Chmarra et al, B) model B with 4ml of Omnipaque, and C) model C with 10 ml of 
Omnipaque. D) Illustrates a comparison between model C and a baseline (no tumour). 
6.2.2. Swine Lung Model Investigation Results 
The resulting CT image from the swine lung model was overlaid with an airway 
reconstruction using 3DSlicer [11], [167]–[170] software platform and captured 
images from the bronchoscopic feed (see Figure 6.6). The sites targeted with the 
increased contrast agent (i.e. model D at points c, e, f, h) demonstrated greater contrast 
to those of model C (i.e. reduced contrast agent at points a, b, d, g). Site (a) shows a 
slight dispersion of model material similar to a circumferential endobronchial lesion. 
This sample was placed using the sheath from a modified 21 gauge SmoothShot 
aspiration needle. Well placed endobronchial fiducials of good size (≈15mm3) 
resembling cancerous lesions can be observed in all the remaining sites with some 
locations completely obstructing airway segments ((e) and (g)). The mean time-to-
placement was 2 minutes with a further 5 minutes required before the samples 
congealed to form a dense tissue-like nodule. 




Figure 6.6. CT image from inflation swine lung overlaid with video bronchoscopic images. 
Sites a, b, d & g contain agarose model C, and the remaining sites contain agarose model D.  
6.2.3. Pre-Clinical Animal Investigation Procedure 
Agarose tumour models (C and D) and the tripe model were evaluated in vivo during 
pre-clinical porcine investigations (n=3). The models used were landrace swine (18, 22 
and 40 kg) which were sedated for the duration of the experiment and euthanized 
immediately following the procedure without recovery. The investigations were approved 
by both the Irish Department of Health (approval no: B100-4441) and UCC Ethics 
Committee (approval no: 2012-17) and were conducted by respiratory clinicians. 
The study end-points were to qualitatively evaluate the ease of use of administering 
the models and to assess their accuracy and efficacy in simulating soft-tissue pulmonary 
tumours. During the study, the animal was subject to CT imaging before and after model 
insertion. CT scan parameters were 0.625 mm slice thickness, 0.625 mm slice separation 
and tube current of 60 mA at 120 kV with standard kernel reconstruction. The agarose 
tumour models were again heated on a hotplate magnetic stirrer before cooling to 38-
45˚C for multiple injections by an experienced endoscopist (6 for n=1, 8 for n=2 and 1 
for n=3). The insertion temperatures were derived from earlier bench top trials where the 
mixture temperature was allowed to cool in controlled incremental steps and a 
corresponding sample was injected through a 21 gauge sheet until no longer possible. 
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Each agarose model, with an approximate volume of 41 ml, was injected 
transluminally using a 21 gauge SmoothShot aspiration needle, and endoluminally 
with a 1.8 mm catheter via luer access port (see Figure 6.4). After each injection, the 
catheter was removed and the working channel was flushed with cold (4 ˚C) saline 
solution to promote rapid coalescence of the tumour model, confirmed by camera 
visualisation. 
Iodine-enriched tripe tumour models were introduced through the endotracheal tube 
with the bronchoscope and endoscopic biopsy forceps (Radial Jaw™ 4, Boston 
Scientific). The tripe models (0.70.2 cm3), were positioned in the upper right, lower 
right, upper left, and lower left lobes with real-time fluoroscopy (BV Pulsera, Philips) 
to confirm placement. Both agarose and tripe models were sampled endoscopically 
subsequent to CT imaging. 
6.2.4. Pre-Clinical Investigation Results 
The first pre-clinical investigations examined the use of agarose model C as a 
radiopaque lung tumour marker. As illustrated Figure 6.7, a single large contrasting 
nodule, 15 mm long, is visible in the middle lobe of the right lung. A pneumothorax 
(partial lung collapse) of the left lung is also evident. This pneumothorax was likely 
caused due to trauma during transbronchial model insertion. Over-advancement of the 
needle may have breached through the pleural membranes leaking ventilated air into 
the thoracic cavity causing the pneumothorax. The use of transbronchial placement in 
subsequent animal trials was limited to reduce the risk of further pneumothoraxes. 
Scarring of the internal structure was also observed as a result of the heated (65˚C) 
material on insertion prompting subsequent trials to use lower injection temperatures 
(38-45 ˚C).  
 
Figure 6.7 CT slice images from the first pre-clinical investigation illustrating a slice 
through the a) Transverse and b) Coronal plane, of an agarose tumour model measuring 
approximately 15 mm in length positioned in the middle right lobe. 
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Subsequent animal investigations evaluated agarose model D, as well as the iodine-
enriched tripe model. Tumour models were identified by visual CT inspection. Figure 6.8 
compares CT images taken before and after model tumour placement during the second 
animal investigation. Three different agarose tumour sites are noted, with stark contrast 
where detected. As with the swine lung model, the average time-to-placement was 2 
minutes. However of the eight locations targeted, only three are clearly visible. Instead 
of creating structured fiducials when placed in the upper airways, the agarose model 
appeared to coat the airway wall as it passed deeper into the bronchial passages reducing 
its radiopacity. This was most likely a result of slower time-to-coalescence as the core 
body temperature is only slightly lower than the gelling temperature of agarose. At a 
concentration of 1.5%, agarose has a gel point of 36±1.5°C [162], which may be sufficient 
for human use (37°C). However, the porcine model has a higher normal body temperature 
of 38.7-40°C. The insertion temperatures were reduced in the third trial. 
 
Figure 6.8. Resulting CT images taken before and after tumour model insertion during 
the second pre-clinical animal investigation. Areas of visible contrast circled in the right 
column are absent in their corresponding pre-tumour images in the left column. The 
areas indicated are sites where the agarose based models were deposited. 
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Unlike the agarose model, the tripe model exhibited a clear and vivid contrast under 
CT imaging resembling tumour like obstructions with definite structure during the 
second trial. Figure 6.9 compiles a number of different imaging techniques to identify 
and locate the tripe models. The background image is a picture of a CT scout 
(scanogram) as used for planning every scan slice. The scout clearly identified the 
position of two radiopaque tripe models in the left and right lower airways measuring 
approximately 20 mm in length. The average time taken to place a tripe tumour was 
approximately 2 minutes. A detailed slice along the coronal plane through the models 
is also pictured in the upper left image of Figure 6.9 illustrating the stark contrast of 
the models against the background image density. The models were placed under real 
time fluoroscopy and the resulting c-arm image is pictured in the lower left region of 
the image. The remaining two images picture the tripe models before and after 
endobronchial insertion. 
 
Figure 6.9. Tripe tumour models visible in lower right and left lobes (main) with overlaid 
images of a CT slice through the models (A), a C-arm X-ray image taken in real time while 
placing the models (B), and images of the tripe modes prior to insertion and positioned in 
vivo (C and D). 
Once the tumours were identified in the CT image, target markers were manually 
selected at the locations of contrasting fiducials. Eight tripe tumour models were 
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inserted during the third pre-clinical trial. The locations were selected to evenly distribute 
the models between the upper, middle and lower airways in both the left and right lung. 
Figure 6.10 shows the 3D slicer reconstruction [169], [170] of the bronchial airways with 
selected target markers corresponding with model placement. Once the centre line was 
extracted and the target pathway to each fiducial was created, the mean time-to-target 
measured 11.2 seconds. The target markers remained in place despite delays in sampling 
(t+4hrs) and facilitated precise sampling at these locations under virtual bronchoscopy 
[169] using a biopsy forceps (Radial Jaw 4, Boston Scientific). A comparison of the 
performance characteristics for all the models can be seen in Table 6.3. 
 
Figure 6.10. Selected target fiducials subsequent to CT scan during the third animal 
investigation. Areas of visible contrast resulting from tripe tumour model placement were 
selected by an experienced endoscopist. 
6.2.5. Discussion of Tumour Model Results 
The aim of this study was to develop novel soft-tissue mimicking, radiopaque tumour 
models and to assess their aptness in a clinically accurate physical simulation. Numerous 
models have been developed to mimic the characteristics of biological tissue particularly 
in the area of ultrasonic propagation and elastography [152], [156]–[159], [171], [172]. 
However, a method of combining both the physical characteristics of biological tissue 
and the contrasting ability of radiopaque markers in the airways has still to be fully 
explored. This study investigated two possible tissue mimicking radiopaque models 
which may be used to model pulmonary lesions.  
Agarose presents key benefits as a tumour model. It forms a bulk substance when 
cooled providing a soft tissue-like structure. The agarose used in this analysis (type I-A: 
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low EEO), which was sourced from Sigma Aldrich, has a specified gel strength of 
>2500 g/cm2 at 1.5% concentration. It can be introduced into the bronchial airways 
either endoluminally or transluminally. Model D was modified to improve injectability 
with an agarose concentration of 1.5%, and enhanced image contrast with the addition 
of Omnipaque (20%). This recipe evolved from trial and error and originating from 
Model A with a concentration of 7.5% proposed by Chmarra et al. (2014). Through 
experimentation it proved possible to inject Model D concentration through a 1.8 mm 
sheath at 40˚C. Despite seeing congealed nodules in an inflatable swine lung that 
resembled well formed, tumour-like models on review by clinical experts, reproducing 
same in a live breathing specimen is problematic. Agarose tumour placement resulted 
in material congealing in the lower airways. This is most likely due to material 
migration under continuous ventilation and prolonged liquid-to-gel transition time (t 
> 4 minutes). Another factor that contributed to the lengthy gel transition time is the 
normal core body temperature of the porcine model which can be 3°C greater than that 
of a humans. While this current configuration may be sufficient at 37°C in humans, it 
does not appear to work in the porcine model. The introduction of chilled saline helps 
to promote rapid congealing of the agarose material. However, this requires suction to 
remove excess fluid from the field of view. Alternatively, in future trials, an agarose 
gel, such as type VI-A with a higher gelling temperature (41 ± 1.5°C at 1.5%) may be 
used. 
The iodine infused tripe model presents a more desirable solution as a tumour model 
for the in vivo setting. Tripe is easy and cheap to use; it can be prepared quickly, 
positioned rapidly within the pulmonary vessels (although not via the bronchoscope’s 
working channel), and results in a clear image contrast under CT imagery when 
enriched with iodine. Tripe in itself is a biological soft tissue from the lining of a 
bovine stomach with similar characteristics to tumour models on visual inspection of 
CT images. It is easy to manipulate with endoscopic instruments and remains 
substantially intact despite continuous grasping and releasing with biopsy forceps. 
Distal airway placement is inhibited due to the requirement for forceps manipulation. 
The tripe sample must also be fresh and kept refrigerated to avoid deterioration and 
odorous build up. The sample is then brought to room temperature before insertion to 
reduce material stiffness on insertion. A table comparing the performance of the tripe 
and agarose models can be seen in Table 6.3.   
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Table 6.3. Summary of performance characteristics of tumour models. 
 Agarose A Agarose B Agarose C Agarose D Tripe 








Yes Yes Yes Yes No 
CT Visibility 
(Hounsfield Unit) 
85±8 293±49 720±76 777±300 1707±430 











65˚C 60-55˚C 50-45˚C 45-38˚C N/A 












of the airway 
branches 
More prone to 
migration and 






visible. May also 
be injected 
transbronchially  




Sample size may be 
too large to reach 
narrow distal areas. 
Very high image 
contrast comparable 
with dense bone 
































Longer shelf life 








that may be 
biopsied.  
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The soft tissue explant (chicken fillet) was the first physical simulation used to 
assess early tumour models and provided an image contrasting comparison between 
the tumour model and soft tissue under CT. However the homogenous nature of a 
single chicken fillet lacked the complexity and intricacies of a lung. The inflatable 
swine lung provided a more realistic representation, one which could be controlled to 
simulate artificial breathing. However, the ex vivo swine lung could not accurately 
replicate the dynamic axial contractions encountered in a live breathing specimen. The 
lungs were inflated in a vacuum thus keeping the bronchus accessible to the 
bronchoscope, obviating the need to initiate ventilation, which in turn did not 
accurately reflect the clinical setting. 
In addition the preserved swine lung lacks the humidity present in a live model 
which resulted in a misleading ease of nodule formation of the agarose model. The 
live porcine model presented a realistic experience of in vivo radiopaque tumour 
model placement, albeit at a higher temperature to the human model. In order to reach 
distal airways of the porcine lung, an adolescent specimen was used providing a 
shorter snout-to-bronchial distance. This in turn increased the risk of premature 
mortality due to infection or anaesthetic difficulty. Adolescence also increased the 
risk of pneumothorax and larger animals were investigated subsequently (n=3). 
 
The immediate application for these tumour models may be seen in bronchoscopic 
training providing a radiopaque target with similar material density properties to soft 
tissue. The tumour models may be deployed ex vivo or in vivo and once located under 
computerised tomography, the trainee may steer towards the lesion analogue before 
sampling the model for confirmation of localisation. The second immediate 
application for these models is to evaluate existing and emerging bronchoscopic 
imaging and navigation systems such as virtual bronchoscopy.  
Both the iodine infused agarose and tripe models simulate a viable analogue of a 
radiopaque pulmonary lesion. The use of several different physical models aided the 
assessment of both agarose and tripe as tumour models. The time-to-placement and 
time-to-target in both the swine lung and pre-clinical investigations suggests a user 
friendly and quick method to create fiducials that can replicate the imaging effects of 
pulmonary lesions. For ex vivo evaluations, agarose produces well-formed injectable 
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fiducials as seen in the inflatable lung model. However, the iodine enriched tripe models 
present a more effective tumour model for in vivo investigations. Alternative agarose 
material with higher gel transition temperatures should be further investigated for the in 
vivo setting. Despite limitations, the tumour models presented in this work can be 
deployed endobronchially, located with CT imaging for subsequent sampling, and 
simulate pulmonary tumour nodules for endoscopic training and device evaluation. 
6.3.1. Project Implementation within a QMS 
The work described in this chapter may be retrospectively applied to a design control 
process. However, firstly the objective for doing so must be clearly defined. Previous 
Chapters looked at devices with clinical and commercial potential and focused on both 
the market requirements as well as the product development. Whereas projects, which are 
simply research orientated, may have different objectives. If the ultimate aim is to simply 
develop a tumour model for training purposes in ex vivo or simulated models for trainee 
endoscopists, it is therefore not defined as a medical device and is not subjected to the 
international medical standards and directives. However, there may still be a commercial 
application and if so, implementing a design control process, which maps the route for 
commercial feasibility and a traceable design history file, would be enormously 
advantageous.  
If the design team wish to further progress with the artificial tumour model project to 
evaluation in a clinical setting, it is therefore deemed a medical device and would be 
bound by ISO 13485 and the MDD 93/42/EEC. The intended use in this case may be 
deemed as an implantable short/long term device in which case it may be classified as a 
Class III device with all the additional requirements that entails.  
Unless a truly compelling commercial argument can be made through the 
development of a Market Requirement Specification and subsequent business models, it 
would not be feasible to pursue this project as a medical device. A more realistic 
proposition is to develop the models as an ex vivo training tool. In this case, the cost and 
time implications are dramatically reduced. Tractability and biocompatibility of 
materials, despite being still important from a production quality point of view, are not as 
essential. The selection of suppliers would no longer be bound to those with qualified 
medical device quality systems and moves more towards the consumables market which 
will ultimately reduce cost of goods sold. A controlled design process is still necessary to 
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maintain standards of production quality and post market surveillance. Development 
of verification and validation protocols will be essential to trouble shooting any and 
all design/production defects. However, ultimately the process for CE marking is 
much more straight forward, and once minimal risk is demonstrated by the 
manufacturer, he/she may prepare a Declaration of Conformity and may affix the CE 
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 Summary and Future Work 
 
“I never did anything worth doing by accident, nor did any of my inventions come by 





An examination of user-centred medical devices has been presented in this thesis. 
The primary goal was to develop these projects within a controlled framework. However, 
each device achieved varying levels of success in realising this aim. Furthermore, this 
thesis presented additional research with novel outcomes and findings in the area of 
artificial tumour models and explores how this may fit into such a design control 
framework. This chapter summarises the novel contributions derived through this thesis, 
reflects on the implementation of design control, and highlights proposals for future work. 




The object of this thesis was to design and develop novel devices within a 
controlled process to bridge the gap between traditional academic research, and 
industrial applicability, in medical device design. A simplified design control 
framework was presented (Chapter 2) and applied either retrospectively or throughout 
the development of three novel technologies (Chapters 3-5) derived from user-defined 
clinical. This thesis also presented novel research in the fields of artificial tumour 
modelling (Chapter 6) and discussed the merits of retrospectively applying such a 
project within a controlled framework.  
The work presented in this thesis poses a broad scope for future work in furthering 
the quality control system, advancing technological device development, executing 
clinical evaluation and achieving commercial application. The following sections will 
describe in more detail the pitfalls and future requirements addressing each chapter. 
7.1.1. Quality Management System (QMS) 
The current QMS is established to record and control design iterations and 
evaluation methods. The focus is to create a development plan that considers 
converting real clinical needs to design specification and to organise appropriate 
verification and validation activities to demonstrate technical feasibility. However, as 
indicated in Chapter 2, within the university setting, the execution of the full design 
control process is unlikely. The current QMS only focuses on the document and design 
control activities and management responsibilities with vendor controls adopted from 
the university procurement policy. Therefore in order to seek ISO13485 accreditation, 
further development is required to capture the full range of controls of the 
international standard. However, accreditation is not necessarily required. For clinical 
study approval, documented fulfilment of the medical device directive’s essential 
requirements within the scope of the study protocol must be presented to the national 
competent authority, whilst also fulfilling the requirements of the local ethics 
committee. A document control system which can demonstrate sufficient technical 
and clinical safety through certified verification and validation can successfully meet 
these requirements without ISO 13485 accreditation. Therefore, the proposed future 
work is to expand the QMS to cover all aspects of the essential requirements for pre-
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CE marked devices and to execute future projects in the UCC BDRG through this quality 
framework.     
 
Figure 7.1 Project progress development within a control process overview. 
7.1.2. SecuRetract Laparoscopic Bowel Retractor 
The SecuRetract device presented in Chapter 3 proposed a number of advantages over 
commercially available devices which were evaluated through preliminary technical 
analysis, pre-clinical experimentation and end-user feedback. The SecuRetract project 
was developed in parallel with the development of the QMS and was therefore 
retrospectively applied to the design control process. Despite now in Phase III of the 
control process, many of the documents within the design history file are far from 
completion. Limited resources restrict progress in certain key areas. For a surgical 
invasive Class IIa device like SecuRetract, extensive biological, design and sterilisation 
testing is required to ensure full compliance with the regulations. However, these are often 
high cost specialised activities and go beyond the traditional research carried out within 
the University setting. The main positive from retrospectively applying the design control 
process was encouraging end user feedback throughout. During the initial stages of device 
development, predicate concept solutions were often over developed before clinical 
engagement resulting in wasted time on unsuccessful ideas. The design control process 
focusses ones attention on achieving key milestones in a most effective manner.  
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Further pre-clinical trials are required to validate the updated prototype design 
before a first-in-man clinical study may be conducted to validate clinical utility. A 
clinical study will also demonstrate the difference in efficacy compared to 
commercially available retractors, validating the clinical benefit. In order to comply 
with the requirements of the Irish competent authority (HPRA) to undertake a clinical 
study, the following proposed future works are required:  
 Compile a Design History File to satisfy the needs of ISO 13485 Section 7.  
 Finalise risk analysis in accordance with ISO 14971.  
 Carry out sterilisation verification (e.g. utilising biological indicators on an 
ethylene oxide sterilization cycle).  
 Carry out design verification on sterilised sample units (protocols to satisfy 
prerequisites from risk and regulatory requirements).   
 Bio-compatibility testing (through equivalence to commercially available 
materials and technology if possible). 
It is not envisioned that shelf-life testing, transportation testing, or process 
validation is required within the scope of the pre-CE clinical study. These works will 
be carried out on a verification batch manufacture, fabricated by a qualified supplier, 
and co-ordinated via a spin-out entity from University College Cork to champion the 
commercial opportunity of SecuRetract.   
7.1.3. ProDural Epidural Syringe 
The work presented in Chapter 4 describes the design and development of an 
epidural location device which has the potential to reduce the incidence of dural 
punctures, to reduce the rate of false positive applications, and to reduce the steep 
learning curve associated with epidural administration. The resulting device, 
ProDural, retains the loss-of-resistance technique preferred by anaesthetists, whilst 
providing an additional visual indication that the epidural space has been reached. The 
ProDural project has achieved the key objectives associated with Phase II of the 
design control process and future work will focus on optimising the design for 
manufacture and to fulfil the stage gate objectives of Phase III and IV to enable 
clinical validation. Capital investment is required to design the tooling and moulds 
required to blow a custom syringe and to validate finalised production processes for a 
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minimally viable product. This presents opportunities to partner with multinational, mass 
volume corporations and to explore business licencing prospects. 
Clinical studies are required to validate the clinical utility. This will require the 
determination of the size and cost of any future clinical studies with a sufficient 
confidence level to show the clinical efficacy of ProDural in improving procedural 
outcomes. Further due diligence is required to fully assess the intellectual landscape and 
to add sufficient novelty to secure patent protection. This may involve further design 
refinement. The minimum achievable cost of goods sold (COGS) at scale should be 
determined to calculate a reasonable price premium which could be absorbed by the 
payers, while still ensuring a customer cost saving. These activities will require additional 
resources which may be supported by non-venture capital sources of funding to advance 
the project needs (industry partnerships, migraine headache/patient interest groups, etc.). 
7.1.4. SafeTrac Intubation Device 
The SafeTrac device presented in Chapter 5 represents an exciting commercial 
opportunity in the vast intubation market. Globally, there are more than 65 million annual 
intubations performed and the current prototype may offer a cost-effective, steerable 
option to improve intubation. SafeTrac is the only device to have been developed from 
the beginning within a design control process. However, the project has only just begun 
to execute the tasks as part of Phase II of the control process. Further time is required to 
continue its development within the QMS which will provide the first true evaluation of 
the presented design process.  
Despite a promising preliminary assessment of a functional concept prototype, 
additional design and development is required to add significant novelty to secure patent 
protection and to enhance the value proposition. Further design iteration exploring 
different materials and geometries is required with continuous feedback from clinicians. 
Optimising the design to reduce the cost of manufacture is critical to the application of 
ETT placement. However, end-user surveys have identified several potential beneficial 
enhancements that may include CO2 sensors to detect inadvertent placement in the 
oesophagus, which may justify a higher cost point. The SafeTrac project presents the 
broadest scope of development and is ideally placed to attract government support and 
researchers to further develop the technical and commercial potential. This low risk 
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device employees simple technology and can significantly benefit from further design 
development and analysis.     
7.1.5. Radiopaque Pulmonary Tumour Model 
The tumour models presented in Chapter 6 were initially developed to provide 
artificial lesions to evaluate an emerging bronchoscopic imaging and navigation 
system being developed at the Biomedical Design Research Group at UCC. The 
tumour models were developed to evaluate this new system during pre-clinical animal 
investigations and provided detectible and retrievable markers. The iodine-infused 
agarose model and tripe model may also have immediate application in bronchoscopic 
training, providing a radiopaque tissue-like target. The tumour models may be 
deployed ex vivo or in vivo and once located using CT-imaging, the trainee may steer 
towards the lesion analogue before sampling the model for confirmation of 
localisation. However, further refinement of the agarose model is required to promote 
rapid congealing at body temperature and improve ease of injection through lower 
gauge aspiration needles (21 / 22 gauge). This may involve selecting different types 
of agarose samples with higher gelling temperatures. In addition, further mechanical 
analysis will need to be carried out to compare the stiffness and bulk density of the 
congealed agarose gel to actual malignant growths. 
The tripe model provides a cost effective and easy to prepare soft-tissue model. It 
was noted during experimentation that despite extended soakage time in a high 
contrast medium, the tripe did not effectively absorb the iodine contrast and required 
further injection prior to application. Therefore, alternative means of infusing the tripe 
to improve initial absorption and subsequent retention of the contrast medium should 
be investigated. In addition, further analysis is required to characterise the physical 
mechanical properties of the tripe sample and to compare same with soft tissue. 
Initially there was no intention of developing the tumour project within a design 
control process as the primary object was to create an effective fiducial to target under 
CT imaging. However, during the development of this project, the novelty and 
application of such models to aid in bronchoscopy training become increasingly 
evident. Therefore, this project was included as part of this thesis to promote 
discussion as to how such a research project may be retrospectively applied to a design 
control process. Implantable devices such as the agarose and tripe tumour model, if 
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intended for use in human beings, with qualify as a Class III medical device. Class III 
device require extensively more testing and verification to gain approval and have much 
more complicated and lengthy approval processes (e.g. PMA in the USA). Therefore, the 
author would advise that should this project be pursued further, the purpose should be to 
develop artificial radiopaque models for ex vivo training only. In this instance, the design 
control process may be applied whilst ignoring certain requirements such as sterility and 
biocompatibility, reducing the overall cost and project lead times, and still ensuring 
quality product development. This also presents the opportunity of partnering with 
anatomical training companies such as CAE Healthcare (Blue Phantom).  
 
This objective of this PhD thesis was to develop novel, user-cantered medical devices 
within a design control framework. Despite identifying and developing novel 
technologies with commercial application, the author did not achieve full execution of 
any project within the defined procedures of the QMS. It is the hope of the author that the 
basis of the QMS which was developed will be expanded upon and refined to allow it to 
be flexible as well as compliant with the international design control requirements. 
Furthermore, it is a goal that ultimately such a system may be exported internationally to 
aid in compliant medical device development, not just for hardware devices, but also for 
software.   
The principal advantage of implementing a QMS and design control process, besides 
being an absolute requirement for clinical implementation, is that it focuses the design 
team with a step wise approach to product development with clear defined objectives at 
each phase. The complete process not only prescribes the development from a technical 
point of view, but also identifies the clinical, performance, user and market requirements 
that should feed into deriving the design inputs and specifications. The current milestones 
at each phase were modified from those presented in literature to meet the author’s 
experience, particularly during the very early stage of expository work. As the system is 
tested through future product development, it may be amended though simple change 
controls to account for the growing team’s needs. 
The major disadvantage and criticism, experienced by the author, is that the 
development, implantation and execution of a quality management system and product 
development is perhaps too much for one person or small teams. It is vital that once fully 
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up and running, the responsibility for executing and maintaining is appropriately 
distributed but also controlled by the single final approval of the principal investigator 
on all major reviews. Where possible, software based project management and 
automatic scheduling can relieve the burden of paperwork, and certified e-signature 
applications such as Adobe Acrobat Pro can expedite approval processes. 
Furthermore, procedural training may be achieved by employing online training 
programs such as Moodle and protected cloud storage may be used for document 
archiving and retrieval. One designated quality assurance manager will still be 
required to ensure compliance across a research group and centre. However, a flexible, 
efficient system can only aid in a research’s design and development process and 
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1. Introduction and Scope 
1.1 General 
The Quality Manual of the Biomedical Design Research Group (BDRG) at University College 
Cork’s (UCC) School of Engineering is compiled in accordance with EN ISO 13485 (Medical 
Devices – Quality management system requirements – Requirements for regulatory purposes 
ISO 13485:2003). 
The purpose of this document is to define and communicate the processes established for the 
effective monitoring and operation of the BDRG quality management system. 
The quality management system is designed to provide a framework for medical device design 
that meets regulatory and end user requirements. This manual also outlines the methods by 
which the BDRG maintains the effectiveness of the quality management system in line with the 
applicable quality and regulatory standards.  
1.2 Scope and Application 
The BDRG design and develop devices for clinical use. This document covers the design, 
prototyping and evaluation of medical devices conceived within the BDRG. All medical devices 
developed by the BDRG are intended for clinical investigation and/or future commercial 
approval. 
The BDRG are not claiming any exclusions from ISO 13485. However some non-applicable 
clauses have been identified due to the nature of our activities: 
 The BDRG does not provide installation or servicing for customers.  The installation 
and servicing requirements of Sections 7.5.1.2.2 installation activities and 7.5.1.2.3 
servicing activities are not applicable. 
 The BDRG does not manufacture or supply implantable or active implantable devices, 
therefore the following clause are not applicable; 
o 8.2.4.2 Particular requirements for implantable medical devices  
o 7.5.3.2.2 Particular requirements for active implantable medical devices and 
implantable medical devices 
 The BDRG does not ‘place devices on the market’ or distribute commercialised medical 
devices. The post market surveillance requirements are therefore excluded from this 
quality management system (QMS). 
1.3 Organisational Profile 
The Biomedical Design Research Group (BDRG) is a core research group in the School of 
Engineering at University College Cork. The group’s primary purpose is to identify and solve 
unmet clinical needs through user-centered design in keeping with best industrial practices for 
the development of medical devices.  





1.4 Organisational Structure 
The Biomedical Design Research Group 
adheres to UCC’s corporate procurement 
and health and safety policies and solely 
carries out developmental research and 
clinical evaluation. Clinical product 
manufacturing, packaging and 
sterilisation are outsourced to regulated 
suppliers. Working closely with the UCC 
Technology Transfer Office, the 
intellectual property surrounding each of 
the devices will be defined and, where 
appropriate, protected by patent 
applications. 
The organisational structure and the 
roles and responsibilities of individual 
functions apply to each project 
undertaken by the BDRG and are 
transferable to newly appointed research 
personnel. An organogram of the BDRG’s organisational structure can be seen Figure 1.  
1.5 Biomedical Design Research Group Quality Policy 
Every member of the group is responsible for the quality of his or her own work. The group is 
committed to designing and developing high quality products that are safe and effective and 
which meet or exceed users’ needs and expectations. The group will achieve this commitment 
by; 
 Understanding and meeting the needs of end-users through research, design and 
testing. 
 Complying with applicable national and international regulations. 
 Maintaining and continuously improving the effectiveness of the quality management 
system. 
2. References 
Reference Title & Description 
EN ISO 13485:2012 Quality management systems for medical devices 
EN ISO 14971:2012 Application of risk management to medical devices 
MDD 93/42/EEC Medical Device Directive of the European Union as it applies to 
the Quality Management System 
Note: See Appendix 4 for referenced procedures 
 
 
Figure 1 BDRG organisational structure 





3. Definitions and Abbreviations 
Term Definition 
Medical Device Any instrument, apparatus, implement, machine, appliance, implant, in 
vitro reagent or calibrator, software, material or other similar or related 
article, intended by the manufacturer to be used, alone or in 
combination, for human beings for one or more of the specific purpose(s) 
of 
 diagnosis, prevention, monitoring, treatment or alleviation of 
disease, 
 diagnosis, monitoring, treatment, alleviation of or compensation for 
an injury, 
 investigation, replacement, modification, or support of the anatomy 
or of a physiological process, 
 supporting or sustaining life, 
 control of conception, 
 disinfection of medical devices, 
 providing information for medical purposes by means of in vitro 
examination of specimens derived from the human body, 
and which does not achieve its primary intended action in or on the 
human body by pharmacological, immunological or metabolic means, 
but which may be assisted in its function by such means. 
Implantable 
medical device 
Medical device intended 
 to be totally or partially introduced into the human body or a natural 
orifice, or 
 to replace an epithelial surface or the surface of the eye, 
by surgical intervention, and which is intended to remain after the 
procedure for at least 30 days, and which can only be removed by 
medical or surgical intervention. 
Active medical 
device 
Medical device, operation of which depends on a source of electrical 
energy or any source of power other than that directly generated by the 
human body or gravity and which acts by converting this energy. 




Assessment and analysis of clinical evidence pertaining to a medical 
device to verify the clinical safety and performance of the device when 
used as intended by the manufacturer. 
Complaint Written, electronic or oral communication that alleges deficiencies 
related to the identity, quality, durability, reliability, safety or 
performance of a medical device that has been released from the 
organisation’s control. 





Distributor Any natural or legal person in the supply chain who, on his/her own 
behalf, furthers the availability of a medical device to the end user. 
Advisory notice Notice issued by the organisation, subsequent to delivery of the medical 
device, to provide supplementary information and/or to advise what 
action should be taken in 
 the use of a medical device, 
 the modification of a medical device, 
 the return of the medical device to the organisation that supplied it, 
or 
 the destruction of a medical device. 
Importer Any natural or legal person with responsibility to first make a medical 
device manufactured in one jurisdiction available in another specified 
jurisdiction. 
Labelling Written, printed, graphic or electronic information 
 affixed to a medical device or any of its containers or wrappers, or 
 accompanying a medical device, 
 provided for a medical device by other means 
Related to identification, technical description, intended purpose and 
proper use of the medical device, but excluding shipping documents. 
Life-cycle All phases in the life of a medical device, from the initial conception to 
final decommissioning and disposal. 
Manufacturer  Any natural or legal person with responsibility for design and/or 
manufacture of a medical device with the intention of making the 
medical device available for use, under their name; whether or not such 
a medical device is designed and/or manufactured by that person or on 
their behalf by another person(s). 
Post market 
surveillance 
Systematic process to collect and analyse experience gained from 













4. Quality Management System 
4.1 General Requirements 
4.1.1 System Scope 
The quality management system is established to implement the requirements of ISO 
13485:2012 and European Directives MDD 93/42/EEC, and to establish policies and procedures 
that support the objectives of the research group. 
4.1.2 System Structure 
This quality manual provides policy and other top-level guidance (Level I), and makes reference 
to standard operating procedures (SOPs) for detailed procedures on the operation of the system 
(Level II). Detailed procedures for supporting activities are found in Appendices, Forms, Records 
and other Level III documents. The sequence and interaction of processes needed for the quality 
system is outlined in Appendix 3 BDRG Process Flow Chart. Quality system documentation also 
defines criteria and methods needed to ensure that the operation and control of quality system 
processes are effective. This includes assignment of responsibilities and allocation of resources 
for the process, instructions on how to carry out and operate the process, definition of methods 
for monitoring, measuring, and analysing the processes and actions necessary to achieve 
planned results and continually improve the processes. The PI is responsible for determining 
resources and information requirements necessary to support the operation and monitoring of 
quality system processes. 
4.1.3 System Processes 
The Principal Investigator approves initial release and changes to this document through the 
change control request (CCR) process.  
Internal audits are used to evaluate the effectiveness of the quality system and drive 
improvement by monitoring and measuring the outcome of these processes. Management 
review also ensures availability of adequate resources and technology to support the QMS. The 
monitoring of process objectives is outlined in F 5.6-01 Key Process Metrics. 
Where processes are outsourced, the BDRG complies with UCC’s procurement policy. Additional 
criteria to meet the requirements of ISO 13485 are enacted for processes and material intended 
for clinical use as outlined in SOP 7.4 Purchasing and Vendor Management Procedure.  
4.1.4 Clinical Evaluations 
The scope of the quality system covers the design and development of medical products for 
clinical research and eventual commercialisation. 
Clinical evaluation activities are also covered as follows: 
 Any clinical investigations conducted utilising investigational medical devices will be 
conducted in accordance with ISO14155 clinical investigation of medical devices for 
human subjects – good clinical practice. 
 Roles and responsibilities for any clinical investigations will be defined in an approved 
study specific clinical management plan. 





 Identifying the processes and documentation required for the clinical evaluation in 
support of the technical activities and applying these processes. 
 Ensuring that the processes used and the control of these processes is efficient and 
effective. 
 Monitoring, control and analysis of the processes on an ongoing basis. 
Procedures Relating to Clause 4.1 Quality System  
SOP 7.4  Purchasing and Vendor Management Procedure 
SOP 5.6   Management Responsibility Procedure 
4.2 Documentation Requirements  
4.2.1 General 
A quality management system based on the specific requirements of ISO13485 and 
incorporating additional end user requirements has been implemented by the BDRG. The 
documented quality management system shall include the following: 
(a) Documented statement of a quality policy and quality objectives (see Appendix 1); 
(b) A quality manual is reviewed as required and approved by the PI and QA/RA 
Administrator through the change control process; 
(c) Quality procedures shall be documented and implemented for each activity undertaken 
by the research group to ensure a consistent and systematic approach in product design 
and development; 
(d) Documents needed to ensure the effective planning, operation and control of its 
processes; 
(e) Quality records to demonstrate compliance to our documented quality management 
system, and user requirements; 
(f) Any other documentation specified by national or regional regulations.  
 
The documented quality management system in operation in the BDRG is structured into three 
levels as follows; 
Level 1: The Quality Manual; 
 The quality manual is the top level document that describes the overall quality system 
in accordance with the stated quality policy and ISO 13485:2012. 
Level 2: Procedures; 
 The standard operating procedures establish the research groups’ practices, 
procedures, policies and requirements. They are drafted from both a technical and 
clinical perspective and use a general format, with flow charts and diagrams as 
applicable. The quality manual references the applicable SOP(s). Standard operating 
procedure numbers are assigned according to the corresponding ISO 13485 Clause. E.g. 





SOP 4.2 is the procedure for Document Control Procedure (ISO 13485 clause 4.2). Level 


































Figure 2 QMS Structure 
Level 3: Forms, Records and Specifications; 
 The third level of documentation includes Forms and Records which provide evidence 
about a past event stating results or activities performed. 
 Laboratory Notebooks record the design and development activities of the research 
associate. 
 Product Specifications define product characteristics, including functional 
characteristics, risk management, validation and verification, packaging and sterilization 
processes, and manufacturing processes. 
The Design History File (DHF) contains design and development history for the device, such as 
product requirements, design and development plan, FMEA/risk management, quality plan, 
design change records, validation documents etc. These are all examples of level 3 
documentation. 
4.2.2 Quality Manual 
The Quality Manual (this document) defines the policies, application, scope, exclusions and 
documentation of the quality management system. The quality manual includes; 
 The scope of the quality management system, and details of and justification for any 
exclusion. 
 Reference to documented procedures established for the quality system which clearly 
show the relationship between the requirements of the standard and documented 
procedures. 
 A process map that clearly identifies the description and interaction between the 
processes of the quality management system (see Appendix 3). 





4.2.3 Control of Documents 
A documented procedure is in place ensuring that documents defining products, processes, and 
the quality system are approved before controlled release and distribution. This is achieved 
electronically via a shared cloud network which has restricted access to project personnel only. 
A master document list is maintained with the latest revision of each document in the quality 
management system. Different rights and permissions are associated with each member of the 
project team and the overall management and maintenance of the shared network is the 
responsibility of the QA/RA Administrator or designee. Obsolete documents are removed from 
the master document list and are stored in an obsolete folder. These documents are only 
accessible to the QA/RA Administrator and PI or designee. External documents such as industry 
or agency standards are controlled in the same way as internally generated documents. The 
QA/RA Administrator is responsible for document control. However, all personnel are 
responsible for using the correct documents, at the prescribed revision level, at all times. 
SOP 4.2 Document Control and SOP 4.2.3 Change Control Procedure details the following 
requirements: 
(a) Review and approve documents for adequacy prior to issue; 
(b) Review and update as necessary and re-approve documents; 
(c) Ensure that the changes and the current revision status of documents are identified; 
(d) Ensure that relevant versions of applicable documents are available; 
(e) Ensure that documents remain legible & readily identifiable; 
(f) Prevent unintended use of obsolete documents and to apply suitable identification to them 
if they are retained for any purpose. 
A review of all Standard Operating Procedures shall be completed on an annual basis to ensure 
that the contents are current and valid. For external documents an annual review is also 
conducted to ensure document revisions are current. 
4.2.4 Approval and Issue 
Documents are approved by the individual’s assigned responsibility for the particular document. 
Once a document has been approved it is uploaded to the shared cloud network by the QA/RA 
Administrator and filed in the master document folder. 
Documents are maintained on the shared network as read only in the document control system. 
If a document or process requires a change/amendment during the course of the project, it 
should follow the Change Control Process as outlined in SOP 4.2.3 Change Control Procedure. A 
Master Change Control Log is maintained for all changes. 
4.2.5 Control of Records 
The BDRG establishes and maintains quality records to provide evidence of conformance and 
the effective operation of our documented quality management system and the end user’s 
specific requirements.  Quality records shall be legible, readily identifiable and retrievable.  
Records are identified, indexed and grouped to facilitate their retrieval.  
 
 






Retention periods for quality records are determined on the basis of the event to which the 
record pertains, and on regulatory and contractual requirements as applicable. Retention times 
of quality records, and disposition requirements, shall be referenced in SOP 4.2 Document 
Control Procedure. 
Procedures Relating to Clause 4.2 Documentation Requirements  
SOP 5.6   Management Responsibility Procedure 
SOP 4.2   Document Control Procedure 
SOP 4.2.3 Change Control Procedure 
5. Management Responsibility  
5.1 Management Commitment 
The BDRG is committed to implementing, and maintaining a documented quality system. This 
commitment includes: ensuring that user, regulatory and legal requirements are understood 
and appropriately addressed, the quality policy is understood and implemented at all levels of 
the group, quality objectives and plans are established as necessary and that the responsibilities 
of all functions affecting quality are clearly defined. The Principal Investigator is responsible for 
establishing, implementing, and continuously improving the quality system. Personnel and other 
necessary resources are provided to accomplish the goals of the quality system. 
There are several processes by which the Principal Investigators communicate to the rest of the 
research group regarding user, regulatory and legal requirements and the importance of 
meeting these requirements. 
 Informational meetings and project meetings are conducted periodically. 
 Training is conducted on a regular basis according to the requirements specified in the 
training SOP and this training is documented and includes training to regulations, etc. 
 New employees go through a series of training, so they have a thorough understanding 
of the research group as well as clinical and regulatory requirements. 
Management Reviews and internal audits are conducted periodically to ensure that the quality 
system is effective. Management review is the mechanism by which opportunities to improve 
are identified and resources are allocated to achieve those improvements. Quality objectives 
are defined at these reviews. 
Procedures Relating to Clause 5.1 Management Commitment 
SOP 5.6   Management Responsibility Procedure 
5.2 User Centered Design 
The BDRG shall ensure that user needs and requirements are identified to allow for design 
solutions which meet user requirements as well as applicable regulatory requirements. User 
needs, including other applicable requirements, will generally be identified by way of structured 





academic programs (e.g. Bioinnovate, UCC BioDesign), direct clinical engagement & technology 
partners. User requirements are determined, converted into internal requirements, and 
communicated to the appropriate people in the organisation. 
Procedures Relating to Clause 5.2 Customer Focus 
SOP 7.3A Design Control Procedure 
5.3 Quality Policy 
The BDRG has documented a quality policy. Management ensures that the quality policy is;  
 Appropriate to the purpose of the group; 
 Reflects the organisation’s quality objectives and the framework for setting and 
reviewing same; 
 Outlines the commitment to comply with requirements and to maintain the 
effectiveness of the quality management system;  
 Communicated and understood within the group. 
The quality policy shall be communicated to all group personnel by posting in the group office 
areas. The quality policy shall also be communicated and explained during induction and 
personnel understanding of the policy by personnel shall be examined. The policy shall be 
reviewed and updated as appropriate during the management review meeting in order to 
ensure the policy’s continuing suitability for the group. Refer to Appendix 1 for the current 
Quality Policy. 
Procedures Relating to Clause 5.3 Quality Policy 
SOP 5.6   Management Responsibility Procedure 
5.4 Quality Management System Planning 
The planning for the quality management system is carried out by the Principal Investigator and 
project leads during management review meetings where quality objectives are set and 
reviewed. Quality planning includes identification and determination of quality system 
processes, priorities for continual improvement, and resources needed to achieve quality 
objectives and to maintain and improve the quality system. When a change is made to the 
quality system as a result of an internal audit or management decision, it is reviewed for 
effectiveness and appropriate justification and approvals are required to implement the change. 
This change is documented as indicated in the change control process as outlined in the Change 
Control SOP 4.2.3. 
Procedures Relating to Clause 5.4 Quality Planning 
SOP 4.2 Document Control 
SOP 5.6 Management Responsibility  
SOP 7.5  Control of Outsourced Manufacturing 





SOP 6.2 Training Procedure 
SOP 7.3A Design Control 
SOP 7.4 Purchasing and Vendor Management 
SOP 8.2.2 Internal Auditing 
5.5 Responsibility, Authority and Communication 
5.5.1 Responsibility and Authority 
Approved organograms are maintained by the QA/RA Administrator electronically. Some 
individuals within the group perform multiple roles. However, the roles and responsibilities 
relating to quality are clearly defined in later sections of this manual, in job descriptions, and in 
SOP’s. Independence and authority necessary to manage, perform, and assess tasks affecting 
quality is maintained by the Principal Investigator. Job descriptions are assigned by the Principal 
Investigator. 
5.5.2 Roles, Responsibilities & Competencies 
Management Team 
The management team (comprising of at least the PI (Principal Investigator), the Research 
Associate (Res) and the Quality Assurance and Regulatory Affairs (QA/RA) Administrator) is 
responsible for the leadership and direction of the group. The management team is also 
responsible for establishing the Quality Policy, and reviewing it for continuing suitability. 
Principal Investigator (PI) 
 Establish and support the quality policy by providing the necessary resources. 
 Establish quality goals and objectives for the group. 
 Participate in management reviews. 
 Review and approve new and revised quality and product documentation. 
Research Associate (Res) 
 Coordinate functional and other technical requirements with users or the Principal 
Investigator. 
 Design and initiate specification documentation for medical devices. 
 Review and approve product and supporting documents for initial release and changes. 
 Coordinate design control activities on assigned products. 
 Initiate required documents for prototype or developmental products. 
 Support ongoing device improvements, through capability and quality improvement 
activities. 
 Initiate and review SOPs and supporting documents. 
 Coordinate and when applicable carry out validation and verification of medical devices. 
 Maintain positive identification and traceability of all products. 
 





Quality Assurance and Regulatory Affairs Administrator (QA/RA) 
 Coordinate and manage the group’s quality assurance and regulatory issues. 
 Establishing and maintaining the quality system. 
 Ensuring that processes needed for the quality management system are established 
implemented and maintained according to the requirements of ISO 13485. 
 Regular reporting on the performance of the quality system to the management team, 
using the information in these reports to initiate continuous improvement actions on 
the processes and systems used by the organisation. 
 Arranging biannual management review meetings. 
 Liaising with customers and third party auditors in matters relating to the quality 
system. 
 Promoting awareness of customer and regulatory requirements throughout the 
organisation. 
 Initiate and monitor corrective/preventive actions (CAPA). 
 Coordinate internal audits and associated corrective actions (CA). 
 Prepare certifications and other required quality documentation in support of device 
release. 
Management Representative 
The Quality Assurance and Regulatory Affairs Administrator (QA/RA) is the management 
representative for the BDRG and has the following responsibility and authority: 
 Acting as Principal Investigator’s agent in establishing, implementing, maintaining, the 
effectiveness of and improving the quality system; 
 Reporting the performance of the quality system and any need for improvement to the 
Principal Investigator;  
 Serving as the group’s liaison with users and other external parties on matters related 
to product quality and reliability.  
Contract Manufacturer 
The BDRG will contract the services of a contract manufacturer to manage the manufacture, 
packaging and sterilisation of their products. The specific role of the contract manufacturer is 
outlined SOP 7.4. 
Individual Roles 
Refer to the individual Job Descriptions which outlines the key responsibilities and authorities 
for each person in the group.  
5.5.3 Internal Communication 
 On a periodic basis, the Principal Investigator will disseminate information regarding the 
project status. This will generally take place in the context of regular group meetings. 
 Methods of communicating the effectiveness of the QMS include management review, 
circulation of minutes of management review meetings and internal audit meeting 
minutes. 





Procedures Relating to Clause 5.5 Responsibility, Authority and Communication 
SOP 5.5 Regulatory Audits Procedure 
SOP 5.6 Management Responsibility Procedure 
5.6 Management Review 
5.6.1 General 
The principal investigator and the QA/RA Administrator formally review the quality system for 
compliance and effectiveness on an annual basis. The QA/RA Administrator (or designee) is 
responsible for calling and facilitating the review and minutes. Management Review Meeting 
minutes are prepared and circulated by the QA/RA Administrator (or designee) as required to 
provide pertinent information regarding the quality of the medical device or the effectiveness 
of the quality management system.  
The results of the management review shall be communicated to all relevant group personnel 
and the progress of actions shall be examined prior to the next review. SOP 5.6 Management 
Responsibility Procedure has been established to outline the management review process at the 
BDRG. This procedure includes the required inputs and outputs of the management review 
meeting. 
5.6.2 Review Input  
The management team selects inputs to the management review process to evaluate efficiency 
as well as effectiveness of the quality management system. The review inputs may include 
quality metrics, user feedback, audit results both internal and external if applicable and 
corrective and preventive action. Other inputs may be added as deemed appropriate: 
 Follow–up actions from previous management reviews. 
 Review suitability of the quality policy. 
 Results of audits (internal and external). 
 End user feedback. 
 Progress of the quality objectives. 
 Process performance: Key Process Metrics (F 5.6-01). 
 Design and development opportunities and issues. 
 Types, numbers and status of non-conformities, corrective and preventive actions. 
 Continued suitability of the QMS and any changes that could affect the quality 
management system.  
 Recommendations/suggestions for improvement. 
 Training requirements/plans. 
 Supplier/subcontractor performance. 
 Any other business. 
 
 





5.6.3 Review Output 
All actions arising out of the management review meeting shall be recorded, responsibility 
assigned and completion dates decided. The management representative shall ensure that 
actions are completed in a timely basis.  
Management review outputs shall include: 
(a) Improvements needed to maintain the effectiveness of the quality management system, 
(b) Improvement to the device relating to end user requirements, 
(c) Resource requirements. 
The output shall include a statement regarding the effectiveness of the quality management 
system and its processes established for the achievement of the quality policy and the 
objectives, and the extent to which those objectives have been met based on the established 
respective criteria.   
Procedures Relating to Clause 5.6 Management Review 
SOP 5.6 Management Responsibility Procedure 
6. Resource Management 
6.1 Provision of Resources 
6.1.1 General 
The Principal Investigator determines and provides the resources necessary for the 
implementation, maintenance, and continual improvement of the entire quality system. The 
Principal Investigator assigns appropriate resources to enhance user satisfaction through 
meeting user and regulatory requirements. Resources include personnel, infrastructure, work 
environment, process equipment, materials, information, suppliers and financial resources.  
6.1.1 Resource Determination  
The Principal Investigator determines appropriate resource needs during periodic project 
reviews and during management review meetings. Resource needs are established through 
consideration of end-user feedback and quality management improvements. The Principal 
Investigator considers all the resources necessary to accomplish these needs, including 
personnel assignments, allocation of space or equipment, training, procurement decisions, 
budgets, etc. 
Procedures Relating to Clause 6.1 Provision of Resources 
SOP 6.2 Training Procedure 
SOP 5.6 Management Responsibility  
 
 





6.2 Human Resources 
6.2.1 General 
The BDRG shall ensure that personnel performing work affecting quality of the product shall be 
competent on the basis of appropriate education, training, skills and experience. The QA/RA 
Administrator is responsible for the training and awareness programs for group personnel, such 
as general orientation, rules and regulations, quality system, safety, and other group systems 
and issues.  
6.2.2 Qualification Documentation 
Written job descriptions are in place for all activities affecting product quality in order to 
document the qualifications and duties of the positions determined to be necessary by the 
Principal Investigator. 
6.2.3 Assignment of Resources 
Resources are assigned based on experience, education, skills and training to appropriate tasks 
to meet established project and quality objectives. 
6.2.4 Competence 
The PI will assess the competency of all group personnel on an on-going basis by way of informal 
weekly updates and assessing the quality of completed tasks/activities. In the case where 
personnel are not performing satisfactorily, corrective measures including increased 
supervision, assigning direct and focused objectives and additional training may be used. 
6.2.5 Awareness 
The PI and QA/RA Administrator complete a training plan for each personnel which determines 
his/her training requirements (F6.2-03 Training Plan). 
6.2.6 Training 
SOP 6.2 Training Procedure has been established to provide training for all personnel performing 
activities affecting quality and ensuring that end user and regulatory requirements are met. 
Training needs are assessed on inducting new personnel to the BDRG. The training needs are 
updated as required by the PI and QA/RA Administrator. Qualifications are reviewed prior to 
joining the group. All personnel are made aware of the relevance and importance of their 
activities and how they contribute to the achievement of the quality objectives. Training records 
shall be maintained for all internal and external training performed. Training on all quality 
documents is carried out using the online learning platform Moodle and is described in SOP 6.2 
Training Procedure. 
Where training is carried out, whether internal or external, the BDRG shall evaluate the 
effectiveness of the training. Training effectiveness can be evaluated by surveying the employee, 
evaluating the work performance of the trained individual, internal audits or assessment post-
training delivery. Training effectiveness is reviewed at Management Review.  
Procedures Relating to Clause 6.2  Human Resources 
SOP 6.2 Training Procedure 
SOP 6.2.2 Moodle Instruction Manual 







Management is responsible for identifying the need and requirements for new and/or 
modification of existing infrastructure and facilities. Building and facilities maintenance is carried 
out by the UCC Buildings and Estates Department. The BDRG is subject to the health and safety 
policies of the UCC Health and Safety office. 
University College Cork provides and maintains the overall infrastructure. This includes 
buildings, workspace and associated utilities.  
The funding allocated or obtained for each project finances the equipment, tools, computer 
systems, etc. for each project. IT Systems are maintained and upgraded as required by the 
School of Engineering IT Administrator. 
6.3.2 Plant, Facility & Equipment Management 
The BDRG shall maintain the premises in a state of order, cleanliness and repair appropriate to 
the work being carried out.  SOP 6.3 Calibration and Equipment Maintenance outlines the 
controls around equipment calibration and maintenance.  
6.3.3 Outsourced Services 
Manufacturing packaging and sterilisation is outsourced to suitably qualified subcontractors – 
reference SOP 7.4 Purchasing and Vendor Management Procedure and SOP 7.5 Control of 
Outsourced Manufacturing Procedure.  
Procedures Relating to Clause 6.3  Infrastructure 
SOP 4.2  Document Control 
SOP 7.4 Purchasing and Vendor Management Procedure 
SOP 7.5 Control of Outsourced Manufacturing 
SOP 6.3 Calibration and Equipment Maintenance 
6.4 Work Environment  
6.4.1 General 
UCC provides the necessary resources for a safe and suitable work environment. The university 
also manages the health & safety of the work environment by utilising safety systems of work. 
The Human Resources office of UCC has overall responsibility for employee welfare, including 
university induction training, fire safety management, and routine facility maintenance. UCC 
maintains a health and safety policy and a comprehensive safety statement. Equipment and 
work environment needs are addressed through the PI. 
The BDRG outsources the manufacturing, packaging and sterilisation activities. Therefore no raw 
materials, processing material, sub-assemblies or final product intended for human use is 
handled at UCC. Materials for research activities are handled in the laboratory. Control of 
subcontracted activities is detailed under SOP 7.5 Control of Outsourced Manufacturing. 
 





Procedures Relating to Clause 6.4 Work Environment  
SOP 7.5 Control of Outsourced Manufacturing. 
7.0 Product Realisation   
7.1 Planning of Product Realisation 
The BDRG plans and develops the processes needed for product realisation. These processes 
include the steps necessary to design and develop new devices, as well as the implementation 
of procedures and controlled records to detail the processes used to create and inspect the 
devices. In planning product realisation, management determines and documents the following, 
as appropriate: 
• Quality objectives and requirements for the device, in particular, regulatory 
requirements for the various regions that the device may be sold in. 
• Identification of end user requirements. 
• The need to establish processes, documents, and provide resources specific to the 
device. 
• Risk management planning and reporting. 
• Required verification, validation, monitoring, inspection, and test activities specific to 
the device and the criteria for device acceptance.  
• Records needed to provide evidence that the realisation processes and resulting device 
fulfil requirements. 
Management has established appropriate risk management programs to ensure that risk 
assessment is included as part of the planning of product realisation; reference SOP 7.1, Risk 
Management. The Risk Management File is updated as changes to the Quality Management 
System are made. ISO 14971 is used as a guidance document for risk management activities.  
The output from product realisation planning includes all of the forms, procedures, technical 
documentation, and other records associated with the development of products and processes. 
Procedures Relating to Clause 7.1 Planning of Product Realisation   
SOP 7.5 Control of Outsourced Manufacturing 
SOP 7.4  Purchasing and Vendor Management 
SOP 4.2 Document Control Procedure 
SOP 8.3A   Control of Non Conformances 
SOP 7.3A Design Control 
SOP 8.5 CAPA 
SOP 7.1 Risk Management 





7.2 End User Related Processes  
7.2.1 Determination of Requirements 
The BDRG ensures that end user requirements are identified including: 
 Requirements specified by the end user, including the requirements for ergonomics, 
environmental conditions, tolerances and other operational related requirements. 
 Requirements not stated by the end user but necessary for specified use or known and 
intended use. 
 Statutory and regulatory requirements related to the product. 
 Any additional requirements necessary to ensure the end user’s satisfaction, such as 
providing technical information or specific documentation. 
7.2.2 Review of Requirements related to the Product 
The BDRG personnel ensure that all requirements related to the device development are 
identified and documented. This is implemented during the design process, which is used to 
verify and approve the design inputs and outputs. 
Records of requirement review and actions arising from the review are maintained. Where 
product requirements are changed, the BDRG personnel shall ensure that all the pertinent 
documents are amended and that relevant personnel are informed of the changed 
requirements. 
7.2.3 End User Communication 
Management has implemented effective arrangements for communicating with end users in 
relation to: 
 Product information, including details about products, sales and service information. 
 Enquiries, contracts, or order handling, including amendments. 
 User feedback, including clinical engagement.  
Procedures Relating to Clause 7.2 Customer Related Processes  
SOP 7.3A  Design Control 
SOP 7.5A Control of Outsourced Manufacturing 
7.3 Design and Development  
7.3.1 Design and Development Planning  
Design control procedures including design verification and validation procedures are 
maintained. Product development procedures are intended to balance the freedom to innovate 
and the discipline required to consistently meet user and regulatory requirements. Design 
activities prior to the formal documentation of design inputs are at the discretion of the 
engineer, and records are kept in laboratory notebooks. Subsequent to the formal 
establishment of the design inputs, design activities are planned, controlled, and regularly 
reviewed. 
 





7.3.2 Design and Development Inputs 
During the planning phase of product development, inputs related to product requirements will 
be determined. SOP 7.3.2 Defining Design Inputs procedure has been established to outline this 
activity. Design inputs are collected from many sources, including users, key opinion leaders 
(KOLs) in the field of use, similar products, and others. These inputs will form the basis for a 
Design History File (DHF) for that design. These Design History Files will become the main record 
of all product development performed at later stages of the design process. 
Design Inputs will include: 
• Functional, performance, and safety requirements as applicable to the intended use. 
• Any statutory and regulatory requirements that apply to the product. 
• Information relating to existing designs that are similar to the new product. 
• Risk assessment information as applicable.  
Inputs of the design development process will be reviewed and approved after they have been 
determined. This review is intended to ensure that the requirements are complete, 
unambiguous and not in conflict with each other.  
7.3.3 Design and Development Outputs 
Design outputs are documented and are compared to design inputs to ensure that input 
requirements are met. Design outputs may include, but are not limited to, design specifications, 
engineering drawings, laboratory notebooks, SOP’s, forms, testing and technical reports. Design 
outputs are reviewed and approved particularly before clinical evaluation.  
These outputs will also include documentation related to the safety and performance 
characteristics of the product where appropriate that are essential for its safe and proper 
intended use. All design output records are included in product Design History Files.  
7.3.4 Design and Development Review 
SOP 7.3A Product Design Control procedure includes the requirements for design review.  During 
the course of design development, reviews of existing information about a new design will be 
discussed and reviewed with appropriate personnel to ensure that any problems are identified 
and corrected so that the product can meet all stated requirements. Records of all design 
reviews are included in Design History Files as design review minutes. 
Participants in design reviews shall include representatives of functions involved with the design 
phase being reviewed, as well as other specialist personnel who may be required to provide 
technical input such as clinicians.  
7.3.5 Design and Development Verification 
Design and development output will include all relevant information necessary to verify that the 
new product meets all stated development input requirements. Through the design and 
development system established by management, this verification is performed and the results 
are approved and recorded. All stages of the design and development process are recorded in 
relevant Design History files, ensuring that a complete history of a product’s development is 
available for review. SOP 7.3.3 Design Verification and Product Validation procedure outlines 









7.3.6 Design Validation 
In addition to design verification, the design and development system also ensures that product 
designs are validated during the final stages of the development process. This validation ensures 
that the final product is able to meet all of the performance and safety requirements for the 
intended use/application of the product. Validation also includes an evaluation of performance 
of the final product. Records of this validation are maintained as part of a Design History File. 
Validation is completed before release of the final product from Product Development. SOP 
7.3.3 Design Verification and Design Validation procedure outlines the requirements for this 
activity. Product validation may include the performance of clinical evaluations and/or 
evaluation of the performance of a medical device, as required by national or regional 
regulations.  
7.3.7 Control of Design and Development Changes 
Changes to existing designs are reviewed, verified, and validated before they are approved and 
implemented, as per SOP 4.2.3 Change Control. This review will ensure that the finished product, 
as well as components for the product will continue to function as intended. All design changes 
are documented within individual Design History Files. SOP 4.2.3 Change Control procedure 
outlines the controls around Design Changes. 
Procedures Relating to Clause 7.3 Design and Development  
SOP 7.3A  Product Design Control  
SOP 7.3.2 Defining Design Inputs  
SOP 7.3.3 Design Verification and Design Validation  
SOP 7.3B Design History File Preparation  
SOP 7.3C Technical File Preparation and Maintenance 
SOP 4.2.3 Change Control 
SOP 7.1A Risk Management 
7.4 Purchasing 
7.4.1 Purchasing Process 
As the BDRG is a part of UCC, it uses the procurement policies and procedures of UCC, under the 
University’s ISO 9001 certified quality management system. This complies with national public 
procurement guidelines and rules. 
The BDRG ensures that purchased products conform to specified purchase requirements. UCC 
evaluates and selects suppliers based on their ability to supply products and services in 
accordance with requirements. Records of supplier performance and supplier evaluation are 
retained on file and are reviewed as part of the UCC Management Review process. 
In addition to the University polices, the BDRG evaluates all new suppliers with regard to their 
quality and process capability and where applicable, compliance with ISO13485. SOP 7.4 
Purchasing and Vendor Management Procedure has been established and implemented to 
ensure that purchased material conforms to the specified purchase requirements. This 





procedure does not apply to the suppliers of equipment or materials not unique to medical 
device design such as stationery, printing or office supplies.  
The criteria for selection of suppliers are defined in SOP 7.4 Purchasing and Vendor Management 
Procedure.  Suppliers which meet the criteria will be approved and added to the Approved 
Vendor List (AVL). Products and/or services may be purchased only from suppliers who are listed 
on the Approved Vendor List. Materials which are purchased before "design freeze" stage do 
not necessarily need to be from suppliers on the AVL.  
Quality performance of suppliers is monitored by delivery time and quality of received goods, 
and this is reviewed at the management review meeting. Suppliers demonstrating inadequate 
performance may be asked to implement corrective action.  Where there is no improvement in 
performance, the supplier will be removed from the Approved Vendor List. Records of supplier 
evaluations and performance are maintained in accordance with SOP 4.2 Document Control 
Procedure. 
7.4.2 Purchasing Information 
Purchase orders (PO) are placed via the UCC Agresso online payment system. PO’S are 
automatically generated once the vendor has been approved and added to the Agresso 
database and the raised requisition has been approved by the project code approver. The PO 
should include product information described in the product text section of the requisition 
entry. 
7.4.3 Verification of Purchased Material 
Prior to issue, all purchased material within the scope outlined in SOP 7.4 Purchasing Procedure 
shall be verified to ensure that the material meets specified purchase requirements. If the BDRG 
wishes to perform verification at the supplier’s premises, the verification arrangements and 
method of verification shall be documented. Records of the verification are maintained as per 
SOP 4.2 Document Control procedure. 
Procedures Relating to Clause 7.4 Purchasing  
SOP 7.4 Purchasing and Vendor Management Procedure 
SOP 7.4.1 Supplier Auditing Procedure 
SOP 4.2   Document Control Procedure 
7.5 Production and Service Provision 
7.5.1 Control of Production and Service Provision 
7.5.1.1 General Requirements 
The BDRG does not place products on the market or distribute commercialised medical devices. 
However the BDRG has established procedures necessary to plan and carry out production of 
medical devices for clinical investigation purposes.  
Controlled conditions may include, but are not limited to, the following (as applicable): 
 The availability of information that describes the characteristics of the product, 
including relevant documentation required by national or international regulations 
(such as Device Master Records or Technical Files). 





 The availability of SOP’s at Point of Use to the personnel that require them, including 
reference materials and/or measurement standards. 
 The requirements for equipment where that equipment could affect the performance 
or safety of the product or the safety of personnel. 
 The availability and use of monitoring and measuring devices, particularly for the testing 
and/or verification of medical devices that have a measurement function. 
 The implementation of monitoring and measurement, including the inspection of 
incoming materials, in process products, and finished products. 
 The implementation of release, delivery, and post-delivery activities. 
 Labeling and packaging requirements and any special environmental controls or 
employee training necessary to ensure product conformity. 
Management has established the necessary processes to record traceability information for 
each batch of BDRG products used in a clinical setting to ensure that safety or performance 
issues can be appropriately addressed. These records include the amount manufactured, 
production history, inspection status information, and amount released for distribution.  Batch 
records are verified and approved.  
7.5.1.2 Control of production and service provision – specific requirements 
7.5.1.2.1 Cleanliness of product and contamination control 
The manufacture and sterilisation of BDRG products are outsourced to a qualified subcontractor, 
see;  
 SOP 7.4 Purchasing and Vendor Management Procedure  
 SOP 7.5 Control of Outsourced Manufacturing 
7.5.1.2.2/7.5.1.2.3 Installation and Servicing Activities  
The BDRG does not carry out installation or servicing activities and is not applicable, please see 
section 1.2. 
7.5.1.3 Particular Requirements for Sterile Medical Devices 
The BDRG maintains records of the process parameters for the sterilisation process which is 
used for each sterilisation batch. Sterilisation records are traceable to each production batch of 
medical devices. Sterilisation activities are outsourced to a suitably qualified subcontractor. 
Procedures Relating to Clause 7.5.1 Control of Production and Service Provision 
SOP 7.4  Purchasing and Vendor Management Procedure 
SOP 7.5 Control of Outsourced Manufacturing 
7.5.2 Validation of processes for production and service provision 
7.5.2.1 General Requirements 
Any process that cannot be verified by subsequent monitoring or measurement will be validated 
prior to its acceptance as a standard manufacturing process. This validation includes any 
processes where deficiencies become apparent only after the product is in use. This validation 
will demonstrate the ability of the processes to achieve planned results. Records of any 
validation will be maintained as part of the BDRG Quality Management System. 





Process validation activities are carried out by the outsourced manufacturer as approved by the 
BDRG Principal Investigator. 
The outsourced manufacturer process validation procedures shall include; 
(a) defined criteria for review and approval of the processes, 
(b) approval of equipment and qualification of personnel, 
(c) use of specific methods and procedures, 
(d) requirements for records, and 
(e) re-validation. 
Procedures Relating to Clause 7.5.2 Process Validation 
SOP 8.5.1B Customer Complaints Handling 
SOP 4.2  Document Control 
SOP 4.2.4 Quality Records  
7.5.3 Identification and traceability 
7.5.3.1 Identification 
The ability to trace a batch of product back to all raw materials used in its manufacture and to 
trace any lot of raw material to products it became part of is an essential feature of our Quality 
Management System.  A part number and lot number control of all materials is used to 
manufacture products. This provides complete traceability from receipt of raw materials 
through final shipment to the end user. For all devices, the part number and lot number will be 
printed on each individual device. Management is responsible for assigning part numbers.  
Where manufacturing of the device is outsourced, subcontractors shall demonstrate their ability 
to provide product through using a suitable traceability system.  Where medical devices are 
returned, SOP 8.3A Control of Non-Conformances shall be used to ensure that medical devices 
returned to the organisation are identified and distinguished from conforming product. 
7.5.3.2 Traceability 
7.5.3.2.1 General 
Traceability is maintained on all our products, from raw material to finished goods, with a unique 
identifier on the product. The BDRG has overall responsibility for the coordination of all 
traceability management systems, which will be managed directly by the body responsible for 
handling the components and products; outsourced manufacturer and distribution agents. This 
is referenced in SOP 7.5A Control of Outsourced Manufacturing procedure.  
7.5.3.2.2 Particular Requirements for active Implantable Medical Devices and 
Implantable Medical Devices 
The BDRG does not manufacture or supply implantable or active implantable devices, therefore 
this clause is not applicable, please see section 1.2. 
7.5.3.3 Status Identification 
The BDRG ensures that the product status with respect to monitoring or measuring 
requirements is identified. Where manufacturing is outsourced, the BDRG ensures that this 
activity is maintained at the supplier premises through design transfer, supplier approval and 





auditing activities. Product status shall be identified throughout production and storage of the 
product in order to ensure that only product which has passed the required inspections and 
tests (or released under authorised concession) is dispatched or used. 
 
Procedures Relating to Clause 7.5.3 Identification and Traceability  
SOP 8.3A Control of Non Conformances 
SOP 7.5 Control of Outsourced Manufacturing 
7.5.4 Customer Property 
The BDRG shall exercise all due care with customer property while they are under the group’s 
control or being used by the group. If customer property is lost, damaged or otherwise found to 
be not suitable for use, the BDRG shall report this to the customer according to SOP 8.3A Control 
of Non-Conformances and maintain records according to SOP 4.2 Document Control Procedure. 
Customer property can include intellectual property or confidential health information. 
Procedures Relating to Clause 7.5.4  Customer Property  
SOP 7.5.2 Process Validation and Equipment Qualification Requirements for Suppliers 
SOP 4.2 Document Control 
7.5.5 Preservation of Product 
Procedures have been established to ensure that products and components will be preserved 
throughout the manufacturing process to ensure product conformity with specifications. These 
procedures include identification, handling, packaging, storage and protection and will be in 
effect up to and including the time of delivery to the intended destination. Where applicable, 
these procedures also include environmental controls to ensure that factors in the environment 
do not degrade the quality of BDRG products or components. 
Management procedures or documented work instructions to ensure that products with limited 
shelf lives or components with limited shelf lives are monitored to ensure that expired products 
or components are not used in manufacturing processes. Any special storage conditions shall be 
controlled and recorded.  
Raw materials, sub-assemblies or final product are not stored in the BDRG premises; these are 
under the control of the contract manufacturer and sterilisation provider, both of whom are 
certified to ISO 13485 requirements. 
Procedures Relating to Clause 7.5.5 Preservation of Product  
SOP 4.2 Document Control Procedure 
SOP 8.3A Control of Non Conformances 
SOP 7.5 Control of Outsourced Manufacturing Procedure 
SOP 7.4.3 Laboratory Material Management 





7.6 Control of Monitoring and Measuring Devices 
A documented procedure outlines controls employed by the BDRG to manage measuring 
devices. Equipment subject to calibration shall be positively identified by means of a label 
indicating, at a minimum, the date calibrated, the due date for the next calibration and the 
person who performed the calibration.  A Master List of Gauges is maintained, which states 
whether the equipment is calibrated internally or externally, or for reference purposes only.  
Where necessary to ensure valid results, measuring equipment shall; 
• Be calibrated or verified (or both), at specified intervals or prior to use, against 
measurement standards traceable to international or national measurement standards; 
where no such standards exist, the basis for calibration or verification shall be recorded.  
This record shall be maintained according to SOP 4.2.4 Quality Records Procedure; 
• Be adjusted or re-adjusted as necessary; 
• Be identified in order to determine its calibration status; 
• Preventative maintenance completed in line with manufacturers recommendations; 
• Measurement equipment needs to be operating within the appropriate range as 
recommended by the manufacturers; 
• Be safeguarded from adjustments that would invalidate the measuring result; 
• Be protected from damage and deterioration during handling, maintenance and 
storage. 
In addition, the BDRG will assess and record the validity of the previous measuring results when 
the equipment is found not to conform to requirements. Records of the results of calibration 
and verification are maintained. 
Where computer software is used for monitoring or measurement, the ability of the computer 
software to satisfy the intended application shall be confirmed. 
Procedures Relating to Clause 7.6 Control of Monitoring and Measuring Devices 
SOP 7.5.2  Process Validation and Equipment Qualification Requirements for Suppliers 
SOP 7.5 Control of Outsourced Manufacturing Procedure 
SOP 6.3 Calibration and Equipment Maintenance 
8.0 Measurement, Analysis and Improvement  
8.1 General 
The BDRG plan and implement the monitoring, measurement, analysis and improvement 
processes needed to: 
 Demonstrate that the device conforms to requirements. 
 Ensure conformity of the quality system, and 
 Continually improve the effectiveness of the quality system. 





The effectiveness of the quality system is monitored by internal audits, the monitoring of quality 
objectives, the management review process and by monitoring user feedback.  Results of these 
activities are reported to management and are used to identify opportunities for improvement.   
Procedures Relating to Clause 8.1 General 
SOP 5.6 Management Responsibility Procedure 
SOP 8.4  Quality Review Meeting 
8.2 Monitoring and Measurement 
8.2.1 Feedback 
The BDRG ensure that monitoring of end user satisfaction is carried out on an ongoing basis. 
This is carried out via: 
 Feedback during management meetings; 
 User feedback; and 
 Corrective and preventive action is carried out to enhance user satisfaction as required. 
 
  8.2.2 Internal Audit 
SOP 8.2.2 Internal Auditing Procedure has been established and maintained for planning and 
implementing quality audits to verify whether quality activities and related results comply with 
planned arrangements, to the requirements of ISO 13485, Medical Device Directive 93/42 EEC 
and to the BDRG’s established quality management system. The audit process is also intended 
to determine if the quality management system is effectively implemented and maintained. 
Internal quality audits shall be carried out on a regular and systematic basis and are scheduled 
on the basis of status and importance of the activity to be audited.   
The internal audit process is intended to ensure that the BDRG is compliant with the following 
standards and regulations; 
 ISO 13485 Quality management system requirements for Medical Devices. 
 BDRG quality management system requirements. 
 Medical Device Directive 93/42/EEC of the European Union as it applies to the Quality 
Management System. 
8.2.3 Audit Schedule 
All activities relevant to the quality system are audited once per year to determine the 
effectiveness of the system. The internal audit plan shall reflect the status (based on results from 
previous audits) and importance of the processes and areas being audited. Audit frequency must 
be increased in response to non-conformances and, where appropriate, user complaints. The 
audit criteria, scope, frequency, methods, responsibilities and requirements for planning and 
conducting audits, and for reporting and maintaining results, are defined and documented in 
SOP 8.2.2 Internal Auditing Procedure.   
8.2.4 Audit Results 
The results of internal audits shall be recorded and presented to management, who is then 
responsible for addressing any non-conformities which may have arisen without delay. 





Corrective actions arising from internal audits shall be verified and the results of this verification 
shall be reported at the management review meeting.  
Internal quality audits shall be carried out by trained personnel assigned by management and 
auditors must be independent of the function being audited.  The internal audit function may 
also be outsourced to a suitably qualified external auditor. 
8.2.5 Monitoring and Measurement of Processes 
The robustness of the quality management system is measured and monitored by internal 
quality audits and during the management review process. Identification of improvements to 
processes or the continued suitability of processes is assessed during these audits and the 
identification of possible improvements/corrective actions is determined. Some of the key 
processes that are monitored are as follows: 
 Internal quality audits 
 Other internal audits 
 User satisfaction 
 Product acceptance/ non-conformance 
 Management review process 
The intended purpose of these key processes is quantified by their output, for example 
conformance to device specifications. 
8.2.4 Monitoring and Measurement of Product 
8.2.4.1 General Requirements 
The BDRG monitors and measures a range of characteristics of the product to verify that product 
requirements are met. This will be carried out at appropriate stages of the product realisation 
process in accordance with planned arrangements and documented procedures. 
Evidence of conformity of the product with the acceptance criteria is maintained. Records also 
indicate the person(s) authorising the release of the product.  
8.2.4.2 Particular Requirements for Implantable Medical Devices 
The BDRG does not manufacture or supply implantable or active implantable devices, therefore 
this clause is not applicable, please see section 1.2. 
Procedures Relating to Clause 8.2 Monitoring and Measurement 
SOP 7.1A  Risk Management 
SOP 8.2.2 Internal Auditing 
SOP 8.5.1A Adverse Event Reporting 
SOP 5.6 Management Responsibility  
SOP 7.4 Purchasing and Vendor Management 
SOP 8.4 Quality Review Meeting 





8.3 Control of Non-Conforming Material 
The BDRG has established documented procedure for the control of non-conformances; SOP 
8.3A Control of Nonconformances.  The scope of this procedure does not include nonconforming 
material or product in a supplier’s facility, which shall be controlled under the supplier’s Quality 
System (see SOP 7.5 Control of Outsourced Manufacturing).   
Non-conforming product which has left the suppliers facility is dealt with in the following 
procedure; 
 SOP 8.3B Product Field Action Procedure 
When nonconforming product is detected after delivery or use has started, appropriate actions 
to the effects (or potential effects) of the nonconformity will be taken through the BDRG 
corrective/preventive action system SOP 8.5 CAPA Procedure. These actions will be documented 
and records will be included as Quality Records. A review of the SOP 7.1 Risk Management File 
shall take place in light of user complaints due to the detection of nonconforming product. 
In the event of rework, the rework activity shall be documented in an instruction which has 
undergone the same authorisation and approval as the original work instruction. Prior to 
authorisation and approval of the rework instruction, a determination of any adverse effect of 
the rework upon product shall be made and documented 
Procedures Relating to Clause 8.3 Control of Non-Conforming Product 
SOP 8.3A   Control of Non-Conformances Procedure 
SOP 7.5 Control of Outsourced Manufacturing 
SOP 8.3B  Product Field Action 
SOP 8.5 CAPA 
SOP 7.1A Risk Management 
8.4 Analysis of Data 
The BDRG has established documented procedures to determine, collect and analyse 
appropriate data to demonstrate the suitability and effectiveness of the quality management 
system and to evaluate if improvement of the effectiveness of the quality management system 
can be made. This review shall include data generated as a result of monitoring and 
measurement and from other relevant sources such as; 
 User feedback; 
 Product conformity; 
 Internal audit results; 
 Non-conformances; 
 Process and product characteristics and trends; 
 Opportunity for preventive action; 
 Supplier data. 
Records of data analysis are maintained as quality records.  





Procedures Relating to Clause 8.4 Analysis of Data 
SOP 5.6   Management Responsibility Procedure 
SOP 8.4 Quality Review Meeting 
SOP 7.5 Control of Outsourced Manufacturing 
8.5 Improvement, Corrective and Preventive Action 
8.5.1 General 
The BDRG has a system to identify and implement any changes necessary to maintain the 
continued suitability and effectiveness of the quality management system through the 
following; 
 The quality policy; 
 Quality objectives; 
 Internal and external audit results; 
 Analysis of data; 
 Corrective and preventive actions; 
 Management review meetings. 
The BDRG has established a documented procedure for the review and reporting of adverse 
events which meet defined reporting criteria to regulatory authorities; SOP 8.5.1A Adverse 
Event Reporting. This procedure shall take in the different regulations depending on the territory 
in which the product is to be distributed.  
8.5.2 Corrective Action 
Corrective action is recognised as a key element in the continued improvement of the quality 
management system. Corrective actions are taken to eliminate the causes of an existing non-
conformance, or other undesirable situation in order to prevent recurrence. This procedure is 
outlined in SOP 8.5 Corrective and Preventive Action Procedure. 
The principal investigator ensures adequate resources are available to identify and implement 
corrective and preventive actions. 
SOP 8.5 Corrective and Preventive Action Procedure defines the requirements for: 
 Reviewing nonconformities, including customer complaints; 
 Determining the causes of nonconformities; 
 Evaluating the need for action to ensure that nonconformities do not recur; 
 Determining and implementing action needed including, as appropriate, updating 
documentation; 
 Records of the results of any investigation and of action taken; 
 Reviewing the corrective action taken and its effectiveness. 
All User complaints are logged, and an investigation is carried out to determine the root cause 
of the complaint. The QA/RA Administrator is responsible for ensuring that user complaints are 





followed up by checking the status on a monthly basis. An analysis of user complaints is carried 
out at each Management Review meeting. 
8.5.3 Preventive Action 
The need for preventive action is determined on the basis of information and data gathered 
regarding performance of processes, nonconformity rates, user returns and complaints, and 
quality system audit findings.  Appropriate information and data is collected and analysed to 
detect unfavorable trends that, if not checked, will increase the risk of nonconformities. The 
steps required to eliminate potential non-conformities shall be determined and documented. 
When implemented, the actions shall be reviewed for effectiveness and shall form part of the 
Management Review. Preventive actions taken shall be appropriate to the effects of the 
potential problems. 
SOP 8.5 Corrective and Preventive Action Procedures define requirements for; 
• Determining potential nonconformities and their causes; 
• Evaluating the need for action to prevent occurrence of nonconformities; 
• Determining and implementing action needed; 
• Records of results of any investigation and of action taken; 
• Reviewing preventive action taken; 
• Reviewing preventive action taken and its effectiveness. 
Procedures Relating to Clause 8.5 Improvement, Corrective and Preventive Action 
SOP 5.6   Management Responsibility Procedure 
SOP 8.5 Corrective and Preventive Action Procedure 
SOP 8.5.1A Adverse Event Reporting 
SOP 8.3B Product Field Action 
9. Revision History 
CC No. Superseded text Updated text Revision Date 
N/A 
N/A This is the first issue of 
this document. 
N/A This is the first issue of 
this document. 
   N/A N/A 
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The signatures below certify that this procedure has been reviewed and accepted, and demonstrates that 
the signatories are aware of all the requirements contained herein and are committed to ensuring their 
provision. 
 
 Name Signature Position Date 
Reviewed by 
  [insert position]  
Approved by 
  [insert position]  
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Note: The Biomedical Design Research Group (BDRG) is a core research group in the School of Engineering 
at University College Cork. The group’s primary purpose is to identify and solve unmet clinical needs 
through user-centred design in keeping with best industrial practices for the development of medical 
devices. Under the current remit of the BDRG, medical devices will be design and developed within a QMS 
compliant with the design control requirements of EN ISO13485. It is not the intention of the BDRG to 
become the legal manufacturer. Therefore the purpose of this Technical File is to describe the product 
specific design activities that may be by a future manufacture before proceeding to fulfil the regulatory 
requirements to place the device on the market. 
1.1. Administrative Details 
1.1.1 Organisational Information 
[To be completed on transfer of this document to legal manufacturer] 
1.1.2 Notified Body 
[To be completed on transfer of this document to legal manufacturer] 
1.1.3  Certification 
[To be completed on transfer of this document to legal manufacturer] 
1.1.4 Declaration of Conformity 
Revision [Completed on transfer] 
Legal Manufacturer’s Name [Completed on transfer] 
Legal Manufacturer’s Name [Completed on transfer]  
Product Name and Description SecuRetract is a minimally invasive laparoscopic 
mesenteric bowel retractor which is introduced 
into the peritoneal cavity via a surgical cannula 
and has duration of continuous use of less than 60 
minutes. The contact area which is exclusive to the 
distal portion of the device comprises a number of 
inflatable balloons which provide a soft interface 
with the internal organs. The intended use of the 
retractor is to surround the bowels by forming a 
semi-circular curved profile, and retracting said 
bowel from the operating field. On conclusion of 
the procedure, the retractor is disposed of. The 
device is actuated by a manual mechanical means. 
Product Code GCJ 
Classification IIa (CE), II (FDA) 
Device risk class Medium Risk 
I the undersigned, hereby declare that the medical device(s) described above and bearing the CE marking, 
conform to the applicable provisions of EC Medical Device Directive 93/42/EEC, complies with the 





applicable principles of safety and performance, has met the applicable conformity assessment elements 
and are therefore eligible to bear the CE marking as defined therein. 
 
Signature:   _____________________ 
Full Name Printed:  _____________________ 
Position:   _____________________ 
Date:    _____________________ 
Place:    _____________________ 
  





1.2. Product Description 
1.2.1. Device Identification 
1.2.1.1. SecuRetract Classification 
SecuRetract is a minimally invasive laparoscopic retractor which is introduced into the peritoneal cavity 
via a surgical cannula and has duration of continuous contact of less than 60 minutes (i.e. Transient Use). 
The contact area which is exclusive to the distal portion of the device comprises a number of inflatable 
balloons which provide a soft interface with the internal organs. On conclusion of the procedure, the 
retractor is disposed of. The device is actuated by a manual mechanical means. SecuRetract may therefore 
be deemed as a Surgically Invasive Device as the distal end of the retractor both enters and exits through 
an artificially created opening (i.e. a surgical cannula).   
 
Figure 1. SecuRetract laparoscopic retractor pictured in the inflated and curved position 
SecuRetract is classified as a Class 2a device via classification rules defined within the Annex IX of European 
Directive 93/42/EEC as amended, and schedule 9 of related Irish regulation (S.I. No. 252/1994), and in 
particular to rule seven pertaining to surgically invasive devices for short term use. Conformity can be 
achieved through a notified body subsequent to adhering to Annex II of the Medical Device Directive 
93/42/EEC.  
For FDA Classification guidelines, a device which falls with the controls of product Code GCJ, associated 
with endoscope and accessories, may be deemed as a class 2 device. A number of predicate Class 2 devices 
such as the A-Lap™ retractor (EZsurgical, 510(k) application K082291) and the ExtraHand™ balloon 





retractor (Medtronic, 510(k) K962005) have been identified. Premarket notification 510(k) is the most 
direct route for regulatory approval in the U.S. and substantial equivalence may be shown to a predict 
devices such as the A-Lap retractor.  
Table 1 provides a list of deployable retractors which have gained regulatory approval from the FDA via a 
510(k) approval process. The table also lists the classification for each retractor which in each case is a 
Class II device. 
Table 1 Examples of existing device approvals and classification type 
Device Company Retractor Type Class 510(k) Number 
A-LapTM Retractor EZsurgical Deployable  II K082291 
Laparoscopic Balloon 
Retractor 
Origin Medsystems INC Balloon II K926480 
ExtraHandTM Balloon 
Retractor 
Origin Medsystems INC Balloon 
Retractor 
II K962005 
Laparoscopic Retractor Surgical Innovations Snake Retractor II K112659 
Laparoscopic Retractor Cardinal Health INC Snake Retractor II K092684 
Karl Stortz Pivot Arm Lap 
Sleeve, Endo-Retractor 
Karl Stortz Retractor II K946330 
Laparoscopic Surgical 
Retractor 
Advanced Surgical Retractor II K933032 
Virtue Male Sling System 
with Alexis Wound Retractor 
Coloplast Corp. Sling II K111881 
Mini Lap Retractors Mini Lap Technologies Graspers II K093449 
Aesculap Sovereign mini 
system 
Aesculap Graspers II K123102 
 
1.2.1.1. Conformity assessment procedure 
Article 11(2) of Council Directive 93/42/EEC concerning Class IIa medical devices describes the conformity 
assessment process. In the case of devices falling within Class IIa, other than devices which are custom-
made or intended for clinical investigations, the route to conformity may follow CE Declaration of 
conformity (Annex II MDD 93/42/EEC) (see Figure 2). 
1.2.1.2. Products Covered 
The product covered under this Technical File is SecuRetract, a novel, atraumatic retractor used in 
laparoscopic surgery. 
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Figure 2. Flow chart for conformity assessment procedures for medical devices as provided for in MDD 
93/42/EEC 
1.2.2. Device Description 
1.2.2.1. Intended use 
SecuRetract is a minimally invasive, disposable, deployable, mesenteric bowel retractor for the use in 
laparoscopic surgery. One of the most common challenges encountered during laparoscopy is that of the 
distended loops of bowel or overlaying organs spilling into the operating field and thus obstructing the 
surgeon’s view. SecuRetract can be inserted into the peritoneal cavity through a surgical cannula in its 
deflated state. Once the region of interest has been identified, the impeding organs are retracted by 
manipulating the device until it hooks around these organs. The device is then inflated, increasing the 
contact area and finally withdrawn from the operating field, retracting the organs in the process. During 
the installation of SecuRetract, the patient may be placed in the Trendelenburg position (steep head 
down) to assist in placement. After the retractor is inserted, the distal tip, comprising a leaf spring 
sheathed within flexible extruded tubing, may be curved creating a hook shape by actuating the control 
handle. The radius of curvature may be modified as required and the retractor is placed between the 
bowel and its attached mesentery. The distal end of SecuRetract is then inflated increasing the contact 
area between the retractor and the bowels as well as creating a soft interface due to the cushioned effect 
of the modular balloons. As a result of the increased contact area and the curved profile of the retractor, 
a more effective withdrawal of the distended loops of the bowels can be obtained. Once the device has 
been positioned, the patient may return to the supine position where he or she can remain for the 
remainder of the procedure. The device can be deflated and removed back through the surgical cannula 
without incurring or causing damage. The device can subsequently be reinserted as required and is 
disposed of once the procedure is complete. 






Figure 3. SecuRetract atraumatic retractor illustrating key design features with a computer render of 
SecuRetract in use  
1.2.2.2. Description of device 
SecuRetract answers this important clinical need identified by a number of leading colorectal surgeons. 
SecuRetract is a minimally invasive, disposable, retractor for use in laparoscopic surgery with a number 
of advantages over competing technologies (see Figure 4). This novel retractor has the potential to ease 
surgical procedures as well as improving patient outcomes by alleviating a number of common 
complications currently experienced by the gold standard approach in laparoscopic retraction. 
SecuRetract facilitates quick and easy insertion through a small 5 mm instrument port (trocar) though its 
sleek minimal cross-sectional profile. SecuRetract can be easily manipulated to hook around the 
obstructive organ via an intuitive ergonomic design before being inflated to provide a soft interface 
reducing the risk of injury to the soft internal organs. Finally SecuRetract effectively withdraws the 
obstruction from the operating space providing an essential clear operating space to perform the 
procedure.  






Figure 4. SecuRetract assembly with control handle, shaft and balloons with steps for deployment. 
The hook-shaped inflatable design is unique within the laparoscopic retraction market and provides a 
soft interface for tissue manipulation. Competing devices are generally designed for liver or large organ 
retraction and lack the capability to effectively retract the messy loops of the small bowel. In addition, 
SecuRetract is easily deployed through a small 5 mm trocar reducing trauma, unlike the 12 mm ports 
necessary for most competing devices. Finally, the device represents an atraumatic inflatable interface 
with a high degree of controllability which removes risk of tissue injury during use.  
1.2.2.3. Intended user profiles for product 
SecuRetract may be used by any member of the surgical team during elective or emergency laparoscopic 
surgery. The primary clinical indication for this device is bowel retraction during laparoscopic colectomy 
as a treatment to colorectal cancer. However SecuRetract may also be used to manipulate and retract 
intrusive internal organs during colon resection for intestinal blockage, ulcerative colitis, intestinal 
trauma, colon polyps, diverticulitis and ischemic bowel disease. SecuRetract may also be used during 
alternative clinical applications including hysterectomy, cholecystectomy, prostatectomy, appendectomy 
and nephrectomy if necessary where the bowel obstructs the surgical field of view. 
The initial placement of the retractor is typically performed by the lead surgeon who may then nominate 
a member of the surgical team to operate the retractor for the majority of its time in use. SecuRetract 
may also be clamped to the surgical bed thus providing a stand-alone solution. SecuRetract may be 
removed and redeployed multiple times per procedure and disposed of after the procedure is complete. 
1.2.2.4. Summary and explanation of tests, performance evaluation and stability studies 
A summary of the design verification and validation is detailed in SecuRetract TF-02 Part B. This summary 
includes a description of the bench-top testing from both clinical and non-clinical studies and their results, 





sterilisation information, biocompatibility study, validation studies and packaging integrity and 
transportation testing.  
1.3. Labels, Packaging and Instructions for Use 
1.3.1. Packaging configuration / kit size 
The SecuRetract will be placed in a sterilisable pouche with Tyvek back along with a syringe to facilitate 
inflation of the balloons during administration, and an instructions of use leaflet. Clean room 
manufactured sterile pouches will be used to protect SecuRetract. The Tyvek barrier allows for EtO 
sterilisation. One pouche will be placed per box and three box will be placed into an outer carton. The 
overall box measures 700(l) x 190(w) x 25(h) mm. Depending on market, SecuRetract may also be 
packaged in separate vacuum formed trays sealed with an air tight lid. The tray will accommodate the 
SecuRetract in the straight and deflated position. A number of sealed trays may be included per box. The 
number of trays per box may vary, for example a single box may comprise 3 or 5 units dependent on end 
user requirements. 
[Insert specific detail of sterilisation and packaging suppliers and processes] 
1.3.2. Lifetime/shelf life of product and environmental limitations 
A critical material for the lifetime of SecuRetract is the elastomeric polyurethane that is used to construct 
the balloons on the distal end of the retractor. The properties of most rubber and elastomeric materials 
change as a result of aging. The amount of property change varies with time, environmental conditions 
and mechanical stress. The environmental conditions include the ambient temperature, the amount of 
light and the oxygen or ozone to which the materials are exposed during their time in storage. The 
recommended storage conditions for rubber and elastomeric products according to the Hydril Engineering 
Bulletin – EB94-001 may be seen in Table 2. 
Table 2 Storage parameters for rubber and elastomeric products 
Storage Parameter Recommended Storage Minimum Acceptable Unacceptable Storage 
Temperature Less than 27°C Less than 49°C Greater than 49°C 
Light Complete darkness Indirect light Direct light 
Stress  Separate packages Sacks of loose parts Pinched, stretched, creased 
Environment Clean dry air Humid air Oil, grease and/or water 
Oxygen and Ozone Sealed Package Open air Near electric motors 
According to the Hydril Engineering Bulletin – EB94-001 polyurethanes have a maximum life under 
recommended storage conditions of 6 years. [Insert further detail of shelf life verification] 
1.3.3. Labelling 
[Insert specific detail and example of labelling] 
Note: Labelling serves to communicate safety and performance related information to users of medical 
devices and/or patients as well as to identify individual devices.  Such information may appear on the 
device itself, on packaging (or as a packaging insert), or as information for use. Annex 1(13.3) of MDD 





93/42 EEC outlines the requirements for manufactures to provide sufficient information to use their 
device safely and properly, taking account of the training and knowledge of the potential users, and to 
identify the manufacturer. 
The label requirements which are applicable to SecuRetract from Annex 1 (13.3) of the MDD 93/42 are {a, 
b, c, d, e, f, h, I, k}. The label will include the following: 
(a) The name and address of the manufacturer; 
(b) Details necessary to identify the device and the contents of the packaging especially for the end users; 
(c) The word ‘STERILE’; 
(d) The batch code, preceded by the word ‘LOT’, or the serial number; 
(e) The date by which the device should be used expressed as the year and month; 
(f) An indication that the device is for single use.  
(h) The device is intended for clinical investigations, the words ‘exclusively for clinical investigations’; 
(i) Storage and/or handling conditions; 
(k) Warnings and/or precautions to take; 
1.3.4. Instructions for use (IFU) 
[Insert specific detail and example of IFU] 
Note: Annex 1(13.6) of MDD 93/42 EEC outlines the requirements for manufactures relating to the 
instructions for use. For Class IIa devices, like SecuRetract, no instructions for use are needed if they can 
be used without any such instructions (Annex 13.1 MDD 93/42). However, the manufacturer may decide 
that instructions for instructions are required and will be provided to the end users. The instructions for 
use will include the following information: 
(a) Details referred to in Section 1.3.3 of MDD 93/42 for Labelling, with the exception of (d) and (e); 
(b) The design, manufacturing and packaging performances intended by the manufacturer and any 
undesirable side effects; 
(c) SecuRetract must be connected to other medical devices (inflation apparatus such as a syringe) in 
order to inflate the balloons on the distal end; 
(d) Information needed to verify that the device is properly installed and inflated; 
(g) Instructions in the event of damage to the sterile packaging; 
(h) An indication that the device is for single use and information on known characteristics and technical 
factors known to the manufacturer that could pose a risk if the device were to be re-used; 
The instructions for use must also include details allowing the medical staff to brief the patient on any 
contra-indications and any precautions to be taken. These details should cover in particular:  
(k) Precautions to be taken in the event of changes in the performance of the device; 
(q) Date of issue or the latest revision of the instructions for use. 
* The numbering of each requirement corresponds with the requirements listed in section 13.6 of Annex 1 
MDD 93/42 EEC. 
1.4. Relevant Regulations 
Regulation Title & Description 





MDD 93/42 EEC European Council Directive Concerning Medical Devices 
[insert regulation] [insert associated title as required] 
1.5. Standards/Common Technical Specifications Applied 
Standards/ Tech’ Spec’ Title & Description 
I.S. EN ISO 13485:2012 Medical devices - quality management systems - requirements for 
regulatory purposes. 
I.S. EN ISO 15223-1:2012 Medical devices - symbols to be used with medical device labels, labelling 
and information to be supplied - part 1. 
ISO 15223-2:2010 Medical devices - symbols to be used with medical device labels, labelling 
and information to be supplied - part 2. 
EN 1041:2008 Information supplied by the manufacturer of medical devices. 
ISO 11607-1:2006 Packaging for terminally sterilized medical devices - Part 1: Requirements 
for materials, sterile barrier systems and packaging systems. 
ISO 11607-2:2006 Packaging for terminally sterilized medical devices - Part 2: Validation for 
material, sterile barrier and packaging systems. 
[Other as applicable] [insert associated title as required] 
1.6. Internal References 
Reference Title & Description 
TF-02 Part B Securetract Technical File Part B – Proprietary Documentation 
BDRG-DHF-02 Securetract Design History File 
BDRG-QM Quality Manual 
SOP 7.3 C Technical File Preparation And Maintenance SOP 
[Other as applicable] [insert associated title as required] 
1.7. Revision History 
Section Superseded text Updated text Revision Date 
N/A This is the first instance of 
this document. There are no 
revisions 
This is the first instance of 

















Appendix 3 – Design File Check List (Uncontrolled Sample) 
 
Design File Check List                                                                       Biomedical Design  
Revision No.: [XX]                                                                         Research Group 
ISO 13485 Clause: 7.3   




           Design File Reference: ____________________________ 
 
A Design File shall be created with the applicable sections. Each applicable section shall be signed 




Applicable Y/N Responsibility 
1 Project Design and 




Design Inputs Applicable Y/N Responsibility 








3 Design Information 
including previous drawings  
  
 





Design FMEA   





Design Outputs Applicable Y/N Responsibility 
1 Material Specifications 
 
  
2 Final Drawings 
 
  
3 Manufacturing Flow Chart 
and Process FMEA 
  
4 Components listings (i.e. 
Bill of Materials (BOM)) 
 
  


















Appendix 3 – Design File Check List (Uncontrolled Sample) 
 
Design File Check List                                                                       Biomedical Design  
Revision No.: [XX]                                                                         Research Group 
ISO 13485 Clause: 7.3   






Applicable Y/N Responsibility 
1 Development Records 
 
  
2 Functional Testing 
Protocols and Reports 
  
3 Sterilisation Testing 
Protocols and Reports 
  
4 Age & transport testing 










Applicable Y/N Responsibility 












Design Transfer Applicable 
Y/N 
Responsibility 
1 Manufacturing Work 
Instructions Present 
  
2 Training Completed 
 
  
3 Device Master Record Present 
(DMR) 
  
4 Process Validation Protocols 
and Reports 
  





Process FMEA Completed   









As part of the final design review meeting the Quality Assurance Administrator will review this list 
and the compiled DHF to ensure it has been adequately completed.  
  





Appendix 4 – ProDural DFMEA 





APPENDIX 4 - PRODURAL DFMEA (UNCONTROLLED COPY)
Risk Source; Component, Function or Standard Identification of Known or Foreseeable Risks Estimation of Risks Risk Evaluation Risk Control Implementation of Risk Control Other Hazards
Number STEP 1 STEP 2 STEP 3 STEP 4 STEP 5 STEP 6 STEP 7 STEP 9
Potential Hazard Clinical Effect Failure source S O
Risk 




What is the intended use and how is the medical 
device to be used?
Injury to the spine and or injection into the subarachnoid space. 
This hazard exists with current epidural administration 
techniques. ProDural does not present any increase risk over 
conventional LOR syringes.
Sever headaches, pneumocephalus, spinal 
cord and nerve root compression, 
subcutaneous emphysema, venous air 
embolism, and neurological injury 
Excessive advancement of the epidural 
needle beyond the epidural space 
resulting in Dura puncture
4 4 3 Yes
The design of ProDural will reduce the current risk of 
accidental Dural puncture (ADP) due to the immediate 
collapse of a visual indicator integrated to the body of the 
device. End users will receive training and instructions prior 
to use.
ProDural does not present any deviancy 
to current practices. The design of 
ProDural will reduce the incidence rates 
of ADP. Extensive training and 
instructions will be issued to end users 
prior to use.
Improved design and operation over 
existing LOR syringes whilst 
maintaining current LOR technique. 
Instructions attached to each unit.
4 3 2 n/a
2 C2.2
 Is the medical device intended to be implanted?
The medical device is not implanted. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
3 C2.3
Is the medical device intended to be in contact with 
the patient or other persons?
ProDural may be described as an external communicating device 
as described in section 5.2.2 of ISO10993. The nature of contact 
is limited to the transfer of fluid from the syringe barrel to the 
posterior tissue. Possible leaching of material from syringe into 
the epidural space by way of fluid transfer. This is an existing 
hazard with conventional LOR syringes. ProDural does not 
present any increase risk over conventional LOR syringes.
May cause infection if not sterile. Spinal 
abscess may occur if bacteria enter the 
epidural space, left untreated may cause 
paralysis and incontinence.
Device/equipment not sterile prior to 
use.
3 2 1 Yes
Employ proper sterile techniques using gloves and anti-
septic skin preparation. Ensure the device has been 
effectively sterilised and packaging remains intact prior to 
administration
Maintain best current practices. Current 
effective sterile techniques will not be 
altered 
Maintain current best practices in 
sterility
3 1 1 n/a
4 C2.4
What materials or components are utilized in the 
medical device or are used with, or are in contact 
with, the medical device?
Potential biological risk. Potential contamination risk.  Potential 
infection risk. These risks exist presently with conventional 
methods for epidural administration. ProDural does not present 
any increase risk over conventional LOR syringes.
Allergic reaction to non biocompatible 
material. Risk of infection if barrel fluid is 
non-sterile. Risk of infection/disease 
transfer if needle is reused.
Chosen construction materials  are not 
biocompatible. Barrel fluid   (e.g. 
saline) is corrupted. If the epidural 
needle which is attached to the 
syringe is reused from a previous 
patient.
4 2 2 Yes
Carry out biological evaluation during design stage to 
ensure that all materials are compatible. Ensure that all 
saline used is still in date and the integrity of the container 
has not been compromised. Never reuse the device. 
Dispose of all equipment immediately after application.
Biological evaluation. As with current 
practice, only intact and in-date saline 
may be used in the application of 
determining the epidural space and all 
components are to be discarded after 
use.
Biological evaluation during design 
stage. No deviation from current 
application practices.
4 1 1 n/a
5 C2.5
Is energy delivered to or extracted from the patient?
No energy is delivered to or extracted from the patient. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
6 C2.6
Are substances delivered to or extracted from the 
patient?
The barrel of the syringe is partially or complete filled with a 
injection medium (air or saline). This may contain contaminates 
which may be subsequently injected into the 
epidural/subarachnoid space. The site may be subsequently 
aspirated to ensure that CSF is not extracted ensuring correct 
needle placement. This hazard currently exists with present 
practices.
May cause infection if not sterile. Spinal 
abscess may occur if bacteria enter the 
epidural space, left untreated may cause 
paralysis and incontinence.
Substance compromised and is no 
longer sterile. Saline has surpassed its 
use by date and sterility may no longer 
be preserved.
3 2 1 Yes
Ensure the device has been effectively sterilised and 
packaging remains intact prior to administration. All saline 
used is still within its intended use by date and container is 
still intact.
Maintain best current practices. Current 
sterile techniques will not be altered. 
Maintain current best practices in 
sterility
3 2 1 n/a
7 C2.7
Are biological materials processed by the medical 
device for subsequent re-use, transfusion or 
transplantation?
No biological materials are processed by this device. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
8 C2.8
Is the medical device supplied sterile or intended to 
be sterilized by the user, or are other microbiological 
controls applicable?
The device will be delivered sterile in a sealed packaging. A 
possible hazard is that the packaging has been compromised 
during transportation and the device may no longer be sterile.
Possible infection.
Packaging has been compromised 
during transportation.
3 2 1 yes
Ensure that the device has been securely packaged and 
sealed prior to transportation. Employ a reputable logistics 
company.
Establish a quality control system to 
ensure all the relevant checks are carried 
out prior to product shipping. Post market 
surveillance.
Established QMS 2 1 0 n/a
9 C2.9
Is the medical device intended to be routinely 
cleaned and disinfected by the user?
The device is a disposable device and should be discarded after 
use.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
10 C2.10
Is the medical device intended to modify the patient 
environment?
There is no modification to the patient environment. The current 
epidural administration technique will be employed with the 
addition of a visual indicator to signal correct epidural space 
localisation. 
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
11 C2.11
Are measurements taken?
There are no measurements taken. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
12 C2.12
Is the medical device interpretative?
The medical device is used to identify the epidural space. The 
device comprises an inflatable diaphragm which immediately 
collapses when the epidural space is reached. However a 
premature collapse may be incorrectly interpreted as successful 
identification of the epidural space.
False positive reading which will fail to 
deliver pain relief when subsequent drop is 
administered.
Leakage between layers of fatty tissue 
during application. 
2 4 2 Yes
Correct material selection and age testing carried out prior 
to final product manufacture. Continual quality controls 
during manufacture. End user training prior to use to 
reduce incidence of false positive.
Continual product manufacturing quality 
controls. End user training programmes. 
Post market surveillance. 
Established QMS 2 2 1 n/a
13 C2.13
Is the medical device intended for use in conjunction 
with other medical devices,  medicines or other 
medical technologies
ProDural will be used in conjunction with a number of existing 
components used in epidural administration such as an epidural 
needle and a catheter. ProDural represents no increase in risk or 
additional hazard compared to conventional LOR epidural 
syringes when used with accompanying components. 
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
14 C2.14
Are there unwanted outputs of energy or 
substances?
The preferred method for sterilisation is using Ethylene Oxide 
(EtO). This is commonly used to sterilise plastic syringes such as 
existing LOR syringes. EtO is a primary irritant and is now 
classified by the IARC as a known human carcinogen. Exposure 
to EtO is regulated by the EPA and OSHA. 
Irritant and known carcinogen. Exposure is 
very limited.
Incorrect sterilisation technique not in 
line with international standards such 
as ISO 11135
4 2 2 Yes
Document the sterilisation requirements in line with best 
international practice and ensure a quality control regime is 
employed during the sterilisation process.
Continual product manufacturing quality 
controls. Post market surveillance. 
Established QMS 4 1 1 n/a
15 C2.15
Is the medical device susceptible to environmental 
influences?
Extreme high temperatures (>200oC) or extreme cold 
temperatures (-40oC)  may alter the mechanical properties of 
the device. However at such extremes, the containers holding 
the device would be destroyed and the device could not be 
used. 
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
16 C2.16
Does the medical device influence the environment? The device does not affect power and cooling, it does not emit 
toxic materials and it does not generate  electromagnetic fields.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
17 C2.17
Are there essential consumables or accessories 
associated with the medical device?
The device may be sold as part of an epidural kit which would 
include an epidural needle and catheter as well as other 
consumables. However there is an exception for the UK market 
whereby a special connection is required to connect to the 
epidural needle as described in  patient safety alert 
NPSA/2011/PSA001. 
Epidural medicine administered by the 
intravenous route. Intravenous medicine 
administered by the epidural route. 
Intravenous medicine administered by the 
regional anaesthetic route. Regional 
medicine administered by the intravenous 
route.
Mis-connection and wrong route 
errors. The wide use of the Luer 
connector design enables wrong route 
patient safety incidents to occur.
4 2 2 Yes
Develop a safe connector designed for spinal and epidural 
use only in line with interventional best practice.
Design specification to prevent mis-
connection and/or wrong route errors.
Design specification during the design 
phase.
4 1 1 n/a
18 C2.18
Is maintenance or calibration necessary? No maintenance or calibration is necessary. The device is 
delivered fit for use and disposed of directly after application. 
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
Residual Risk 
ISO 14971 annex 
ref. if app.
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Does the medical device contain software?
The device does not contain software. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
20 C2.20
Does the medical device have a restricted shelf-life?
Natural rubber: 3-5 years. Silicone: 20 years. Data sourced from 
Table 1 of MIL-HDBK-695 which lists the age resistance generally 
associated with rubber products. 
Mechanical failure Material deterioration 2 2 1 Yes
Suitable storage conditions controlling temperature and 
humidity. Product controls. Effective age testing. Product 
storage and distribution controls. 
Carry out age testing. Establish product 
storage and distribution controls. Indicate 
shelf life on product labelling
Age testing, establish QMS and post 
market surveillance, appropriate 
labelling.
2 1 0 n/a
21 C2.21
Are there any delayed or long-term use effects?
Permanent deformation may occur in the elastomeric 
diaphragm if excessive pressures are exerted without rupturing 
the diaphragm. 
The diaphragm would not return to a 
perfectly smooth status once the epidural 
space has been reached. The inflated 
diaphragm would still collapse indicating the 
space has been reached.
Excessive force exerted on the plunger 
without further advancement of the 
device.
2 2 1 Yes
Diaphragm material selection to reduce the occurrence of 
permanent deformation by ensuring the material remains 
elastic for higher pressures.
Material selection reduction though 
bench top testing until the most effective 
material is identified.
Appropriate material selection. 2 2 1 n/a
22 C2.22
To what mechanical forces will the medical device 
be subjected?
From literature review the estimated pressure experienced in 
the syringe barrel due to plunger advancement is 37.5 ± 20.0 
kPa. However from end user surveys it was concluded that far 
lower pressures are experienced in practice (approx. 14-20 kPa)
Incorrect localisation of the epidural space/ 
mechanical failure.
Excessive pressure is exerted leading 
to diaphragm rupture.
3 3 2 Yes
Diaphragm material selection to reduce risk of rupture at 
high pressures.
Material selection reduction though 
bench top testing identifying the most 
effective material is identified.
Appropriate material selection. 2 2 1 n/a
23 C2.23
What determines the lifetime of the medical device?
Change in the physical properties of the material over time. 
Change may occur due to temperature, humidity, light, 
radiation, ozone/oxygen and loading. Physical properties may 
also be altered during the sterilisation process.
Mechanical failure Material deterioration 2 2 1 Yes
Suitable storage conditions controlling temperature, 
humidity, exposure radiation. In addition the device will be 
stored in a sealed packaged container which will reduce 
exposure to oxygen and light. Correct sterilisation method 
to reduce impact on mechanical properties. EtO has little if 
any effect on the physical characteristics of silicone and 
rubber.
Carry out age testing at design stage. 
Establish product storage and distribution 
controls. Indicate shelf life on product 
labelling
Age testing, establish QMS and post 
market surveillance, appropriate 
labelling.
2 2 1 n/a
24 C2.24
Is the medical device intended for single use? The device is a disposable device and should be discarded after 
use. A potential hazard is the device is reused.
Cross contamination Reuse of device 4 3 2 Yes
The device includes a clip which has to be removed prior to 
each use indication if the device has been used before. This 
will be included during design stage.
Design specification to include an 
indicator to signal that it is the first time 
the device has been used.
First time use indicator designed 
during the design and development 
stage.
4 1 1 n/a
25 C2.25
Is safe decommissioning or disposal of the medical 
device necessary?
There is no special requirement when disposing of this device. 
The same disposable procedure currently used should be 
employed. The device is discarded with the biohazard waste in 
line with current practice.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
26 C2.26
Does installation or use of the medical device 
require special training or special skills?
No. The device innovation of visual indication is augmentry & 
not replacing current LOR techniques. The device is used in 
exactly the same manner as current LOR syringes & no special 
training beyond the current best practice is required.
Incorrect use of the device leading to 
complications such as accidental dura 
puncture and or false localisation of the 
epidural space.
Over reliance on the visual indicator 
with neglect to correct LOR technique. 
Uncontrolled advancement of the 
needle
4 2 2 Yes
Suitable training to be carried out prior to use. Instructions 
to be included with the device.
Create training video and documentation
Create training video and 
documentation
4 1 1 n/a
27 C2.27
How will information for safe use be provided?
The device is used in a similar manner to current LOR syringes 
with the addition of a visual indicator. Minimum if any training is 
required. Hazard of incorrect use.
Incorrect localisation of the epidural space. Incorrect use of the device 3 2 1 No n/a n/a n/a 3 2 1 n/a
28 C2.28
Will new manufacturing processes need to be 
established or introduced?
The device will be manufacture using conventional injection 
moulding methods and sourcing appropriate material for the 
diaphragm.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
29 C2.29
Is successful application of the medical device 
critically dependent on human factors such as the 
user interface
Successful application of the medical device is dependant on the 
tactile feeling and visual indication once a pressure drop is 
detected on entering the epidural space. Mechanical stiffness 
may reduce the effectiveness of determining a pressure drop 
thus diminishing the performance of the device.
Incorrect localisation of the epidural space 
which may lead to neurological injury and or 
failure to deliver pain relief.
Mechanical stiffness when advancing 
the plunger. Elongation stiffness in 
inflating the diaphragm. Difficulty 
holding the device. Difficulty seeing 
the diaphragm collapse
4 2 2 Yes
The syringe body is constructed in line with conventional 
LOR syringes and a low friction plunger seal will be 
employed to ensure fluid plunger transmission. The 
diaphragm will comprise of a bright colour which enhances 
visibility. 
Ethnographic evaluation to be carried out 
on the final design to ensure an 
ergonomic solution. Effective material 
investigation.
Design evaluation. Material selection. 4 1 1 n/a
30  C2.29.1
Can the user interface design features contribute to 
use error?
A poor ergonomic design may reduce the effectiveness of the 
design. However the syringe body is designed in line with 
existing LOR syringes thus should not present a deficit. 
Incorrect localisation of the epidural space 
which may lead to neurological injury and or 
failure to deliver pain relief.
Mechanical stiffness when advancing 
the plunger. Elongation stiffness in 
inflating the diaphragm. Difficulty 
holding the device. Difficulty seeing 
the diaphragm collapse
4 2 2 Yes
The syringe body is constructed in line with conventional 
LOR syringes and a low friction plunger seal will be 
employed to ensure fluid plunger transmission. The 
diaphragm will comprise of a bright colour which enhances 
visibility. 
Ethnographic evaluation to be carried out 
on the final design to ensure an 
ergonomic solution. Effective material 
investigation.
Design evaluation. Material selection. 
Post market surveillance. 
4 1 1 n/a
31  C2.29.2
Is the medical device used in an environment where 
distractions can cause use error?
The medical device will be administered prior to surgical 
intervention and in obstetrics. The device incurs no additional 
distractions over existing epidural syringes. The patient should 
remain still  as directed by the physician in line with current 
practices.
Incorrect localisation of the epidural needle. 
Neurological injury and or failure to deliver 
pain relief. 
Patient moving during application. 4 2 2 No
No additional risk reduction methods can be applied here. 
The procedure requires the patient to remain still for a 
short duration (approx. 5 - 15 seconds) as in current 
practice. The occurrence of failure owing to disturbance is 
low.
n/a n/a 4 2 2 n/a
32  C2.29.3
Does the medical device have connecting parts or 
accessories?
The device is connected distally to an epidural needle during 
application. The epidural needle is unchanged from current 
designs. However there is an exception for the UK market 
whereby a special connection is required to connect to the 
epidural needle as described in the patient safety alert 
NPPSA/2011/PSA001. 
Epidural medicine administered by the 
intravenous route. Intravenous medicine 
administered by the epidural route. 
Intravenous medicine administered by the 
regional anaesthetic route. Regional 
medicine administered by the intravenous 
route.
Mis-connection and wrong route 
errors. The wide use of the Luer 
connector design enables wrong route 
patient safety incidents to occur.
4 2 2 Yes
Develop a safe connector designed for spinal and epidural 
use only.
Design specification to prevent mis-
connection and/or wrong route errors.
Design specification during the design 
phase.
4 1 1 n/a
33  C2.29.4
Does the medical device have a control interface?
The device does not have a control interface n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
34  C2.29.5
Does the medical device display information?
The device comprises a visual indicator that signals when the 
epidural space has been reached. A hazard may exist whereby it 
is difficult to see this indicator.
Incorrect epidural localisation.
Difficulty visualising the visual 
indicator
3 3 2 Yes
Chose a bright, contrasting colour for the diaphragm 
material to improve visibility
Select a material which allows for 
apparent discrimination between the 
inflated and deflated states. Post market 
surveillance.
Material selection in line with design 
and operational criteria. Post market 
surveillance.
3 2 1 n/a
35  C2.29.6
Is the medical device controlled by a menu?
No the device is not controlled by a menu. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
36  C2.29.7
Will the medical device be used by persons with 
special needs?
No. The device will only be used by trainee/experienced 
physicians. 
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
37  C2.29.8
Can the user interface be used to initiate user 
actions? No alternative actions may be initiated by the user interface. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
38 C2.30
Does the medical device use an alarm system?
No the device does not use an alarm system. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
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In what way(s) might the medical device be 
deliberately misused?
Inappropriately excessive force may be applied to the plunger 
causing the diaphragm to rupture due to exorbitant inter-barrel 
pressure (pressures > 62 kPa). These pressures far exceed 
current operational parameters. The device may be advanced 
too quickly not taking account of the haptic and visual feedback. 
Severe headaches, pneumocephalus, spinal 
cord and nerve root compression, 
subcutaneous emphysema, venous air 
embolism, and neurological injury 
Misuse of the device ignoring best 
current clinical practices.
4 3 2 Yes
Ensure that best clinical practice is adhered to. Provide 
operational instructions.
Formulate a training programme which 
may comprise of physical demonstration 
and/or teaching videos. Develop an 
instruction brochure. 
Establish training plan. Develop 
instruction guide. Post market 
surveillance.
4 1 1 n/a
40 C2.32
Does the medical device hold data critical to patient 
care? The medical device does not hold data critical to patient care. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
41 C2.33
Is the medical device intended to be mobile or 
portable?
The device is a light weight syringe used to locate the epidural 
space and may be carried and used in the user's hand. The 
device may fall during application.
Contamination of the device prior to use 
leading to subsequent clinical complications 
such as infection.
Device falling or spilling to the ground 
or to a dirty surface.
3 3 2 Yes
Instruct the end user to dispose of the device and retrieve a 
sterile alternative. Follow current sterility practices.
Maintain best current practices. Current 
sterile techniques will not be amended. 
Instruct end users to maintain current 
best practices in sterility
3 1 1 n/a
42 C2.34
Does the use of the medical device depend on 
essential performance?
The effectiveness of the medical device depends on the 
proficiency and skill of the physician. The advancements made in 
this device over preceding technologies should enhance the 
operational accuracy and effectiveness of epidural 
administration.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
43 Line Voltage Line Voltage has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
44 Leakage Current Leakage Current has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
45 Electric Fields Electric Field has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
46 Magnetic Fields Magnetic Field has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
47 Ionizing radiation Ionizing radiation has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
48 Non-ionizing radiation Non-ionizing radiation has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
49 High temperature High temperature has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
50 Low temperature Low temperature has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
51 Gravity Gravity has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
52 Vibration Vibration has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
53 Stored energy Stored energy has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
54 Moving parts
Breakage of moving parts such as the plunger seal and the 
plunger. Diaphragm securing cap may  get dislodged.
Poor performance. Unable to use as 
intended.
Manufacturing error. Damage during 
transportation. Misuse. 
2 2 1 Yes
Establish quality controls ensuring compliance in product 
manufacturing. Ensure a good quality shipping contractor. 
Instruct end user to dispose of any device with visible 
evidence of misuse and or damage. Develop training 
programme for end users to demonstrate correct action for 
use. 
Establish a QA system. Employ a 
reputable logistics company. Label device 
indicating disposal if damage is visible. 
Post market surveillance. Provide 
adequate training programme.
Establish a QA system. Employ a 
reputable logistics company. Label 
device indicating disposal if damage is 
visible. Post market surveillance. 
2 1 0 n/a
55 Torsion, shear and tensile force
Potential damage to the device is excess torsion, shear and or 
tensile force is exerted. 
Poor performance. Unable to use for 
intended application.
Damage during transport. Misuse. 2 1 0 No n/a n/a n/a 2 1 0 n/a
56 Moving and positioning of patient
The patient should be positioned in accordance with best 
current practices. No deviation from current positioning practice 
should  be observed.
There is little clinical risk associated with the 
patients position. The clinician will decide if 
the patient is to assume the lateral or sitting 
position as with current practice.
n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
57 Acoustic energy Acoustic energy has no effect. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
58 High pressure fluid injection
High pressure injection of the inter-barrel fluid into the epidural 
can reduce the effectiveness of subsequent drug infusion. 
However may aid in distribution of anaesthesia if the inter-barrel 
fluid is saline
Reduction in effectiveness of the epidural 
anaesthesia
Excessive force applied to the syringe 
plunger leading to high  inter-barrel 
pressure during fluid injection.
2 3 1 Yes Maintain current interventional best practice.
Maintain current interventional best 
practice.
Post market surveillance. 2 2 1 n/a
59 Other issues No other energy hazard n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
60 Bacteria Bacteria may grow in device.
May cause infection if not sterile. Spinal 
abscess may occur if bacteria enter the 
epidural space, left untreated may cause 
paralysis and incontinence.
Device not manufactured in a clean 
room. Sterilisation not effective. 
Device damaged in storage or in 
transport. 
3 2 1 Yes
Employ proper sterile techniques using gloves and anti-
septic skin preparation. Ensure the device has been 
effectively sterilised and packaging remains intact prior to 
administration. Assemble device in a clean room 
environment.
Maintain best current practices. Current 
sterile techniques will not be amended. 
Ensure quality control during the 
manufacturing and transport processes. 
Instruct end users to maintain current 
best practices in sterility. Establish 
QMS to control manufacturing, 
sterilisation, storage and 
transportation of medical device.
3 1 1 n/a
61 Viruses
A virus may be passed from one patient to another if device is 
reused.
Cross contamination. Virus transferred from 
one patient to the next.
Reuse of device. Device not sterile. 4 3 2 Yes
The device design includes a clip which has to be removed 
prior to each use indicating that the device has not been 
used before. 
Design specification to include an 
indicator to signal that it is the first time 
the device has been used.
Design specification during the design 
phase.
4 1 1 n/a
62 Other agents (e.g. prions)
Potential of allergic reaction to proteins contained in natural 
latex rubber or other polymers.
Allergic reaction to non biocompatible 
material. 
Non-medical grade material chosen in 
the design. Non conformity to 
biological evaluation. 
3 2 1 Yes
Carry out biological evaluation during design stage to 
ensure that all materials are compatible
Biological evaluation. 
Biological evaluation during design 
stage. 
3 1 1 n/a
63 Re- or cross-infection
Re- or cross-infection may occur from one patient to another if 
device is reused.
Cross contamination. 
Virus/infection/disease transferred from 
one patient to the next.
Reuse of device. Device not sterile. 4 3 2 Yes
The device design includes a clip which has to be removed 
prior to each use indicating that the device has not been 
used before. 
Design specification to include an 
indicator to signal that it is the first time 
the device has been used.
Design specification during the design 
phase.
4 1 1 n/a
64
Exposure of airways, tissues, environment or 
property
Residues left over from sterilisation process. Air born 
contaminates. These hazards are presently experienced in 
conventional epidural administration.
Risk of introducing infection, bacteria or 
toxic particle into the epidural/spinal area.
Poor sterilisation technique. 
Corruption of device packaging 
integrity. Misuse. Spill onto a dirty 
surface
3 2 1 Yes
Establish quality controls ensuring compliance in product 
manufacturing. Compliance with best sterility practices 
within the hospital environment.
Product manufacturing and sterilisation 
control.
Establish a QA system. Post market 
surveillance. 
3 1 1 n/a
65 Toxicity of chemical constituents 
Ethylene oxide used in the sterilisation process is  regarded as a 
toxic agent and should be completely cleansed from the device 
subsequent to sterilisation. Refer to risk number 14. Potential of 
allergic reaction due to proteins in certain polymers (refer to risk 
number 4). 
Irritant and known carcinogen. Exposure is 
very limited. Allergic reaction to device 
construction material.
Incorrect sterilisation technique not in 
line with international standards such 
as ISO 11135. Non biocompatible 
material.
4 2 2 Yes
Document the sterilisation requirements in line with best 
international practice and ensure a quality control regime is 
employed during the sterilisation process. Biological 
evaluation. Careful material selection in design stage.
Continual product manufacturing quality 
controls. Post market surveillance. 
Biological evaluation.
Establish a QMS. Biological evaluation 
at design stage.
4 1 1 n/a
66 Other issues No other biological hazard n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
67 Incorrect or inappropriate output or functionality Incorrect localisation of the epidural space/ natural cavity.
Neurological injury, sever headaches, failure 
to administer pain relief
Balloon rupture, misuse of device, not 
following current administration 
guidelines.
4 4 3 Yes
Design increases reliability by incorporating a visual 
indicator to signal when the epidural space has been 
reached. Design specification to include a robust design. 
Design validation through mechanical trials.
Detailed design considering clinical need 
and validation of final design through 
bench top and pre-clinical trials.
Detailed design specification. Detailed 
validation. 
4 2 2 n/a
68 Incorrect measurement No measurement is taken with this device. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
69 Erroneous data transfer No data is transferred with this device. n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
70 Loss or deterioration of function
The diaphragm may experience permanent deformation if 
expanded beyond its yield point. This may only occur if excessive 
inter-barrel pressure is experienced beyond the current 
operational parameters.
This may reduce the confidence that the 
epidural space has been reached.
Misuse of the device. Excessive force 
being applied to the plunger. 
2 3 1 Yes
The visual indicator expands to between 400-600% 
elongation for an inter-barrel pressure of 13-20 kPa as 
determined through end user.
Material selection to insure elastic 
behaviour for greater pressures well in 
excess of operational forces applied to 
the plunger.
Design specification and material 
selection. Post market surveillance.
2 2 1 n/a
71 Attentional failure Failure to stop advancement of the epidural needle Accidental Dural puncture, spinal tap. Device misuse. 4 3 2 Yes Maintain current interventional best practice.
Maintain current interventional best 
practice.
Maintain current interventional best 
practice. Post market surveillance. 
4 1 1 n/a
72 Memory failure
As the time taken to use this device is between 10 and 20 
seconds, memory failure is not applicable.
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The physician uses the medical device as intended but has 
inadequate skill (hand to eye coordination, steady advancement) 
to accurately determine the epidural space.
Failure to identify epidural space. Failure to 
administer pain relief.
Inadequate skill levels to carry out 
procedure.
4 1 1 No
Risk reduction not possible as end user does not obtain the 
necessary skill level to perform this procedure.
n/a n/a 4 1 1 n/a
74 Knowledge based failure
The physician may not poses adequate knowledge of the human 
anatomy to accurately distinguish when the epidural space has 
been reached. This  risk currently exists and has changed with by 
the use of the presented medical device.
Failure to identify epidural space. Failure to 
administer pain relief.
Inadequate competency to carry out 
procedure.
4 1 1 No n/a n/a n/a 4 1 1 n/a
75 Routine violation
Deliberate violation of current epidural administration 
techniques due to routine disregard for instructions of use is not 
foreseen.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
76 Other Issues
Skill based mistakes due to inadequate skill level in identifying 
the epidural space.
Failure to identify epidural space. Failure to 
administer pain relief.
Inadequate skill levels to carry out 
procedure.
4 1 1 No
Risk reduction not possible as end user does not possess 
the necessary skill level to perform this procedure.
n/a n/a 4 1 1 n/a
77 Incomplete instructions for use Misuse of device. 
Failure to identify epidural space. Failure to 
administer pain relief. Neurological injury.
Incomplete instructions for use 4 1 1 Yes
Establish a QC system ensuring instruction are adequately 
completed and distributed with packaged device.
Establish QC system Establish QC system 4 1 1 n/a
78
Inadequate description of performance 
characteristics
The device may not perform as intended.
Poor performance. Unable to use for 
intended application.
Inadequate description of 
performance characteristics
2 2 1 Yes
Design validation and verification post design freeze to 
ensure device performs as intended.
Design validation and verification. Design validation and verification. 2 1 0 n/a
79 Inadequate specification of intended use The device may not perform as intended.
Poor performance. Unable to use for 
intended application.
Inadequate specification of intended 
use
2 2 1 Yes
Design validation and verification post design freeze to 
ensure device performs as intended.
Design validation and verification. Design validation and verification. 2 1 0 n/a
80 Inadequate disclosure of limitations The device may not perform as intended.
Poor performance. Unable to use for 
intended application.
Inadequate disclosure of limitations 2 2 1 Yes
Design validation and verification post design freeze to 
ensure device performs as intended.
Design validation and verification. Design validation and verification. 2 1 0 n/a
81
Inadequate specification of accessories to be used 
with the medical device
The device may not perform as intended. Incorrect epidural 
needle size may result in unexpected complications.
Poor performance. Unable to use for 
intended application. Injury as a result of 
incorrect needle size.
Inadequate specification of 
accessories to be used with the 
medical device
3 2 1 Yes
Specify accessories during design stage. Design validation 
and verification post design freeze to ensure device 
performs as intended.
Design validation and verification. Design validation and verification. 2 1 0 n/a
82 Inadequate specification of pre-use checks The device may be accidently reused. Cross-contamination
Reuse of device. Inadequate 
specification of pre-use checks
4 3 2 Yes
The device design includes a clip which has to be removed 
prior to each use indicating that the device has not been 
used before. 
Design specification to include an 
indicator to signal that it is the first time 
the device has been used.
Design specification during the design 
phase.
4 1 1 n/a
83 Over-complicated operating instructions
This hazard is not applicable owing to the simple nature of this 
device.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
84 Incomplete warnings of side effects
Incomplete or inadequate warnings of complications due to 
device misuse.
Clinical complications as discussed 
previously to possible include neurological 
injury. 
Incomplete or inadequate warning of 
outcomes due to device misuse. User 
incompetency.
4 2 2 Yes
Warnings of misuse on device label. Maintain current 
interventional best practice.
Warnings of misuse on device label. 
Maintain current interventional best 
practice.
Warnings of misuse on device label. 
Maintain current interventional best 
practice. Post market surveillance.
0 0 N/A n/a
85
Incomplete warnings of hazards likely with re-use of 
single-use medical device
This device is a single use device. A virus may be passed from 
one patient to another if device is reused.
Cross contamination. Virus transferred from 
one patient to the next.
Incomplete warnings of hazards likely 
with re-use of single-use medical 
device
4 3 2 Yes
The device design includes a clip which has to be removed 
prior to each use indicating that the device has not been 
used before. 
Design specification to include an 
indicator to signal that it is the first time 
the device has been used.
Design specification during the design 
phase.
4 1 1 n/a
86 Inadequate specification of service and maintenance
This device is a single use device. Service and maintenance is not 
required.
n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
87 Other Issues No other information hazards n/a n/a 0 0 N/A No n/a n/a n/a 0 0 N/A n/a
88  - N/A N/A
89  - N/A N/A
90  - N/A N/A
91  - N/A N/A
92  - N/A N/A
93  - N/A N/A
94  - N/A N/A
95  - N/A N/A
96  - N/A N/A
97  - N/A N/A
98  - N/A N/A
99  - N/A N/A
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DIMENSIONS ARE IN MILLIMETERS
SURFACE FINISH: SMOOTH
TOLERANCES: 0.1mm
   LINEAR: 0.1mm
   ANGULAR: 0.1 degrees
Q.A
MFG
APPV'D
CHK'D
DRAWN
0.11 grams
